

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF CALIFORNIA

-----oo0oo-----

CHERYL J. WHITE, SUCCESSOR TO                      NO. CIV. 06-665 WBS GGH  
WILLIAM WHITE,

Plaintiff,    FINAL PRETRIAL ORDER

v.

NOVARTIS PHARMACEUTICALS  
CORPORATION,

Defendant.

\_\_\_\_\_ /

-----oo0oo-----

A Final Pretrial Conference was held in this matter,  
pursuant to the provisions of Rule 16(d) of the Federal Rules of  
Civil Procedure and Local Rule 282, on August 22, 2011. John  
Girardi and John Vecchione appeared as counsel for plaintiff;  
Martin Calhoun and James Bruen appeared as counsel for defendant.  
Following the hearing, the court enters this Final Pretrial  
Order:

I. Jurisdiction-Venue

Jurisdiction is predicated upon diversity jurisdiction,

1 28 U.S.C. § 1332. Venue is undisputed and is hereby found to be  
2 proper.

3 II. Jury-Nonjury

4 The parties have requested a jury trial. Accordingly,  
5 the action shall be tried, pursuant to Federal Rule of Civil  
6 Procedure 48, before a jury consisting of no less than six and no  
7 more than twelve members.

8 III. Jury Instructions and Proposed Form of Verdict

9 No later than ten court days before the trial date,  
10 counsel for plaintiff shall lodge and serve, pursuant to Local  
11 Rule 163, copies of all jury instructions that plaintiff requests  
12 be given on plaintiff's claims. At that time, counsel for  
13 plaintiff shall also file and serve a copy of a proposed form of  
14 verdict.

15 No later than seven court days before the trial date,  
16 counsel for defendant shall file and serve any objections to the  
17 instructions proposed by plaintiff. At the same time, counsel  
18 for defendant shall lodge and serve, pursuant to Local Rule 163,  
19 copies of any and all jury instructions not already proposed by  
20 plaintiff, which defendant requests be given. Also at that time,  
21 counsel for defendant shall file and serve a copy of any proposed  
22 form of verdict and shall also file any objections to plaintiff's  
23 proposed form of verdict.

24 No later than four court days before the trial date,  
25 counsel for plaintiff shall file and serve any objections to the  
26 instructions proposed by defendant and to any proposed form of  
27 verdict.

28 Pursuant to Local Rule 163, any other instructions

1 thereafter presented will be refused unless it is shown either:  
2 (1) that the necessity for the request arose in the course of  
3 trial; could not reasonably have been anticipated prior to trial  
4 from the pleadings, discovery or nature of the action; and the  
5 request for such additional instructions is presented to the  
6 court as promptly as possible; or (2) that the refusal to give  
7 such instructions would constitute plain error.

8           Likewise, any objections to proposed instructions not  
9 made in accordance with this Order will be overruled as untimely  
10 unless it is shown either: (1) that the grounds therefor arose  
11 in the course of trial and the intention to make such objections  
12 is communicated to the court as promptly as possible, or (2) that  
13 the giving of such instructions would constitute plain error.

#### 14           IV. Voir Dire Questions

15           No later than fourteen days before the trial date,  
16 counsel for each party shall submit all proposed jury voir dire  
17 questions.

#### 18           V. Trial Briefs/Motions in Limine

19           No later than fourteen days before the trial date, each  
20 party shall file trial briefs, which shall include any  
21 additional<sup>1</sup> motions in limine, pursuant to Local Rule 285. No  
22

---

23           <sup>1</sup> The parties have already filed numerous motions in  
24 limine. (See Docket Nos. 54, 68, 71, 74, 76, 79, 84, 87, 89, 91,  
25 and 162.) Many of these motions relate to experts. As the court  
26 previously ordered following the initial Pretrial Conference,  
27 "[a]ny challenges to proffered expert testimony based on Daubert  
28 v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and  
Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999), shall be  
raised and resolved outside the presence of the jury just prior  
to when the challenged expert will be called to give testimony.  
Any challenged expert shall be present for such a challenge, and  
shall be available for questioning." (Feb. 8, 2011, Order at

1 later than seven days before trial, the parties may file  
2 oppositions, if any, to the motions in limine.

3 VI. Remaining Claims

4 The remaining claims for trial are (1) strict  
5 liability, (2) negligence, (3) negligent failure to warn, and (4)  
6 breach of implied warranty of fitness for purpose.

7 VII. Witnesses

8 (A) Plaintiff anticipates calling the witnesses  
9 identified at Exhibit "A" attached hereto. Plaintiff states that  
10 this list includes "'Case Wide' witnesses who may be called in  
11 person or (more likely) by video-tape deposition." (Pl.'s  
12 Amended Pretrial Statement at 11 (Docket No. 169).)

13 (B) Defendant anticipates calling the witnesses  
14 identified at Exhibit "B" attached hereto. Defendant's list  
15 includes witnesses that it "expects" to call or "may" call.

16 (C) Except for retained experts, each party may call  
17 any witness designated by any other party.

18 (D) No other witnesses will be permitted to testify at  
19 trial unless:

20 (1) all parties stipulate that the witness may  
21 testify;

22 (2) the party offering the witness demonstrates  
23 that the witness is for the purpose of rebutting evidence which  
24 could not have been reasonably anticipated at the time of the  
25 Pretrial Conference; or

26 \_\_\_\_\_  
27 2:5-12 (Docket No. 166).) The court also "informed counsel that  
28 it is disinclined to decide defendant's motions with respect to  
punitive damages and recovery of the cost of the drug prior to  
trial." (Id. at 2:3-5.)

1 (3) the witness was discovered after the Pretrial  
2 Conference.

3 (E) Testimony of a witness not designated in this  
4 Order, which is offered under paragraph VII(D)(3), above, upon  
5 the grounds that the witness was discovered after the Pretrial  
6 Conference, will not be permitted unless:

7 (1) the testimony of the witness could not  
8 reasonably have been discovered prior to the Pretrial Conference;

9 (2) the court and opposing counsel were promptly  
10 notified upon discovery of the testimony; and

11 (3) counsel proffered the witness for deposition  
12 if time permitted or provided the opposing counsel a reasonable  
13 summary of the testimony if time did not permit a deposition.

14 VIII. Exhibits

15 (A) Plaintiff intends to offer the exhibits identified  
16 at Exhibit "C" attached hereto. Exhibit C includes a list of  
17 "Case Wide" exhibits, "White specific" exhibits, and learned  
18 treatises.

19 (B) Defendant intends to offer the exhibits identified  
20 at Exhibit "D" attached hereto.

21 (C) Each party may offer any exhibit designated by any  
22 other party.

23 (D) No other exhibits will be received in evidence  
24 unless:

25 (1) all parties stipulate that the exhibit may be  
26 received in evidence;

27 (2) the party offering the exhibit demonstrates  
28 that the exhibit is for the purpose of rebutting evidence which

1 could not have been reasonably anticipated at the time of the  
2 Pretrial Conference; or

3 (3) the exhibit was discovered after the Pretrial  
4 Conference.

5 (E) An exhibit not designated in this Order, which is  
6 offered under paragraph VIII(D)(3), above, upon the grounds that  
7 the exhibit was discovered after the Pretrial Conference, will  
8 not be received in evidence unless:

9 (1) the exhibit could not reasonably have been  
10 discovered prior to the Pretrial Conference;

11 (2) the court and the opposing counsel were  
12 promptly notified upon discovery of the exhibit; and

13 (3) counsel provided copies of the exhibit to the  
14 opposing counsel if physically possible or made the exhibit  
15 reasonably available for inspection by the opposing counsel if  
16 copying was not physically possible.

17 (F) Each party shall exchange copies of all exhibits  
18 identified in this Order, or make them reasonably available for  
19 inspection by the other party, no later than seven calendar days  
20 before the trial date. Any and all objections to such exhibits  
21 shall be filed and served not later than four calendar days  
22 before the trial date.

23 (G) The attorney for each party is directed to appear  
24 before trial and present an original (and if physically possible  
25 one copy) of each exhibit to Deputy Clerk Karen Kirksey Smith at  
26 8:30 a.m. on the date of trial.

27 (H) Each exhibit which has been designated in this  
28 Order and presented on the morning of the date of trial shall be

1 pre-marked by counsel. Plaintiff's exhibits shall bear numbers;  
2 defendant's exhibits shall bear letters. If no objection has  
3 been made to such exhibit pursuant to paragraph VIII(F), above,  
4 such exhibit will require no further foundation and will be  
5 received in evidence upon the motion of any party at trial.

6 IX. Further Discovery and Motions

7 No further motions shall be brought before trial except  
8 upon order of the court and upon a showing of manifest injustice.  
9 Fed. R. Civ. P. 16(e). No further discovery will be permitted  
10 except by the express stipulation of all parties or upon order of  
11 the court and upon a showing of manifest injustice. Id.

12 X. Use of Depositions or Interrogatories

13 No later than twenty calendar days before the trial  
14 date, counsel for each party shall file and serve a statement  
15 designating all answers to interrogatories and all portions of  
16 depositions intended to be offered or read into evidence, with  
17 the exception of portions to be used only for impeachment or  
18 rebuttal. No later than ten calendar days before the trial date,  
19 counsel for the opposing party may file and serve a  
20 counter-designation of other portions of the same depositions  
21 intended to be offered or read into evidence and may file  
22 evidentiary objections to the other parties' designation. No  
23 later than seven calendar days before the trial date, the parties  
24 may file evidentiary objections to the opposing party's  
25 counter-designation.

26 XI. Date and Length of Trial

27 The trial is set for October 4, 2011, at 9:00 a.m. in  
28 Courtroom No. 5. Both sides estimate that the jury trial will

1 last 10 to 13 court days.

2 XII. Evidence Presentation Equipment

3 The court has new technical equipment, but may not have  
4 all of the "state-of-the-art" audio visual equipment and may not  
5 have support personnel necessary for the effective presentation  
6 of evidence by electronic means. If any party feels that  
7 electronic presentation is necessary, they should contact the  
8 Courtroom Deputy prior to trial to determine what equipment the  
9 court has and how to use that equipment or bring their own audio  
10 visual equipment to the courtroom and be prepared to operate it  
11 themselves.

12 XIII. Settlement Conference

13 A Settlement Conference is set before Magistrate Judge  
14 Dale Drozd at 10:00 a.m. on September 22, 2011.

15 Each party is ordered to have a principal with full  
16 settlement authority present at the conference or be fully  
17 authorized to settle the matter on any terms. No later than  
18 seven days before the date of the Settlement Conference, each  
19 party shall submit a confidential Settlement Conference Statement  
20 to the settlement judge. Such statements shall not be filed, but  
21 shall be delivered to the chambers of the settlement judge, in  
22 hard copy.

23 XIV. Objections to Pretrial Order

24 Any objections or suggested modifications to this  
25 Pretrial Order shall be filed and served within five court days  
26 from the file-stamped date of this Order. All references herein  
27 to the date of this Order shall refer to the date the tentative  
28 order is filed and not to the date any amended order is filed.



1 If no objections or modifications are made, this Order will  
2 become final without further order of the court and shall control  
3 the subsequent course of the action, pursuant to Rule 16(e) of  
4 the Federal Rules of Civil Procedure.

5 DATED: August 24, 2011

6 

7 WILLIAM B. SHUBB  
8 UNITED STATES DISTRICT JUDGE  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Exhibit "A": Plaintiff's Witnesses<sup>2</sup>

1. Cheryl White
2. Elliott White
3. Guy Acheson
4. Angela Davies
5. Catherine Alexis Friedman
6. Dr. Richard Jackson\*
7. Lauren Jenkins
8. John MacMillan
9. Jon Overholt
10. Carol Richman
11. Robin Robillard
12. Michael Tanaka
13. Talib Najjar, D.D.S.\*
14. Robert Marx\*
15. Suzanne Parisian\*
16. Wayne Ray, Ph.D.\*
17. Katalin Csermak-Renner
18. Deborah Dunsire
19. Stefano Fratarcangeli
20. Carsten Goessl
21. Jonathan Green
22. Yong Hei
23. Regina Landesberg
24. Margaret Linguri (Dean)
25. Diogini Maladorno

---

<sup>2</sup> An asterisk indicates an expert witness.

- 1           26. Robin Konecne Sterner
- 2           27. Peter Tarassoff
- 3           28. Stephanie Petrone
- 4           29. Rainer Boehm
- 5           30. David Epstein
- 6           31. Joanne Machalaba
- 7           32. Emily Chee
- 8           33. Katarzyna Sablinska
- 9           34. Linda Weiss
- 10          35. Any Custodian of Records needed to authenticate a  
11           document objected to by Defendant.
- 12          36. All persons for whom a deposition designation has been  
13           submitted.
- 14          37. Any person named on Defendant's witness list.

1 Exhibit "B": Defendant's Witnesses

2 Witnesses NPC "Expects" to Call:

- 3 1. Guy Acheson, D.D.S. (Fact Witness; Non-Retained Expert  
4 to the Extent Designated in NPC's Designation of  
5 Non-Retained Experts)  
6 American River Dental  
7 10350 Coloma Road  
8 Rancho Cordova, CA 95670
- 9 2. Janet Arrowsmith, M.D. (Retained NPC Expert)  
10 185 Eagle Creek Canyon  
11 Ruidoso, NM 88345
- 12 3. Warren Browner, M.D. (Retained NPC Expert)  
13 2351 Clay Street, 7th Floor  
14 San Francisco, CA 94115
- 15 4. Angela Davies, M.D. (Fact Witness; Non-Retained Expert  
16 to the Extent Designated in NPC's Designation of  
17 Non-Retained Experts)  
18 OSI Pharmaceuticals  
19 2860 Wilderness Place  
20 Boulder, CO 80301
- 21 5. Margaret Dean (Fact Witness)  
22 Novartis Pharmaceuticals Corporation  
23 1 Health Plaza  
24 East Hanover, NJ 07936
- 25 6. Deborah Dunsire, M.D. (Fact Witness)  
26 8 Highmeadow Road  
27 Weston, MA 02493
- 28 7. David Ettinger, M.D. (Retained NPC Expert)  
The Johns Hopkins University School of Medicine  
401 North Broadway, Suite 1440  
Baltimore, MD 21231
8. Alan Felsenfeld, D.D.S. (Retained NPC Expert)  
UCLA School of Dentistry  
43-085 Le Conte Avenue  
Los Angeles, CA 90095
9. Carsten Goessl (Fact Witness)  
2683 Night Jasmine Drive  
Simi Valley, CA 93065
10. Jonathan Green, Ph.D. (Fact Witness)  
Can Be Reached Through NPC Counsel at:  
1350 I Street, NW  
Washington, DC 20005
11. John MacMillan, Jr., M.D. (Fact Witness; Non-Retained

- 1 Expert to the Extent Designated in NPC's Designation of  
2 Non-Retained Experts)  
3 UC Davis Medical Center  
4 2315 Stockton Blvd.  
5 Sacramento, CA 95817
- 6 12. Dionigi Maladorno, M.D. (Fact Witness)  
7 Novartis Pharmaceuticals Corporation  
8 1 Health Plaza  
9 East Hanover, NJ 07936
- 10 13. Lynne McGrath, Ph.D. (Fact Witness)  
11 Novartis Pharmaceuticals Corporation  
12 180 Park Avenue, Building 105  
13 Florham Park, NJ 07932
- 14 14. Jon Overholt, M.D. (Fact Witness; Non-Retained Expert  
15 to the Extent Designated in NPC's Designation of  
16 Non-Retained Experts)  
17 4614 New York Avenue  
18 Fair Oaks, CA 95628
- 19 15. AnneMarie Petraglia, Pharm.D. (Fact Witness)  
20 55 Challenger Row  
21 Ridgefield Park, NJ 07660
- 22 16. Stephanie Petrone (Fact Witness)  
23 Novartis Pharmaceuticals Corporation  
24 1 Health Plaza  
25 East Hanover, NJ 07936
- 26 17. Brian Royse, D.D.S. (Retained NPC Expert)  
27 Davis Oral Surgery  
28 2035 Lyndell Terrace, Suite 110  
Davis, CA 95616
18. Graham Russell, M.D. (Retained NPC Expert)  
20 Feilden Grove Headington  
Oxford, United Kingdom OX3 0DU
19. Katarzyna Sablinska, Ph.D. (Fact Witness)  
Novartis Pharmaceuticals Corporation  
1 Health Plaza  
East Hanover, NJ 07936
20. Nicholas Sauter, M.D. (Fact Witness)  
Novartis Pharmaceuticals Corporation  
1 Health Plaza  
East Hanover, NJ 07936
21. Robert Spaet (Fact Witness)  
Novartis Pharmaceuticals Corporation  
1 Health Plaza  
East Hanover, NJ 07936
22. Michael Tanaka, M.D. (Fact Witness; Non-Retained Expert

1 to the Extent Designated in NPC's Designation of  
2 Non-Retained Experts)  
3 UC Davis Cancer Center  
4 4501 X Street, Suite 3016  
5 Sacramento, CA 95817

- 6
- 7 23. Diane Young, M.D. (Fact Witness)  
8 Novartis Pharmaceuticals Corporation  
9 1 Health Plaza  
10 East Hanover, NJ 07936

11 Witnesses NPC "May" Call:

- 12
- 13 1. Ephraim Abam (Fact Witness)  
14 Novartis Pharmaceuticals Corporation  
15 1 Health Plaza  
16 East Hanover, NJ 07936
- 17
- 18 2. Raymond Aguilar (Fact Witness)  
19 Can Be Reached Through NPC's Counsel at:  
20 1350 I Street, NW  
21 Washington, DC 20005
- 22
- 23 3. Gordon Douglass, D.D.S. (Fact Witness)  
24 3960 El Camino Avenue  
25 Sacramento, CA 95821
- 26
- 27 4. David Epstein (Fact Witness)  
28 Novartis AG  
CH-4002 Basel  
Switzerland
5. Stefano Fratarcangeli (Fact Witness)  
Novartis Pharmaceuticals Corporation  
1 Health Plaza  
East Hanover, NJ 07936
6. Yong Hei, M.D., Ph.D. (Fact Witness)  
Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, CA 91320
7. John Hohneker, M.D. (Fact Witness)  
Novartis Pharmaceuticals Corporation  
1 Health Plaza  
East Hanover, NJ 07936
8. Richard Jackson, D.D.S. (Fact Witness)  
Jackson, Heise & Alpha Oral and Maxillofacial Surgery  
2525 K Street, Suite 101  
Sacramento, CA 95816
9. Jagdish Lallian (Fact Witness)  
UC Davis Health System

1 4900 Broadway  
2 Sacramento, CA 95820

3 10. Susan MacCharles (Fact Witness)  
4 Can Be Reached Through NPC's Counsel at:  
5 1350 I Street, NW  
6 Washington, DC 20005

7 11. Robert Miranda (Fact Witness)  
8 Novartis Pharmaceuticals Corporation  
9 1 Health Plaza  
10 East Hanover, NJ 07936

11 12. Talib Najjar, D.M.D. (Retained Plaintiff's Expert)  
12 University of Medicine and Dentistry of New Jersey  
13 110 Bergen Street  
14 Newark, NJ 07103

15 13. Sharon Pfeiffer (Fact Witness)  
16 UC Davis Health System  
17 4900 Broadway  
18 Sacramento, CA 95820

19 14. Salvatore Ruggiero, D.M.D., M.D. (Fact Witness)  
20 The New York Center for Orthognathic & Maxillofacial  
21 Surgery  
22 474 Montauk Highway  
23 West Islip, NY 11795

24 15. Michael Scott (Fact Witness)  
25 1305 Blackberry Court  
26 Libertyville, IL 60048

27 16. Robyn Sterner, Pharm.D. (Fact Witness)  
28 920 Route 202  
Raritan, NJ 08869

17. Peter Tarassoff, M.D. (Fact Witness)  
12 Knights Bridge Drive  
Randolph, NJ 07869

18. Brina Wright (Fact Witness)  
Can Be Reached Through NPC's Counsel at:  
1350 I Street, NW  
Washington, DC 20005

19. All persons for whom a deposition designation has been  
submitted.

20. Any Custodian of Records needed to authenticate a  
document objected to by plaintiff.

21. Any person named on Plaintiff's Witness List.

Exhibit "C": Plaintiff's Exhibits

Plaintiff's "Case Wide" Exhibits

Pl. Exhibit No.	Date	FROM	TO	SUBJECT	Author	Title
PX-5000	4/19/2005	Young	Cook, Dunsire, Hei and others	Email Subject: Urgent Review of Pharmacist's letter review on ONJ due 4/21 for Aredia/Zomet a		
PX-5001	8/4/2005	Lantw icki	Mounier, Cook, Csermak-Renner and others	Dear Dentist Letter Market Research		
PX-5002	4/4/2003	Boehm	Kamal, Machalaba, Miranda and others	Zometa Team Receives an honorable mention at the 2002 Global Pharma Team Award		
PX-5003	2007				Boehm	Q1 2007 Rainer video Podcast to US Organization
PX-5004	8/8/2005	Kouko uras	Boehm, Vanditti, Midwinter and others	Dear Dentist Letter Study-Market Reaearch Summary		
PX-5005	11/8/2005	Nieba nck	Boehm	Zometa IPT Objectives 2006		
PX-5006	11/21/2006					Transmitt al of Advertise ments and Promotion al Labeling for Drugs and Biologics for Human Use



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5007	11/21/2006					Reprofile Form 3, Reprofile Form 2, PRM Reprofile Forms Form, BBH Segment D Dr. Disc Guide ENG/STAG, BBH Segment D Dr. Disk Guide Discouraged
PX-5008	2006					Better Bone Health Doctor Discussion Guide
PX-5009	12/31/2007					Interactive Marketing
PX-5010	11/24/2003	Miranda	Goessl, Dunsire, Maladorno and others	Zometa New PI available (osteonecrosis)		
PX-5011	7/7/2004	Dunsire	Orloff	Re: FDA Response to Osteonecrosis labeling-Zometa and Aredia		
PX-5012	10/20/2004	Caminis	Dunsire	RE: Meeting with Sol Epstein-Brief Summary		
PX-5013	12/12/2004	Caminis	Maladorno	Re: Draft ONJ working for the next due Aredia Periodic Report- Team Review requested		
PX-5014	2001					Zometa and Aredia National IMS DDD 1996-2001
PX-5015	2006					Units by State 2002-2006

PX-5016	2006					Units by State 2002-2006
PX-5017	2/2/2004					Sales Force Strategy Assessment
PX-5018	11/16/2004	Chee	Brand	Zometa Targeting Project		
PX-5019	12/6/2004	Venditti	Johnson, Dernaree, Linguri and others	October Sales contest results		
PX-5020	12/15/2005					Zoledronic Acid Issue-Management [ZIM] Face to Face Meeting Summary
PX-5021	6/27/2003	Cook	Epstein, Dunsire, Young and others	Final Osteonecrosis Communication Strategy		
PX-5022	6/27/2003					Zometa, Osteonecrosis and Bisphosphonate Therapy, Communication Strategy, Global Version
PX-5023	7/7/2003	Fratarcangeli	Goldfarb, Konecne and others	Osteonecrosis Mini-NEM		
PX-5024	7/8/2003					Kick-Off Meeting, Novartis Emergency Management Team

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5025	7/30/2003					Revised Draft for Approval, Standby Statement, Osteonecrosis and Bisphosphonate Therapy, July 30, 2003
PX-5026	2/20/2004		All Investigators Participating in Zoledronic Acid Studies	Re: Investigator Alert- Informed Consent of Case Reports of Osteonecrosis		
PX-5027	2/20/2004		All Investigators Participating in Zoledronic Acid Studies	Re: Investigator Alert- Informed Consent of Case Reports of Osteonecrosis		
PX-5028	2/20/2004					
PX-5029	3/8/2004		Zometa Investigators			
PX-5030	3/9/2004	Bock	Cook and others	Re: Osteonecrosis of the Jaws Informed Consent Change-Final NEM Team Approved Documents		
PX-5031	5/12/2004	Cook	Petraglia	Communications document		
PX-5032	7/8/2004	Dunsire	Petraglia, Goessl, Maladorno and others	Revised Materials for response to the FDA		
PX-5033	9/2004					Taking Care of Yourself While Living With Cancer

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5034	6/14/2005	Cook	Sablinska	Re; FW: media.nejm.org Table of Contents		
PX-5035	1/13/2003	Csermak-Renner	Hei	Osteonecrosis of the jaw- Zometa and Aredia		
PX-5036	2/3/2003	Csermak-Renner	Hei	Re: Osteonecrosis of the jaw- Zometa and Aredia		
PX-5037	3/14/2003	Maladorno	Csermak-Renner, Bess, Close and others	Aredia FDA call-Osteonecrosis		
PX-5038	7/10/2003	Goessel	Hei	FYI		
PX-5039	12/2003				Maladorno, Close, Csermak	Zometa, Aredia, Osteonecrosis of the maxillofacial region
PX-5040	12/1/2003	Csermak-Renner	Malsdorno	Re: San Antonio Osteonecrosis meeting-Draft Slides		
PX-5041	6/3/2004	Csermak-Renner	Malsdorno	:cases of osteonecrosis of maxillofacial area of novartis argus database excluding aredia and zometa		
PX-5042	9/8/2005	Csermak-Renner	Sablinska	Re: registry study		
PX-5043	1/19/2006	Csermak-Renner	Sauter	Re: Agenda for ONJ Weekly Guidelines Meeting Jan 19		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5044	2/11/2006				Csermak	Spontaneous Reporting of ONJ in the Novartis Safety Database
PX-5045	2/14/2006	Csermak-Renner	Close, Wever, Maladorno, and others	Aclasta/Zometa ONJ Advisory Board-Preliminary summary		
PX-5046	6/10/2003	Fratarcangeli	Dunsire	Re: Issues Management		
PX-5047	7/14/2003					NEM Meeting #3
PX-5048	8/7/2003					NEM Meeting #9
PX-5049	9/15/2003					NEM Minutes
PX-5050	11/10/2003	Dunsire	Epstein, Young, Hage and others	Zometa NEM Update		
PX-5051	4/2/2004	Weiss	Petraglia, Goessl, Dunsire and others	Minutes for NEM Meeting * March 31 2004		
PX-5052	4/26/2004	Tarasoff	Dunsire, Fratarcangeli	Teleconference with Dr. Schwartz		
PX-5053	5/3/2004	Dunsire	Epstein, Young, Hage and others	Osteonecrosis NEM update		
PX-5054	5/12/2004	Weiss	Petraglia, Goessl, Dunsire and others	Minutes for NEM Meeting * May 10 2004		
PX-5055	5/10/2004	Dunsire	Epstein, Young, Hage and others	Update on Zometa Osteonecrosis of the Jaws (attachments)		

PX-5056	5/23/2004	Dunsire	Burke, Young, Bock, Hohneker	Revision of Action Plan for Zometa Briefing Package		
PX-5057	5/26/2004					Minutes of Zometa NEM Meeting 5/26/04
PX-5058	7/9/2004	Dunsire	Graves, Epstein, Reinhardt and others	Re: Time Sensitive Revised materials for response to the FDA		
PX-5059	8/17/2004					NEM Minutes
PX-5060	9/17/2004	Dunsire	Tarassoff	Re: Conversation with Dr. Marx		
PX-5061	11/22/2004	Dunsire	Gorsky, Epstein, Young and others	No Subject (Dear Management Colleagues)		
PX-5062	12/3/2004	Dunsire	Gorsky, Epstein, Young and others	Re: NEM Update on ONJ and ASH		
PX-5063	9/2/2004	Kirchoff	Dunsire	Re: NEM Basel members recognition		
PX-5064	12/16/2009					Declaration of David R. Epstein
PX-5065	1/29/2003	Epstein	Reinhardt	Zoledronic acid/Zometa closing-sticking with the IMB approved strategy-issue in Japan?		
PX-5066	5/1/2003	Epstein	Burke	Osteonecrosis		Zometa SRs Feb 9, 2003
PX-5067	5/2/2003	Fratarcangeli	Maladorno, Stone, Linguri and others	Osteonecrosis: Follow-up to today's teleconference		

PX-5068	5/5/2003	Fratarcangeli	Epstein, Boehm, Guidi and others	Osteonecrosis- Follow-up		
PX-5069	5/8/2003	Epstein	Ebeling	Update		
PX-5070	6/9/2003	Epstein	Fratarcangeli	Re: Issues Management		
PX-5071	6/10/2003	Epstein	Ebeling	Zometa		
PX-5072	6/10/2003	Epstein	Burke	Re: Zometa		
PX-5073	6/10/2003	Dunsire	Fratarcangeli	Re: Issues Management		
PX-5074	6/27/2003	Epstein	Vasella	(No Subject) Background on reports of Osteonecrosis of the Jaw		Background Information - Evaluation- Steps being taken- Osteonecrosis of the Jaw (ON)
PX-5075	6/29/2003	Epstein	Vasella	Osteonecrosis Q & A As promised		Osteonecrosis and Bisphosphonate Therapy Communication Strategy, Zometa, Global Version, 27 June, 2003, For Internal Use Only
PX-5076	7/4/2003	Dunsire	Epstein	Mini NEM		
PX-5077	7/7/2003	Epstein	Fratarcangeli	Draft		
PX-5078	7/8/2003	Epstein	Dunsire	Internal Speakers		

	7/8/2003					Kick Off Meeting Novartis Emergency Management Team July 8, 2003
PX-5079						
PX-5080	7/8/2003	Dunsire	Machalaba	Re: Zometa websites vs Avonex.com		
PX-5081	9/2/2003	Epstein	Vasella	Zometa Letters		
PX-5082	10/15/2003	Epstein	Ebeling	Zometa Mini NEM Update		Novartis Emergency Management Team Meeting Minutes, October 1, 2003
PX-5083	1/16/2004	Epstein	Hendricks	FY/Q4 2003 Investor Relations Backgrounder /Consensus/Q & A		
PX-5084	1/12/2004	Fratarelli	Dunsire	Pharma Award Nomination		
PX-5085	2/3/2004	Epstein	Vasella	Re: Zometa NEM Update		
PX-5086	3/3/2004	Dunsire	Epstein, Burke	Re; Questions for Mr. Reinhardt-srooy- one question in green was missing		
PX-5087	5/13/2004	Epstein	Reinhardt	Urgent-FDA Request for meeting on Osteonecrosis reports with Zometa and Aredia		
PX-5088	5/17/2004	Epstein	Vasella	(No Subject) See attached update on Osteonecrosis		
PX-5089	6/17/2004	Epstein	Vasella	FYI		



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5090	7/15/2004	Epstein	Ebeling	Zometa:FDA Meeting ONJ (July 15, 04)		
PX-5091	7/22/2004	Epstein	Ebeling	Summary of discussion with J. Reinhardt regarding the coordination of Zometa and Zoledronic acid related activities		
PX-5092	8/4/2004	Epstein	Dunsire	Re: NEM Update : FDA Labeling outcome on ONJ		
PX-5093	9/23/2004	Burke	Epstein	today's discussion		
PX-5094	11/11/2004	Hoppe not	Epstein	FDA Response-Zometa Revised PI Submitted 10-29-04		
PX-5095	12/16/2004	Dunsire	Ebeling	Short summary ONJ		ONJ Overview 16 December, 2004
PX-5096	12/22/2004	Epstein	Reinhardt	MDACC-Retrospective study on ONJ		
PX-5097	12/23/2004	Epstein	Reinhardt, Ebeling	Re: ODAC		
PX-5098	2/3/2005	Epstein	Ebeling	For you information -ONJ Reply of Prof. Samson	Jacky Samson	Bisphosphonates and Osteonecrosis of the Jaw
PX-5099	2/22/2005	Epstein	Ebeling	FDA Mtg. Zometa ODAC		
PX-5100	3/5/2005	Ebeling	Hukkelhoven	Re: Today's FDA Advisory Committee meeting on Zometa and aredia		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5101	5/9/2005	Epstein	Ebeling	Re: Update of Dentists		Dear Dentist Letter
PX-5102	5/9/2005	Epstein	Campbell	Re: interested in a rehearsal pre-ASCO analyst call?		
PX-5103	6/8/2005	Epstein	Reinhardt, Ebeling	NEJM Update		
PX-5104	7/4/2005	Vasella	Epstein	Re; Fw; NEJM Correspondence on ONJ to be published next week		
PX-5105	8/3/2005	Campbell	Mallik, Ebeling	Specialty Medicines BoD submissions for your advance review	David Epstein	Novartis Specialty Strategic Plan 2005-2010, Presentation to Board of Directors
PX-5106	9/27/2005	Lantwickski	Altmeyer, Filipovic, Mounier and others	Re: meeting w/ David Epstein to Discuss ONJ-Confirmed		
PX-5107	10/2/2005	Sauter	Lantwickski	Re: Outcome of the Friday Update to David Epstein		
PX-5108	2006					2006 Budget Risks and Opportunities
PX-5109	12/7/2005	Epstein	Celera	ZIM		
PX-5110	2/23/2006	Kincaid	Engelhardt	Re: urgent - Epstein Business review		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5111	8/11/2006	Epstein	Ebeling	Mayo clinic has issued press release on consensus statement on Bisphosphonates in Myeloma	Mayo Clinic	Mayo Clinic: New recommendations for use of bisphosphonates in treatment of multiple myeloma
PX-5112	2/20/2007	Epstein	Boehm	Re: US Points for the MM on February 21		
PX-5113	3/29/2007	Epstein	Pizytulski	2007 Zometa Plan.ppt		
PX-5114	4/11/2007	Epstein	Vasella	Oncology Global ESR-March 07		
PX-5115	4/16/2007					Zometa Turnaround Plan beginning with ZAED-01701480
PX-5116	5/17/2007	Volante	Epstein	Re;FW: Urgent response needed: FDA revised Plan Label21386 Zometa PI-FDA Version		
PX-5117	7/8/2008	Epstein	Lehrer	Re: treatment for Zometa induced ONJ		Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws
PX-5118	2/17/2009	Epstein	Jimenez	Fw; Alert: JAMA letter on Bisphosphonate Safety this week	Kuehn	Long-Term Risks of Bisphosphonates Probed

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5119	1/24/2007	Kamal	Potter, DiTrapani	Fw: Final minutes- PMB Meeting January 15 2007	Kamal	
PX-5120	10/28/2004					Promotional Material/ Zometa Label, Novartis Oncology WebSite Pages
PX-5121	4/30/2003	Fratarcangeli	Maladorno, Stone, Linguri and others	Osteonecrosis: Follow-up to today's teleconference		
PX-5122	5/5/2003	Fratarcangeli	Epstein, Boehm, Guidi and others	Osteonecrosis Follow-up		
PX-5123	5/27/2003	Linguri	Zometa Team	Osteonecrosis		
PX-5124	6/10/2003	Dunsire	Fratarcangeli	Re: Issues Management		
PX-5125	7/7/2003	Fratarcangeli	Goldfarb, Konecne, Csermak-Renner and others	Osteonecrosis Mini NEM		
PX-5126	11/18/2003	Fratarcangeli	Brant-e	Re: invitation letters for faculty and Novartis attendees of Novartis Osteonecrosis Ad Board		
PX-5127	11/20/2003	Fratarcangeli	Brant-e	Invitation letters for faculty and Novartis attendees of Novartis Osteonecrosis Ad Board		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5128	11/25/2003	Fratarcangeli	Brant-e	Invitation letters for faculty and Novartis attendees of Novartis Osteonecrosis Ad Board		
PX-5129	12/5/2003					Advisory Board Agenda
PX-5130	12/5/2003					Novartis Advisory Board Executive Summary Dec 5, 2003
PX-5131	12/19/2003	McCormick	Fratarcangeli, Linguri	RE: Executive Summary		
PX-5132	1/18/2004	Sam Klein	Debbie			
PX-5133	5/1/2003	Maladorno	Abarn, Curtis, Meyer and others	Product team feedback-Aredia and osteonecrosis		
PX-5134	1/7/2004	Fratarcangeli	hlousek-h	Re Fw Executive Summary		
PX-5135	12/28/2003	Spaet	Hei	Update on Zometa Osteonecrosis Advisory Board		
PX-5136	2/20/2004	Dunsire	Goessl, Maladorno, Cook and others	Dr. Berenson		
PX-5137	5/3/2004	Fratarcangeli	Hei	Re ON issue in AZURE Trial Newsletter April 2004		
PX-5138	6/1/2004	Fratarcangeli	Linguri, stefanidou, Fabiani and others	Zometa Brand Review at the June 24 MMB		
PX-5139	7/14/2004	Dunsire	Gorsky, Epstein, Young and others	Osteonecrosis of the jaw Update		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5140	6/17/2004	Goldfarb	Petraglia	FDA Briefing-Privileged and confidential Attorney Work Product		
PX-5141	10/28/2004					Medical Marketing Meeting : Zoledronic Acid Medical Marketing Meeting in Vienna, Austria.
PX-5142	6/21/2010					CV
PX-5143	6/20/2003	Goessl	Hei, Fratarcangeli	ON		
PX-5144	7/8/2003					Kick-Off Meeting Novartis Emergency Management Team, July 8, 2003
PX-5145	10/8/2003	Goessl	Maladorno	Re: Osteonecrosis: Draft Aredia Expert Report for team review		
PX-5146	7/10/2003	Goessl	Hei	FYI		
PX-5147	10/13/2003	Goessl	Urbanowitz	Re: IB Zometa		
PX-5148	5/12/2004	Goessl	Weiss	Re: Minutes for NEM Meeting May 10, 2004		Zometa Osteonecrosis/Osteomyelitis Spontaneous Reports (cumulative)
PX-5149	3/31/2004	Goessl	Orloff	Re: Follow-up Osteonecrosis		

PX-5150	7/7/2004	Goessler	Dunsire	Re: FDA Response to Osteonecrosis Labeling Zometa and Aredia		
PX-5151	5/20/2004	Goessler	Maladorno, Tarassoff, Petraglia, Weiss	First Draft of BB 'current status' section		ON-Current Status
PX-5152	8/30/2004	Hei	Hauser, Petraglia, Goessler and others	Re: ONJ Manuscript		
PX-5153	7/8/2004	Dunsire	Petraglia, Goessler, Maladorno and others	Re: FDA Response to Osteonecrosis labeling Zometa and Aredia		
PX-5154	7/18/2003				Sablin ska	Epidemiological Report entitled Osteonecrosis in Cancer Patients
PX-5155	6/21/2004	Petraglia	Pazdur	Briefing Package		
PX-5156	4/5/2008					CV
PX-5157	10/8/2003	Maladorno	Fratarcangeli	Re; Osteonecrosis: draft Aredia Expert Report for team review-Comments from CG and SF		
PX-5158	6/20/2003	Goessler	Hei, Fratarcangeli	ON		
PX-5159	3/12/2004	Ambatlle	Weiss	Re; Reported cases of osteonecrosis		
PX-5160	3/31/2004	Goessler	Orloff	Re Follow Up Osteonecrosis		

1		5/20/2004	Goessl	Maladorno, Tarassoff, Petraglia, Weiss	First draft of BB "current status" section		
2	PX-5161						
3		10/13/2003	Goessl	Urbanowitz	Re; IB Zometa		
4	PX-5162						
5		7/1/2004	Spaet	Linguri, Johnson	Re; Tough questions		
6	PX-5163						
7		7/7/2004	Goessl	Dunsire	Re FDA Response to Osteonecrosis labeling-Zometa and Aredia		
8	PX-5164						
9		7/8/2004	Dunsire	Petraglia, Goessl, Maladorno and others	Re FDA Response to Osteonecrosis labeling-Zometa and Aredia		
10	PX-5165						
11		7/8/2004	Goessl	Petraglia, Dunsire, Maladorno and others	Re Osteonecrosis article from Dr. Bouquot: A Multifactorial Etiology.pdf		
12	PX-5166						
13		5/12/2004	Goessl	Weiss	Re Minutes for NEM Meeting * May 10, 2004		
14	PX-5167						
15		9/24/2004	Dunsire	Maladorno	Re; case details from (redacted)		
16	PX-5168						
17		9/24/2004	Goessl	Schran	Re FDA Response-Urgent input required by noon (US) Sept 24		
18	PX-5169						
19		8/30/2004					Zometa Briefing Book 30-Aug-2004
20	PX-5170						
21		7/16/2004					Zometa Clinical Research and Development Zometa Briefing Book 16-July-2004
22	PX-5171						
23							
24							
25							
26							
27							
28							



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5172	4/23/2003				Zometa International Project Team	Project: ARD233B/ Bone Mets ZOL446D/ HCM ZOL446E/ Treatment Bone Mets ZOL446G/ Prev Bone Mets
PX-5173	6/8/2003	Green	Hei	Re Urgent-Osteonecrosis Situation		
PX-5174	12/1/2003	Linguri	Dunsire, Goessl, Maladorno and others	ON Ad Board Dec 5		
PX-5175	12/2/2005					Advisory Board Executive Summary
PX-5176	5/1981				Jee, Black, Gotcher	Effect of Dichloromethane Diphosphate on Cortisol-Induced Bone Loss in Young Adult Rabbits
PX-5177	1/21/1981				Gotcher and Jee	The Progress of the Periodontal Syndrome in the Rice Rat
PX-5178	1/21/1981				Gotcher, J.E. Jee, W.S.S.	The Progress of the Periodontal Syndrome in the Rice Rat
PX-5179	1/30/2003	Hei	Csermak Renner	Re Osteonecrosis of the jaw- Zometa and Aredia		
PX-5180	6/9/2003	Hei	Bock	Task force for Zometa		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5181	7/23/2003	Hei	Fratarcangeli, Dunsire	Re Zometa & Aredia Letter to Has on Osteonecrosis/ Info to Investigators		
PX-5182	7/30/2003					Revised Draft for Approval, Standby Statement, Osteonecrosis and Bisphosphonate Therapy, July 30, 2003
PX-5183	7/31/2003					NPC - Standby Statement
PX-5184	10/27/2003	Hei	Fratarcangeli, Dunsire	Osteonecrosis - we should add this to informed consent		
PX-5185	4/16/2004	Hei	Murphy	Re Osteonecrosis-clarification for Mr Nigel Parr		
PX-5186	5/12/2004	Hei	Tarassoff, Caminis, Hauser and others	Re Please comment - short White paper		
PX-5187	5/13/2004	Hei	Maladorno	Re FDA Discussion on reports of Osteonecrosis with Zometa and Aredia		
PX-5188	7/8/2004	Dunsire	Petraglia, Goessl, Maladorno, and others	Re FDA response to osteonecrosis labeling Zometa and Aredia		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5189	8/30/2004	Hei	Hauser, Petraglia, Goessl and others	Re ONJ Manuscript		
PX-5190	9/15/2004	Hei	Tarassoff	ONJ abstract.doc		
PX-5191	6/3/2004	Maladorno	Csermak Renner	Osteonecrosis- Treatment duration to AE- Grand Total : caculations		
PX-5192	7/15/2004					Drug Regulatory Affairs, Zometa/ Aredia, Briefing Package
PX-5193	9/24/2004					Dear Doctor Letter
PX-5194	9/24/2004					Dear Doctor Letter
PX-5195	5/5/2005					Dear Dentist Letter
PX-5196	10/25/2005	Scott	Lantwicki	Re AAOMS ONJ Survey		
PX-5197						Documents Landesberg produced pursuant to the subpoena.
PX-5198	1/10/2002	Petrone	Tarassoff, Weiss, Lacerna	Spontaneous report? Osteonecrosis of the jaw		
PX-5199	1/13/2003	Landesberg	Petrone	Spontaneous report? Osteonecrosis of the jaw		
PX-5200	10/21/2005	Slosberg	Hei	Re: Landesberg \$\$		
PX-5201	10/25/2005	Slosberg	Lantwicki	AAOMS ONJ survey		
PX-5202	11/9/2004	Hei	Jung	Re fyi for the team- ONJ related articles		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5203	12/10/2004	Cook	Lantwicky	Re Statement by Kyle on IMF ONJ Survey data		
PX-5204	12/10/2004	Cook	Petraglia, Goessl, Maladorno and others	E-Mail Subject: Statement by Kyle on IMF ONJ Survey data		
PX-5205						Novartis Pharmaceuticals Corporation's Response to Plaintiffs' Steering Committee's Sixth Set of Interrogatories to Defendant
PX-5206						Novartis Pharmaceuticals Corporation's Responses to Plaintiffs' Steering Committee's Second Request for Admission
PX-5207						Novartis Pharmaceuticals Corporation's Responses to Plaintiffs' Steering Committee's Sixth Set of Document Requests

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5208	8/1/2006					Zometa A ONJ Video
PX-5209	5/12/2004	Miranda	Petraglia	Update: Zometa Core Team 5/12		
PX-5210	6/24/2004	McClure	Linguri	RE A quick hello		
PX-5211	6/17/2009					Defendant's Fact Sheet
PX-5212	6/4/2010					Amended Fact Sheet
PX-5213	6/10/2003	Linguri	Fratarcangeli, Tarassoff, Weiss, Machalaba	Email Subject: Issues Management		
PX-5214	6/10/2003	Linguri	Fratarcangeli, Tarassoff, Weiss, Machalaba	Email Subject: Issues Management		
PX-5215	10/29/2003					
PX-5216	11/5/2003	Linguri	Green	Osteonecrosis Ad Board		
PX-5217	11/14/2003	Linguri	Maladorno	Re Draft agenda of the San Antonio meeting - Osteonecrosis		
PX-5218	12/8/2003	Linguri	Venditti, Johnson, Verma, Scrudato, Barninger	Update on Zometa Osteonecrosis Advisory Board		
PX-5219	4/27/2004	Tarassoff	Hohneker	Jim Berenson Call		
PX-5220	6/16/2004					Memo Field Communication
PX-5221	7/1/2004	Linguri	Tarassoff	Re Discussion with Dr. Bouguot		
PX-5222	7/13/2004	Linguri	Gericke	RE Novartis actions		
PX-5223	5/28/2008					CV

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5224	9/1993				CIBA Pharmaceuticals Basle, Switzerland	Investigational Drug Brochure Orientation Data/ Aredia
PX-5225	4/2000				Novartis Pharma Basle, Switzerland	Zometa Study/ Report of Results
PX-5226	5/2000					Zometa: Strategic Plan Executive Summary
PX-5227	8/2000					Zometa: Global Public Relations Plan
PX-5228	8/27/2000				Held	Zometa GTL Aciton Plan/ Follow-up Action Items
PX-5229	4/25/2001					Zometa in Oncology/ Zoledronic Acid in 'benign'
PX-5230	2000					Joint IPT Marketing Presentat ion
PX-5231	4/2005					Zoledronic Acid in Benign Bone- related Indicatio ns / Target Product Profile/ Confident ial

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5232	2/22/2001				Machalaba	Project: ARD233B/ Bone Mets ZOL446D/ HCM ZOL446E/ Treatment Bone Mets ZOL446G/ Prev Bone Mets
PX-5233	12/20/2000					Telecon Minutes
PX-5234	3/21/2001				Arnold, Freund, Machalaba, Shepard	Zometa IPT and Zoledronic Acid IPT
PX-5235	5/31/2001				Machalaba, Seaman, Kamal	Zometa Project Team Meeting Agenda
PX-5236	6/12/2001					Aredia/Zometa PIND Meeting Minutes of June 12, 2001
PX-5237	9/2/2001					Global Communication Plan Brand Summary
PX-5238	11/13/2001					Aredia Workshop
PX-5239	12/11/2001	Hager	Reitsma and Machalaba and others	Email Subject: ODAC Key Messages		
PX-5240	2/15/2002	Held	Machalaba	Email Subject Zoledronic Acid NEJM Proposal and Next Steps		
PX-5241	3/15/2002	Kappel		URGENT/ PIB Meeting: Global labeling changes for Aredia/ Zometa		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5242	3/18/2002	Dunsi re	Machalaba	Email Subject: Zometa/Aredia Labels		
PX-5243	2002				Kamal	Zoledronic Acid Launching the Blockbuster
PX-5244	7/2/2003					Action Plan in Response to Osteonecrosis SAEs Draft for Input and Approval
PX-5245	7/2003				Machalaba and Tarassoff	ASCO 2003 Update Field Communication
PX-5246	7/2003				Machalaba and Tarassoff	ASCO 2003 Update Field Communication
PX-5247	9/20/2002	Machalaba	Gotsche	Email Subject sNDA PI fo discussion in the IPT		
PX-5248	9/29/2001					Zometa: Global Communication Plan 2002
PX-5249	2003					T3-2003 Implementation Guide for Zometa
PX-5250	1/7/2003	Machalaba	Konecne	Email Subject: Proposed Zometa container labeling		
PX-5251	6/17/2003	Dunsi re	Linguri	Email Subject: Issues Management		



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5252	6/26/2003	Mello r	Shepard	Email Subject: Action Requested: Osteonecrosis Letter to Has		
PX-5253	6/26/2003	Machalaba	Dunsire	Email Subject: Revised Draft Osteonecrosis Communications/Standby Statement & Q & A		
PX-5254	7/1/2003					Action Plan in Response to Osteonecrosis SAEs Draft for Approval
PX-5255	7/2/2003	Machalaba	Dunsire, Venditti	Email Subject: Osteonecrosis Action Plan		
PX-5256	7/3/2003	Machalablab	Fratarcangeli, Hei, Tarassoff and others	Email Subject: Dr. Marx- More background & data collection form		
PX-5257	7/3/2003					Osteonecrosis Case Report Data Collection
PX-5258	7/15/2003	Machalaba	Williams	Email Subject: Zometa Osteonecrosis Data Collection Project		Osteonecrosis Case Report Data Collection
PX-5259	7/15/2003					Zometa Mini-NEM Team

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5260	7/16/2003					Minutes from 7/16/2003 NEM Teleconference
PX-5261	11/15/2005	Machalaba	Lantwicki	Email Subject: ZOL ONJ at next DPB		
PX-5262	3/2004					Development Project Board
PX-5263	1/10/2005	Machalaba	Hohneker	Email Subject: Draft DPB Agenda		
PX-5264	7/25/2003	Machalaba	Sablinska	Email Subject: EPI Study of association of osteonecrosis of all sites and bisphosphonates		
PX-5265	7/16/2003					Meeting # 4 (NEM) Novartis Emergency Management Team July 16, 2003
PX-5266	7/22/2003	Hei	Fratarcangeli, Dunsire, Tarassoff, Machalaba	Email Subject: Osteonecrosis - important!		
PX-5267	8/7/2003					Meeting # 9 (NEM) Novartis Emergency Management Team August 7, 2003 October 1, 2003 NEM Meeting Minutes

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5268	11/18/2005	Machalaba	Lantwicki	Email Subject: ZIM Proposal		
PX-5269	1/15/2007					Portfolio Management Board (PMB) January 15, 2007
PX-5270	10/23/2000					Zometa Workshops
PX-5271	1/2001					Joining Forces to Maximize Zoledronic Acid Profitability to Novartis
PX-5272	3/2005				US Health and Human Services, FDA, CDER, CBER	Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
PX-5273	9/2003				Maladorno, Lombardi, Green, Spaet	Aredia, Clinical Expert Statement : Osteonecrosis of the Maxillofacial Area- Spetember 2003 Overview
PX-5274	6/3/2004	Maladorno	Close	:cases of osteonecrosis of maxillofacial area of novartis argus database excluding aredia and zometa		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5275	6/3/2004	Maladorno	Csermak-Renner	Re Osteonecrosis Treatment duration to AE for Aredia only: caculations		
PX-5276	7/2/2002	Tarasoff	Green	Email Subject: A request		
PX-5277	7/16/2002	Green	Ruggiero	Email Subject: Re: Aredia		
PX-5278	12/6/2002	Weiss	Abam	Email Subject: Medical Inquiry 3 females with necrotic bone- breast cancer, Zometa		
PX-5279	1/10/2003	Petro ne	Tarassoff, Weiss, Lacerna	E-mail Subject: Spontaneous report? Osteonecrosis of the jaw		
PX-5280	6/3/2004	Maladorno	Csermak-Renner	Email Subject: Osteonecrosis- Treatment duration to AE- Grand total: Calculations		
PX-5281	3/26/2003	Fratarcangeli	Hei	Email Subject: Phone call to Dr. Schneider from FDA- Aredia and Zometa osteonecrosis cases		
PX-5282	2/9/2005	Kuriger-Kara	Bock, Hei, Altmeyer and others	Email Subject: Novartis Webcast Adivsory Board members Feb 2005		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5283	7/7/2004	Stanten	Miranda	Subject: Zometa Labeling July 7, 2004. FDA submits it proposed revision to NPC's 6/21/2004 labeling re: osteonecrosis		
PX-5284	9/24/2004				Hohneker	Dear Doctor Letter
PX-5285	7/9/2004	Petra glia	FDA	Subject: Zometa Labeling-Osteonecrosis		
PX-5286	7/7/2004	Petra glia	Dunsire	NEM Meeting 7-8-04		
PX-5287	7/8/2004	Garau d	Hukkelhove n	Re; FDA response to osteonecrosis labeling-Zometa and Aredia		
PX-5288	6/21/2004					NPC - briefing Book to FDA
PX-5289	9/2007					Zometa label
PX-5290	10/2/2006				Malado rno	Clinical Developme nt, Zometa, Osteonecr osis of the Jaw (ONJ): Revision of the Class-Labeling Statement Clinical Expert Report

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5291	9/22/2006	McGrath	Justice	Letter: Zometa: General Correspondence, Zometa Post-ODAC Follow-up, Serial No. 357		Updated Recommendations for the Prevention, Diagnosis, , and Treatment of Osteonecrosis of the Jaws in Cancer Patients: May 2006
PX-5292	2/26/2004	Herald	Miranda	Email Subject: Zometa PI (Osteonecrosis) Bouquet Manuscript		Neuropathic Pain in Maxillofacial Osteonecrosis
PX-5293	9/4/2008	Johnston	Germany	Re: Aredia and Zometa Products Liability Litigation., 3:06-MD-1760		
PX-5294	1/5/2004	Janse	Tarassoff, Dunsire, Hei, Mellor, Moran	Email Subject: ONJ HORIZON letter.doc		Osteonecrosis of the Jaw and use of Bisphosphonates Dear HORIZON Investigator
PX-5295	1/28/2004	Novartis	Investigator			Osteonecrosis of the Jaw and use of Bisphosphonates Dear Investigator
PX-5296	10/8/2006	Kriegman	Das	Email Subject: AAOMS Meeting-ONJ Feedback		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5297	10/11/2006					Once-Yearly Zoledronic Acid 5 mg in Postmenopausal Osteoporosis: The HORIZON Pivotal Fracture Trial
PX-5298	11/3/2006				Weitzman and Erikson	ONJ in oncology and non-oncology patients
PX-5299	6/8/2005				Mesenbink	Clinical Development & Medical Affairs, Compound: Zoledronic Acid Maxillofacial Complication Adjudication Committee Charter

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5300	1/3/2007			Safety Update	Grbic, Landesberg	Clinical Development Aclasta/R eclast Injection CZOL446H- Postmenopausal Osteoporosis Special Expert Evaluation Report (SpEER) of maxillofacial adverse events of 5 mg zoledronic acid given once yearly
PX-5301	5/29/2007	Lantwicki	Altmeyer, Maladorno, Eriksen and others	Email Subject: ZOL2301 / Aclasta: ONJ Manuscript - 2nd Draft for ZIM Review		
PX-5302	3/19/2003	Miranda	Konecne	Phone Call to Dr. Schneider from FDA- Aredia and Zometa osteonecrosis cases		
PX-5303	6/11/2003	Konecne	Shepard, Machalaba and others	Urgent Zometa Teleconference Friday June 13		
PX-5304	7/22/2003					NEM Meeting #5
PX-5305	8/7/2003					NEM Meeting #9
PX-5306	9/17/2003	Stern	Mellor and Miranda	Re: zol CTIBL		



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5307	11/27/2003	Miranda	Robertone	Re: Zometa New PI available (re: osteonecrosis)		
PX-5308	2/25/2004	Miranda	Pease	Important: Zometa PI-Revisions to Post Marketing Experience		
PX-5309	2/25/2004	Maladorno	Bess, Close, Csermak Renner	FDA wants to change the Osteonecrosis USPI statement-Zometa		
PX-5310	2/25/2004	Maladorno	Miranda	RE: Important: Zometa PI-Revisions to Post-Marketing Experience		
PX-5311	2/25/2004	Miranda	Dunsire	Zometa PI-Proposed Revised Osteonecrosis Labeling		
PX-5312	2/26/2004	Miranda	Dunsire, Petraglia and others	Response Sent to FDA re: Zometa PI-Revisions to Osteonecrosis labeling		
PX-5313	2/26/2004	Herald	Pease	Zometa PI (Osteonecrosis) Bouquet Manuscript		
PX-5314	6/24/2004	Miranda	Petraglia	Subject: Zometa-Information request and meeting with FDA		
PX-5315	7/7/2004	Pease	Miranda	Zometa Labeling		
PX-5316	2/20/2004	Miranda	Narang	Re: Latest version of Zometa labeling		

PX-5317	12/2/2005	Lynch	Yong, Lantwicki, Johnson and others	ONJ Ad Board Outcomes (very long email)		
PX-5318	11/14/2003	Miranda	Cook	Re Action List from NEM Meeting 11/14/03		
PX-5319	2/25/2004	Miranda	Dunsire	Zometa PI-Proposed Revised Osteonecrosis Labeling		
PX-5320	5/13/2004	Petraglia	Dunsire, Goessl and others	FDA discussion on reports of Osteonecrosis with Zometa and Aredia		
PX-5321	6/23/2004	Frarancangeli	Petraglia, Goessl, Maladorno and others	Call from Dr. Ruggiero		
PX-5322	7/15/2004	Narang	Reinhardt, Shannon, Garaud and others	Zometa: FDA Meeting ONJ [July 15, 04]		
PX-5323	7/16/2004	Maladorno	Bess, Close	Zometa: FDA Meeting ONJ [July 15, 04]		
PX-5324	8/4/2004	Narang	Dunsire, Gorsky, Epstein and others	Re: NEM Update: FDA Labeling Outcome on ONJ		
PX-5325	12/23/2004	Narang	Burke, Hoppenot, Hukkelhove n and others	re: Zometa		
PX-5326	1/5/2005	Dunsire	Baerlocher	Updated Chronology of Zometa label changes		
PX-5327	2/10/2005	Zheng	Hei	Re; Status of searching for ONJ in Aredia trials		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5328	3/1/2005	Hei	Riva, Altmeyer, Narang, Young	Email Subject: Please review- ONJ Registry Study.ppt		Proposed Registry Study
PX-5329	3/31/2005	Petraglia	Hei, Maladorno, Cook and others	Teleconferen ce next week-odac followup		
PX-5330	4/25/2005	Scott	Dunsire, Altmeyer and others	Email Subject: Revised Dear Dentist Letter		Dear Dentist Letter
PX-5331	4/22/2005	FDA	Petralgia			
PX-5332	11/4/2005					Zometa Community Oncology Advisory Board November 4, 2005 Chicago, IL, Exclusively Prepared for Palio Communications
PX-5333	1/2006				Koukouras	Oncology Business Analysis/Qualitative Research
PX-5334	2/22/2006					Zoldronic Acid Issue Management Meeting Core Meeting Notes
PX-5335	3/27/2006	Niebanck	Sauter	Email Subject: MM Meeting		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5336	4/21/2006					Aclasta/ Zometa Osteonecrosis of the Jaw (ONJ) Update IMB April 21, 2006
PX-5337	5/3/2006					Zoldronic Acid Issue Management Face to Face Meeting Notes
PX-5338	6/14/2006	Niebank	Rao	Email Subject: Sci Ops Presentations on ONJ		
PX-5339	6/15/2006	Niebank	Hitchcock	Email Subject: Dental Community (Reclast)		
PX-5340	11/20/2005					Zometa Steering Committee Meeting November 20, 2005
PX-5341	2/28/2007					
PX-5342	11/21/2003					FDA Memorandum
PX-5343	2/25/2004					Zometa PI Proposal Post-Marketing Experience

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5344	2/25/2004	Maladorno	Miranda, Petraglia, Csermak-Renner	Email Subject: IMPORTANT-Zometa PI-Revisions to Post-Marketing Experience		
PX-5345	2/27/2004	Petraglia	Cook and others	E-mail Subject: Letter to non-US Investigators- Informed Consent-Osteonecrosis		
PX-5346	5/11/2004	FDA	Petraglia	IND 55,831 Zoledronate for Injection		
PX-5347	5/20/2004	Petraglia	Goessl, Maladorno, Cook and others	Action Plan-Preparation of Briefing Package for FDA meeting		
PX-5348	5/27/2004	Petraglia	Goessl, Maladorno and others	Email Subject: Zometa Briefing Package-Additional Section		
PX-5349	6/14/2004	Germo				Osteonecrosis of the Jaw-Prevention, Diagnosis and Treatment Information for People living with Cancer

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5350	6/25/2004	Jung	Petraglia, Goessl, Dunsire and others	Zometa ONJ FDA briefing workplan V1.1 25-Jun-04.ppt- Updated Workplan & Key Action Items		
PX-5351	6/30/2004	Petraglia	Tarassoff	Zometa Labeling- Osteonecrosis		
PX-5352	7/8/2004	Orloff	Dunsire	Re; FDA Response to Osteonecrosis Labeling Zometa and Aredia		
PX-5353	7/9/2004	Petraglia	Pease	Zometa Labeling Osteonecrosis		
PX-5354	8/2/2004	Petraglia	Goessl, Maladorno, Cook and others	Zometa- PI and Dear Dr Letter reply- Osteonecrosis		
PX-5355	8/4/2004	Staten	Petraglia	Action Items		
PX-5356	12/23/2004	Maladorno	Narang	Re Draft letter for FDA - overview of MD Anderson study status- feedbackon comments		
PX-5357	1/21/2005	Petraglia	Hei, Maladorno, Cook and others	Bisphosphonates AERS database search		
PX-5358	1/21/2005	Mello	Petraglia	Re; Due Diligence- Risk Minimization Action Plan		
PX-5359	1/27/2005	Petraglia	Maladorno	Sent to FDA 1-26-05		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5360	1/31/2005	Petra glia	Hei, Maladorno, Cook and others	Follow-up to Telecon of 1-27-05 with the Office of Drug Safety		
PX-5361	1/18/2005	Petra glia	Hei, Maladorno, Cook and others	Due Diligence-Risk Minimization Action Plan		
PX-5362	3/30/2005	McCle llan	Gallo, Laties	ZOM-4039 Patient tear Sheet		Healthy steps to protect your bones: brochure
PX-5363						Chart of Clinical Trials
PX-5364	7/3/2001					Clinical Study 010 Volume 1
PX-5365	7/30/1998					Clinical Study 010 Appendix 1
PX-5366	7/30/1998					Clinical Study 010 Volume 2
PX-5367	9/28/1999					Clinical Study IA03
PX-5368	9/2/2002				Seaman , Chen, Dias	Clinical Development Zometa Study No. 42446-03-010 core and extension
PX-5369	9/30/1999					Clinical Development Zometa Study No. 42446-03-010 core and extension Appendix 1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5370	8/16/2006					Protective and Confidentiality Order
PX-5371	5/9/2005	Kroger	Petrone and others	Email Subject: Questions for ZFAST-Additional Information Requested		
PX-5372	7/9/2004	Paramore	Ambros and others	Email Subject: RSA Monthly Reports-June 2004		
PX-5373	8/28/2005	Merlatt-Guitar	Hei	Email Subject: Important-reporting of cases of osteonecrosis of the jaw (ONJ) in clinical trials involving Zometa		
PX-5374	3/16/2004	Tarasoff	Hohneker and others	Email Subject: Osteonecrosis: Zometa		
PX-5375	12/1/2003	Linguri	Verma and others	Email Subject: **Zometa Issues: 15 Nov 2003 JCO**		
PX-5376						Re: A Symposium in San Antonio, Texas
PX-5377	6/10/2005				Petron e	Overview: Zometa in the Treatment of Bone Metastases
PX-5378	3/9/2006					US Business Review-Zometa



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5379	2004					2004 Zometa CTIBL Clinical Strategy
PX-5380	2006					Oncology Business Unit National Meeting US Clinical Developme nts and Medical Affairs
PX-5381	2/23/ 2005	Hei	Petrone and Lacerna	Email Subject Action Required- Zometa Protocol Amendment regarding ONJ and Dose Adjustment		
PX-5382	7/13/ 2005	Hei	Petrone and Lacerna, Weiss and Tarassoff	Email Subject ONJ in ongoing clinical trials		
PX-5383	1/12/ 2004	Hei	McWhorter and others	Email Subject Osteonecrosi s on the jaws- inclusion in patient informed consent?		
PX-5384	1/13/ 2003	Lande sberg	Petrone	Email Subject Spontaneous report? Osteonecrosi s of the jaw		
PX-5385	3/3/2 005	Weiss	Petrone and Tarassoff	Email Subject ONJ descriptive terms?		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5386						Incidence of Adverse Events Regardless of Study Drug Relationship Occuring in more than 10% of Safety-Evaluable Patients
PX-5387	9/3/2003					Executive Summary/ Zometa Bone Endocrinology Advisory Board Meeting August 14-16, 2003
PX-5388	9/8/2003					Draft: Executive Summary/ Zometa Bone Endocrinology Advisory Board Meeting August 14-16, 2003
PX-5389	1/22/2002	Csermak	Letter to All Investigators in Zoledronic Acid (ZOL446) Studies			
PX-5390	1/20/2003	Wang	Petrone	Re; Final Draft Report (Study No. CZOL446 0705)		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5391	12/9/2004	Landis	Petrone	Re: Amended Task Order for CZOL446EUS15		
PX-5392	1/15/2004	Hei	Petrone and others	Email Subject URGENT: Update of Urologic Clinics of NA manuscript		
PX-5393	4/9/2002	Vande Pol	Brant-e, Kaminski, Petrone	Email Subject Poster comments (My comments/clarifications on the Zometa 705 Poster)		
PX-5394						Follow Up Exam - Week
PX-5395	9/26/2005					ONJ Chronology September 26, 2005, For Internal Use Only
PX-5396	2002					Zometa Phase 4 Summary
PX-5397	2/15/2005					Clinical Trial Team Meeting Minutes
PX-5398	3/10/2000					Summary of Protocol: CZOL446 IA03I1 (Extension Study 1)
PX-5399	12/1/2002					Medical Monitoring Guidelines for Protocol CZOL446EUS32

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5400					Petron e	Clinical Research Overview: GCP, Regulatory Documents, Roles
PX-5401						Oncology US CD MA Trial Contact List
PX-5402						Tracking document
PX-5403						
PX-5404	7/30/2001				Reitson, Chen, Seaman	Integrated Summary of Safety/Zometa
PX-5405	10/8/2002	Petron e	Acrenas	A standard template approval letter for an Investigator Initiated Research Proposal		
PX-5406	3/8/2002				Wang (Medical writer, Kendle International)	Draft of the Clinical Study for The Zometa 705 Trial
PX-5407	2/11/2004	Paramore	Ambros and others	Email Subject: RSA January 2004 Monthly Report		
PX-5408	2/29/2004	Dunsi re	Hei and others	Email Subject: Draft of Osteonecrosis protocol-please clarify		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5409	11/11/2004				Goessl, Schran	Appendix 2 Zometa/ Draft summary of clinical study protocol CZOL446E2 430 in response to FDA request
PX-5410	6/2004					Expert Panel Recommendations for the Prevention, Diagnosis, And Treatment of Osteoporosis of the Jaws: June 2004
PX-5411	4/2005					Osteonecrosis of the Jaw (ONJ) and Bisphosphonates
PX-5412	9/10/2009				FREQ Procedure	FREQ Procedure
PX-5413	2/10/2003	Sablinski	Maladorno, Rodriquez		Email Subject: Jaw osteonecrosis in cancer patients 26 ONJ-cluster	
PX-5414	6/14/2005	Sablinski	Cook		FW: media.nejm.org Table of Contents	
PX-5415	6/15/2005	Sablinski	Cook		Re: FW: media.nejm.org Table of Contents	
PX-5416	6/20/2005	Eriksen	Lantwicki		Re: US Registry Study	
PX-5417						CV

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5418	12/10/2003	Curtis	Abam	Re: Additional Cases of Osteonecrosis	Novartis Employee	
PX-5419	2/21/2005	Hei	Young	ODAC-Status Update on ONJ in clinical trials	Hei to Young	
PX-5420	6/2009 6/2003					Aredia Prescribing Information 6/2009, 6/2003
PX-5421	8/2004					Aredia Prescribing Information
PX-5422	11/2008					Aredia Prescribing Information
PX-5423	8/22/1995	Hedin	Macalush	Medical Officer Review-Aredia Efficacy Proposed labeling for Multiple Myeloma indication & Fax cover sheet 8/16/1995		
PX-5424	12/2005					Zometa Prescribing Information
PX-5425	9/2007					Highlights of Prescribing Information Full Prescribing Information

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5426	2/16/2007	Jamison	McGrath	NDA 21-386 S-002 FDA T-Con Label Review Comments		
PX-5427	9/9/2004					
PX-5428	5/3/2005				Michael Scott	
PX-5429	3/24/2004				Green, Spaet, Choi	Preclinical Safety, Toxicology/Pathology, ZOL446K CV of the experts-nonclinical
PX-5430	8/8/2006				Spaet	Safety Profiling and Assessment, Aredia 1.4.3 CV of the nonclinical expert
PX-5431	5/1987					
PX-5432	3/31/2004				Spaet	Preclinical Safety, ZOL446K, Zoledronic acid, 2.6.6 Toxicology Written Summary
PX-5433	4/5/2004				Green, Choi, Spaet	Preclinical Safety, ZOL446K, Zoledronic acid, 2.4 Nonclinical Overview

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5434	7/18/2003				Maladorno, Lombardi, Green, Spaet	Aredia, Clinical Expert Statement : Osteonecrosis of the Maxillofacial Area
PX-5435	10/17/2003				Maladorno, Lombardi, Green, Spaet	Aredia, Clinical Expert Statement : Osteonecrosis of the Maxillofacial Area- September 2003 Overview
PX-5436	12/19/2003				Maladorno, Lombardi, Green, Spaet	Aredia, Clinical Expert Statement : Osteonecrosis of the Maxillofacial Area- October 2003 Overview
PX-5437	6/18/2004				Maladorno, Csermak, Green, Spaet	Aredia, Clinical Expert Statement : Osteonecrosis of the Maxillofacial Area- May 2004 Overview



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5438	6/21/2004					Drug Regulator Y Affairs, Zometa Injection , Aredia Injection , Briefing Package
PX-5439	3/4/2005					Oncologic Drugs Advisory Committee Meeting March 4, 2005 Zometa and Aredia
PX-5440	8/25/2004				Green, Choi, Spaet	Preclinical Safety, ZOL446K, 2.4 Nonclinical Overview
PX-5441	8/25/2004				Spaet	Preclinical Safety, ZOL446K, 2.6.6 Toxicology Written Summary

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5442	10/2005				Spaet	Safety Profiling and Assessment, ZOL446K CSE Appendix-Nonclinical Overview Zoledronic acid preclinical safety and ADME studies released between January 2000 and September 2005
PX-5443	10/28/2005				Spaet	Safety Profiling and Assessment, ZOL446K, Zometa, Clinical Expert Statement (Clinical Overview) Appendix 1
PX-5444					Spaet	Zolendronate, Synopsis of Pre-clinical Data

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5445	8/17/2007				Spaet	Safety Profiling and Assessment, Aredia (15mg, 30mg, 60mg, 90mg powder and solvent for solution for infusion) CES Appendix 1 : Non-clinical overview
PX-5446	7/18/2003	Dunsi re	Epstein and others	Email Subject: Zometa NEM Team Meeting Minutes- July 11 and July 14		
PX-5447	11/13/2003	Spaet	Hei	Email Subject: Osteonecrosis- beagle dog study		
PX-5448	12/5/2003					Osteonecrosis Advisory Board
PX-5449	12/5/2003					Osteonecrosis Advisory Board
PX-5450	12/5/2003					Osteonecrosis Advisory Board Agenda
PX-5451	3/24/2004	Cook	Linguri	Email Subject: Animal Study		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5452	3/4/2005					Oncologic Drugs Advisory Committee Meeting March 4, 2005 Zometa Background-Preclinical/MOA
PX-5453	4/24/2005	Altme yer	Hei and others	Email Subject: Jpn ONJ Ad Boards-Highlights		
PX-5454	1/10/2003	Konec ne	Seaman, Chen, Schran, Hei and others	Scanned-06Jan03_FDA Fax re NDA 21-386 Zometa		
PX-5455	3/6/2003	Jenni fer Murph y, Consu mer Promo tion Analy st, Regul atory Revie w Offic er (FDA)	Konecne	Re: NDA 21-386, Zometa (zoledronic acid for injection) MACMIS ID# 11456		
PX-5456	5/2/2003	Taras soff	Frararcang eli	Re: Dr. Ruggiero's publication plans-Aredia and osteonecrosis		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5457	6/5/2003					Project: ARD233B/ Bone Mets, ZOL446D/ HCM, ZOL446E/ Treatment Bone Mets, ZOL446G/ Prevention, IPT Minutes
PX-5458	6/13/2003	Chi	Zometa and Aredia IPT	Action Plan in response to reports of bone necrosis with the use of Zometa and Aredia		
PX-5459	7/14/2003					Project: ARD233B/ Bone Mets, ZOL446D/ HCM, ZOL446E/ Treatment Bone Mets, ZOL446G/ Prevention, IPT Minutes
PX-5460	7/8/2003					NEM Kick-Off Meeting
PX-5461	7/18/2003	Konecne	Pazdur, FDA	Aredia Vials, Zometa Injection, Cases of osteonecrosis		
PX-5462	8/6/2003	Koerner	Sterner	Re: Summary of Zometa USPI FDA t-con		
PX-5463	8/25/2003	Shannon	Dunsire	Re: Zometa and Aredia USPI change		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5464	11/3/2003	Porfido	Linguri	Re: ON Aredia and Zometa USPI cost		
PX-5465	9/26/2003	Stern er	Orloff	Zometa Injection, Special Supplement-Changes Being Effected		
PX-5466	11/3/2003	Frata rcang eli	Linguri, Tarassoff	ON USPI change FDA acknowledgement		
PX-5467	7/14/2003	Hakke lhove n	Konecne	Updated HA Letter		
PX-5468	3/29/2004	Klein	Weiss, Tarassoff	E-Mail Subject: osteochemone crosis		
PX-5469	3/1/2004	Malad orno	Dunsire, Goessl, Cook and others	Osteonecrosi s cases as of Feb. 24, 2004		
PX-5470	2003	Taras soff, Cserm ak	To the Editor		Tarass off, Cserma k	To the Editor
PX-5471	1982				Schwar tz	Osteonecr osis of the Jaws: A Complicat ion of Cancer Chempther apy
PX-5472	2002				Sung, Chan, Sakura i, Chung	Osteonecr osis of the maxilla as a complicat ion to chempther apy: a case report

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5473	1999				Chang, Greenspan, Gersbwin	The pathogenesis of osteonecrosis and the relationship to corticosteroids
PX-5474	12/5/2003					
PX-5475	12/5/2003					
PX-5476	4/29/2003	Tarasoff	Hei	Re: Osteonecrosis with bisphosphonates		
PX-5477	7/2/2002	Tarasoff	Green	A Request		
PX-5478	7/8/2002	Tarasoff, Weiss	Ruggiero	This letter is in response to your request for information regarding Aredia (pamidronate disodium)		
PX-5479	5/2/2003	Tarasoff	Frararcangeli	Re: Dr. Ruggiero's publication plans-Aredia and osteonecrosis		
PX-5480	6/9/2003	Frararcangeli	Epstein, Boehm, Burke and others	Issues Management		
PX-5481	8/25/2004	Ruggiero	Brant-e	Re; ONJ manuscript for your review (NVR-242-6242)		
PX-5482	7/8/2004	Goessel	Petraglia, Dunsire, Maladorno and others	Re: Osteonecrosis article from Dr. Bouquot: A Multifactorial Etiology.pdf		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5483	8/2006	Lantw icki	Altmeyer, Eriksen, Mounier and others	Mayo Clinic Proceedings August 2006- FYI to ZIM Communicatio n and KOL Team please recommen dation		
PX-5484	8/4/2003	Ruiz	Tarassoff	Re: Thank you!!		
PX-5485	10/10/2005	Eriks en	Lantwicki	Re: project ZoDent in Italy- Privileged and Confidential		
PX-5486	1/12/2009					
PX-5487	12/5/2003					Osteonecr osis Advisory Board
PX-5488	12/5/2003					Novartis Advisory Board
PX-5489	12/18/2003	Taras soff	Dunsire, Fratarcang eli and others	E-Mail Subject: Toth Letter- Dental Ad Board		UT MD Anderson Cancer Center/ Dr. Toth Letter
PX-5490	12/5/2003				Malado rno, Close, Cserma k	Zometa, Aredia, Osteonecr osis of the Maxillofa cial Region
PX-5491	12/5/2003					
PX-5492	2/5/2004	Hlous ek	Frararcang eli, Linguri	E-Mail Subject: ON Ad Board		
PX-5493	3/19/2004				Marx	Notice of Importanc e Re: Aredia/ Zometa Induced Avascular Necrosis of the Jaw



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5494	3/29/2004					
PX-5495	6/2/2004	Hei	Hlousek	E-Mail Subject: Urgent!.		
PX-5496		Hei	Members of Advisory Board	Email Subject: copy of notes taken during Advisory Board discussion		
PX-5497	5/8/2004	Schubert	Hei	E-Mail Subject: Please Comment-short "white paper"		Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw: May 2004
PX-5498	5/12/2004	Schubert	achoff, Hei, Hauser and others	E-Mail Subject: Please comment: short "white paper"		
PX-5499	5/12/2004	Hoff	Schubert and others	E-Mail Subject: Please comment-short 'white paper'		
PX-5500	5/28/2004	Schubert	Hei	E-Mail Subject: Urgent!-revised document for your approval-Action needed by June 1, 2004		
PX-5501	8/13/2004	Houle	Hlousek	E-Mail Subject: ONJ Manuscript		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5502	9/8/2004	Tarasoff	Damato	E-mail Subject: Advisory Board Update		
PX-5503	9/24/2004	Brant	Tarassoff	E-Mail Subject: Revised Manuscript		Revised Consensus Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws in Patients with Cancer
PX-5504	8/16/2004	Schubert	Brant	E-Mail Subject: ONJ Manuscript for your review		Revisions to Consensus Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws in Patients with Cancer
PX-5505	6/6/2003	Hei	Fratarcangeli, Maladorno, Csermak, Tarassoff	Urgent-Osteonecrosis Situation	Marx	Medical Alert
PX-5506	6/11/2003	Tarasoff	Ruiz	Thank you!!		
PX-5507	7/22/2003	Tarasoff	Ruiz	Email Subject: Re: Thank you!!		
PX-5508	7/23/2003	Maladorno	Close, Bess, Csermak Renner	Meeting with Dr. Marx-Miami-Osteonecrosis cases		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5509	6/28/2005					2006 Zometa KOL Plan
PX-5510	8/29/2006	Roelke	Timoney, Scott	National KOLs and Regional/Local Speakers for Zometa		
PX-5511						List of Zometa KOLs broken out by tumor type brought by Mr. Timoney
PX-5512						List of dental physicians and dentists
PX-5513	2005-2006				Mike Barniger	2005-2006 Lung Cancer KOL Plan
PX-5514	3/2005					Winning Brands: The Power of Influence
PX-5515	2001					Marketing Primer/ Prostate Cancer Update
PX-5516	11/22/2004	Tarasoff	Hukkelhoven	Re: Urgent: Zometa ASH 2004 Ren-ONJ.doc		
PX-5517	9/27/2006	Dorschner	Scott	Broadcast Email for New Zometa Slide Deck		
PX-5518	5/9/2006					Zometa Speaker Training Transcript

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5519						Osteonecrosis of the Jaw (ONJ): Prevention and Management
PX-5520						Zometa in the Treatment of Bone Metastases
PX-5521	1/27/2006					Zometa Interventionz Certification Speaker
PX-5522	8/2007			Reclast Label		Reclast Label
PX-5523	9/2007			Zometa Label		Zometa Label
PX-5524	1991			Aredia Label		Aredia Label
PX-5525	10/2003				Tarassoff Csermak-Renner	
PX-5526	8/2001			Zometa Label		Zometa Label
PX-5527	12/3/1999				Honghui Zhou Peimin Ma	Population Pharmacokinetic Analysis of Zoledronate
PX-5528	8/25/2003	Shannon	Kappel			
PX-5529	9/2003					
PX-5530	5/7/2004	Maladorno		Subject: Osteonecrosis cases as of May 4, 2004.		Maladorno count of cases
PX-5531	5/11/2004	Hei, Hlous ek				

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5532	6/14/2005	Sablinski	Cook			For Review and Approval Osteonecrosis of the Jaw in Cancer Patients: Letters Published in the New England Journal of Medicine Global Communications Document 6/10/2005
PX-5533					Tawfik Kamal	Zometa Global Strategy
PX-5534	2005			Zometa Label		AAOMS Meeting
PX-5535	8/7/2003	Machalaba, Tarasoff	ASMs, OSSs, RSAs, RSDs, BRMs, RDs	Program Schedule AAOMS Meeting		
PX-5536	8/7/2003	Machalaba, Tarasoff	ASMs, OSSs, RSAs, RSDs, BRMs, RDs	Topic Listings, 2005 AAOMS Meeting		
PX-5537	8/7/2003	Machalaba, Tarasoff	ASMs, OSSs, RSAs, RSDs, BRMs, RDs	Osteonecrosis of the Jaw in Cancer Patients		
PX-5538	8/7/2003	Machalaba, Tarasoff	ASMs, OSSs, RSAs, RSDs, BRMs, RDs	Osteonecrosis of the Jaw in Cancer Patients		
PX-5539	12/6/2002	Weiss	Abam	Medical Inquiry		
PX-5540	2/11/2004	Hei	Goessl, Dunsire, Maladorno, Cook and others	ON ICF		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5541	2/12/2004	Petro ne	Baldari	Urgent: Zometa osteonecrosis IC wording		
PX-5542	3/12/2004	Weiss	Arnbattle	Re: Reported cases of osteonecrosis		
PX-5543	3/29/2004					Advisory Board Meeting
PX-5544	3/29/2004	Weiss	Linguri	Re: [Fwd:Bouquot : Novartis Osteonecrosis Advisory Board]		
PX-5545	6/5/2004	Weiss	Rancourt, Abam	Medical Inquiry		
PX-5546	6/25/2004	Weiss	Petraglia, Gericke	(No subject) I am at the MASCC meeting in Miami.		
PX-5547	6/2004					White Paper
PX-5548	4/6/2005					Telecon Meeting Minutes
PX-5549	7/15/2004					NPC FDA presentation
PX-5550	3/2/2005	Hei	Maladorno	Re: FDA Discussion Points for ODAC		
PX-5551	3/4/2005	Hukkelhove n	Allan, Baba, Bible, Costa and others	Today's FDA Advisory Committee meeting on Zometa and Aredia		
PX-5552	3/4/2005					ODAC presentation
PX-5553	3/7/2005	Galen	Riva, Narang, Dunsire and others	ODAC Commentary FYI		
PX-5554	3/16/2005					Meeting Summary
PX-5555	5/11/2004	State n	Petraglia	IND 55,831 Zoledronate for Injection		

PX-5556	5/25/2004	State n	Petraglia	IND 55,831 Zoledronate for Injection		
PX-5557	7/15/2004					FDA/Novartis Meeting Zometa Safety Update- Osteonecrosis
PX-5558	8/6/2004	Petraglia	Pazdur	General Correspondence 8/6/04 Serial No. 288		Slide Presentation by Dr. Young - ONJ
PX-5559	12/23/2004	Epstein	Reinhardt, Ebeling, Dunsire	Email Subject: ODAC		
PX-5560	12/27/2004	Clifford	Petraglia	Agenda for the upcoming meeting Onocologic Drugs Advisory Committee - Disclosures		
PX-5561	3/2005					Zometa ODAC Team
PX-5562	1/24/2005	Kimer	Hei	Email Subject: Some things that I need for preperation for ODAC		
PX-5563	1/28/2005					Potential FDA Key Questions and Answers for ONJ ODAC Meeting Draft
PX-5564	2/1/2005	Scott	Altmeyer, Mounier, Hei, Tarassoff, Narang Petraglia, Carninis, Lacerna	Email Subject: Advisor Update		Availability of Advisors

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5565	1/28/2005					Potential FDA Key Questions and Answers for ONJ ODAC Meeting Draft
PX-5566	1/28/2005					Proposal 29 Questions- Feb 1st, 1:00 p.m. Potential FDA Key Questions and Answers for ONJ ODAC Meeting Draft
PX-5567	2/2005					Zometa ODAC Strategy PMB 02 February 2005
PX-5568	2/3/2005	Scott	Sledge	Subject: Advisor		
PX-5569	2/4/2005	Mounier	Scott	Email Subject: Feb 14 Mock ODAC		
PX-5570	2/5/2005	Scott	Narang, Goldfarb, Cook, Dunsire, Mounier, Petraglia, Altmeyer, Tarassoff	ODAC open mic		
PX-5571	2/7/2005	Young	Narang, Hei	Email Subject: Primary Presentation		
PX-5572	3/4/2005					ODAC Calendar



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5573	2/11/2005					Confidential Advisory Board Meeting ODAC Recent Developments in ONJ
PX-5574	2/11/2005					Confidential Advisory Board Meeting ODAC Recent Developments in ONJ
PX-5575	2/11/2005					Confidential Advisory Board Meeting ODAC Recent Developments in ONJ
PX-5576	2/14/2005	Naranga	Young, Altmeyer, Hei	Email Subject: Updated ODAC Core Deck		
PX-5577	2/16/2005	Hei	Bock, Romaine	Email Subject: Zometa Mock Advisory Committee Meeting		Team Rehearsal and Mock Meeting
PX-5578	2/15/2005	Nalin	Altmeyer	Email Subject: Outcome of today's mtg on core ODAC slides		
PX-5579	2/15/2005	Altmyer	Dunsire, Young, other individuals	Email Subject: Last version of ODAC Core Slides		Draft ODAC Core Slides

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5580	1/28/2005					Proposal 29 Questions- Feb 1st, 1:00 p.m. Potential FDA Key Questions and Answers for ONJ ODAC Meeting Draft January 28, 2005
PX-5581	2/16/2005	Dunsi re	Narang	Email Subject: NVS ODAC Presentation : Closer		
PX-5582	2/18/2005	Altme yer	Young and others	Email Subject: ODAC Slides as Presented to mock ODAC		ODAC Core Slides
PX-5583	2/18/2005	Altme yer to Narang, Young , Lantw icki, Hei	Altmeyer to Narang, Young, Lantwicki, Hei	Email Subject: Outcome of Mock ODAC		Feedback from Post Mock ODAC
PX-5584	2/18/2005	Altme yer to Nalin , Lantw icki	Altmeyer to Nalin, Lantwicki	Email Subject: 18 Feb 05_ Mock Zometa Meeting Notes 2.doc		Feedback from Post Mock ODAC
PX-5585	2/18/2005	Altme yer to Zheng , Hei and other indiv idual s	Altmeyer to Zheng, Hei and other individual s	Email Subject: Important- Additional data/analyse s required for ODAC	Altme yer to Zheng, Hei and other indivi duals	Feedback from Post Mock ODAC

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5586	2/20/2005					Post Mock ODAC Feedback from Advisors updated 20 Feb 2005
PX-5587	2/21/2005	Young	Zheng	Email Subject: Zometa Slides		
PX-5588	2/22/2005	Scott	Lacerna	Email Subject: FDA Mtg. Zometa ODAC		
PX-5589	2/22/2005					Post Mock ODAC Feedback from Advisors Updated 22 Feb 2005
PX-5590	2/23/2005					Post Mock ODAC Feedback from Advisors Updated 23 Feb 2005
PX-5591	2/26/2005					Post Mock ODAC Feedback from Advisors Updated 26 Feb 2005
PX-5592	2/17/2005					Questions asked and feedback from the Zometa Mock FDA Meeting Hilton Short Hills Florham Park, NJ
PX-5593	2/17/2005					Questions and answers

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5594	7/2004					July 2004 meeting documents reviewed by Dr. Young before the deposition
PX-5595	3/2005					March 2005 meeting documents reviewed by Dr. Young before the deposition
PX-5596	2/17/2005					Zometa Mock Meeting Feb 16-17 2005
PX-5597	2/2005					Copy of CD Zometa Intelligence Report Feb 2005
PX-5598	6/17/2004	Goldfarb	Petraglia	Email Subject: FDA Briefing-Privileged and Confidential / Attorney Work Product		
PX-5599	6/23/2004	Fratarcangeli	Petraglia, Goessl, Maladorna and other individuals	Email Subject: Call from Dr. Ruggiero		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5600						Taking Care of Yourself While Living with Cancer, Dental Health and Osteonecr osis of the Jaw
PX-5601	12/23 /2004	Naran g	Burke, Hoppenot	Email Subject: Zometa		
PX-5602	3/200 3			Zometa Label		Zometa label, Mar. 2003
PX-5603						Osteonecr osis Advisory Board
PX-5604						ONJ Chronolog y
PX-5605						Q & As for ASH
PX-5606	2005			Program Schedule AAOMS Meeting		Program Schedule Symposia, 2005 AAOMS Meeting, Hynes Conventio n Center
PX-5607	2005			Topic Listings, 2005 AAOMS Meeting		Topic Listings, 2005 AAOMS Meeting, Hynes Conventio n Center
PX-5608		Petra glia				
PX-5609						Untitled Meeting Transcript/Minutes

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5610						Bisphosphonates and Mandibular Necrosis
PX-5611						Untitled table
PX-5612		Dunsire				
PX-5613						
PX-5614						
PX-5615						Zometa Mock Meeting
PX-5616						ONJ and Bisphosphonates Slide Deck
PX-5617		Eriksen				
PX-5618	3/27/2003		Maladorno			
PX-5619				Labeling Corresp.		
PX-5620				NEM Subcommittee Meeting Summary		
PX-5621	06/23/2003	Csermak-Renner	Konecne	Osteonecrosis tcon minutes		
PX-5622	7/08/2004	John Orloff	Deborah Dunsire	Email Subject: Re: FDA Response to Osteonecrosis Labeling-Zometa and Aredia		
PX-5623	5/02/2003	Stefano Fratarcangeli	Maladorno, Stone, Linguri, Tarasoff, Spaet, Hei, Roth	Email Subject: Osteonecrosis: Follow-up to today's teleconference		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5624	5/05/2005					Important Drug Precaution for Dental Health Professionals With Patients Being Treated For Cancer
PX-5625	9/28/2005					
PX-5626	11/12/2003	Dionigi Maladorno	Deborah Dunshire and Stefano Fratarcangeli	Email Subject: Osteonecrosis cases as of Nov. 4, 2003		
PX-5627	2/12/2004	Dionigi Maladorno	Dunshire, Goessl, Cook, and other individuals	Email Subject: Osteonecrosis cases as of Feb. 6, 2004		
PX-5628	4/26/2004	Peter Tarasoff	Deborah Dunshire, Stefano Fratarcangeli	Email Subject: Teleconference with Dr. Schwartz		
PX-5629						Units by State 2002-2006
PX-5630				Clinical Trial Records		Clinical Trial Records
PX-5631				Clinical Trial Records		Clinical Trial Records
PX-5632				Clinical Trial Records		Clinical Trial Records
PX-5633				Clinical Trial Records		Clinical Trial Records
PX-5634				Clinical Trial Records		Clinical Trial Records
PX-5635				Clinical Trial Records		Clinical Trial Records

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5636				Clinical Trial Records		Clinical Trial Records
PX-5637					Novartis	
PX-5638					Novartis	Amended DFS Fact Sheet
PX-5639						Photographs of Mr. White
PX-5640	12/15/2005					Zoledronic Acid Issue-Management [ZIM] Face to Face Meeting Summary
PX-5641	12/15/2005					Zoledronic Acid Issue-Management [ZIM] Face to Face Meeting Summary
PX-5642	5/21/2008					
PX-5643						
PX-5644	8/19/2009					Notice of Videotape Deposition Pursuant to Rule 4: 14-2
PX-5645				ICD-9 Code Info		ICD-9 Code Info
PX-5646				Novartis Response to PSC's First Requests for admission in MDL 1760, dated June 23, 2008		Novartis Response to PSC's First Requests for admission in MDL 1760, dated June 23, 2008



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5647						Packaging / Labels/ package inserts
PX-5648				Zometa 2003 MPH Tactics		Zometa 2003 MPH Tactics
PX-5649	08/07 /2003	Machalaba and Tarasoff		ONJ in Cancer Patients		ONJ in Cancer Patients
PX-5650	3/22/2005	US Dept of Health and Human Services, FDA, CDER, CBER	Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment		US Dept of Health and Human Services, FDA, CDER, CBER	Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment
PX-5651	3/2004					
PX-5652				Curriculum Vitae of Dr. Robert Marx		Curriculum Vitae of Dr. Robert Marx
PX-5653				Expert and Rebuttal Reports of Dr. Robert Marx		Expert and Rebuttal Reports of Dr. Robert Marx
PX-5654				Curriculum Vitae of Dr. Wayne Ray		Curriculum Vitae of Dr. Wayne Ray
PX-5655				Expert and Rebuttal Reports of Dr. Wayne Ray		Expert and Rebuttal Reports of Dr. Wayne Ray
PX-5656				Curriculum Vitae of Dr. Suzanne Parisian		Curriculum Vitae of Dr. Suzanne Parisian

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5657				Expert, Rebuttal Reports and Supplemental Reports of Dr. Suzanne Parisian		Expert, Rebuttal Reports and Supplemental Reports of Dr. Suzanne Parisian
PX-5658	3/12/2004	Kamal	Fratarcangeli	Email Subject: Re: Action Required- Change of Informed consent for Zometa clinical trials		
PX-5659	4/23/2004	Fratarcangeli	Kamal	Email Subject: Important Zometa BPI Change		
PX-5660	5/18/2004	Kamal			Kamal	OSO April monthly reports
PX-5661	06/25/2004	Dunsi re	Burke et al.	Your tough questions please		
PX-5662						Agenda
PX-5663	9/24/2004					Zometa, Osteonecrosis of the Jaw in Cancer Patients: Updated Situation Overview, Key Messages, Standby Statement and Q & As, Global Version, 24 Sept 2004

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5664	10/18/2004	Fratarcangeli	Kamal	Email Subject: Re: Novartis ASH 2004 Search Term Results		
PX-5665	11/24/2004	Cook	Petraglia, Goessl, Dunsire and others	Update Renal and ONJ Document		Zometa: Osteonecrosis of the Jaw in Cancer Patients: Q & As for ASH Abstracts 3151 and 756, Global Version, 23 November 2004, For Internal Use Only
PX-5666	11/24/2004	Epstein	Vasella	(No Subject) We believe the following factors could result in increased Zometa attention.		
PX-5667	12/2/2004	Cook	Cook and others	Re:Zometa ASH update		
PX-5668	12/3/2004	Dunsire	Gorsky, Epstein, Young and others	Re; NEM Update on ONJ and ASH		
PX-5669	12/6/2004	Maladorno				
PX-5670	12/8/2004	Epstein	Vasella	WSJ.com- Jaw Ailment Shows Industry Moves Slowly on Drug Warnings		
PX-5671	12/8/2004	Cook		oncology PR update: Zometa and Osteonecrosis of the jaw- WSJ article; ASH update ***		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5672	12/9/2004	Epstein	Dunsire	the version that was presented		
PX-5673	12/13/2004	Caminis	Sunsire	Re: Discussion with Dr. Van Poznak on MSKCC ONJ cases		
PX-5674	12/22/2004	Kamal	Roth	Email Subject: Zometa PR PLAN 2005		
PX-5675	1/27/2005	Kamal	Galen	Email Subject: PAM ONC Feb 17 Soundbites exercises		
PX-5676	2/5/2005					ODAC Key Messages, Draft for Review
PX-5677	2/9/2005					ODAC Position Statement, Draft for Review
PX-5678	3/31/2005	McClellan	Goldfarb, Petraglia, Weiss	Zometa ONC T2 Handling Objections-ZOM-8138		
PX-5679	4/8/2005	Filipovic	Kamal	(no subject) It was good talking to you today.		
PX-5680	4/15/2005	Kamal	McCabe	Copy of 2005 ASCO search term list work document.doc		
PX-5681	5/11/2005				Amy Doyle	Global Marketing Spending Results April 2005
PX-5682	5/11/2005					5/11/2005 Oncology Core Team Agenda

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5683	5/19/2005					Osteonecrosis of the Jaw in Cancer Patients: Follow-Up to FDA ODAC Meeting, Global Communications Documents , 19 May 2005
PX-5684	5/19/2005					Osteonecrosis of the Jaw in Cancer Patients: Follow-Up to FDA ODAC Meeting, Global Communications Documents , 19 May 2005 Internal Use Only
PX-5685	5/23/2005	Cook	Lantwicki	Re: Zometa News-Isn't the statement inaccurate		
PX-5686	6/10/2005	Ambatlle		Email Subject: Zometa News #3		
PX-5687	7/1/2005	Roth	Cook, Mounier	Email Subject: PR Update: Zometa ONJ Global Communications Document re: 7 July New England Journal of Medicine ONJ letters.		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5688	7/18/2005	Kamal	Mounier	Email Subject: Rep Survey		
PX-5689	7/18/2005	Mounier		Email Subject: Rep survey		
PX-5690	8/4/2005	Lantwicki	Mounier, Cook, Csermak-Renner and others	Dear Dentist Letter Market Research		
PX-5691	8/19/2005	Conte ras		Email Subject: Survey		
PX-5692	9/8/2005	Conte ras		Email Update on ONJ Survey		
PX-5693	10/15/2005	Kamal	Hei	Email Subject: Re: ONJ Internal training/discussion during ECCO in Paris		
PX-5694	11/8/2005	Hei	Jacob, Hegazy, Chouycharoen and others	Slides on ONJ from ECCO internal training		
PX-5695	11/14/2005	Cochrane		Email: Subject: After Pam Onc Media training		
PX-5696	11/14/2005	Cochrane		Email Subject: After Pam Onc media training		
PX-5697	12/15/2005					Zoledronic Acid Issue, Management [ZIM], Face to Face Meeting Summary
PX-5698	2006				Kathy Koukouras	Zometa ONC Detail Watch 2006

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5699	1/27/2006					Managing ONJ Communications
PX-5700	2/15/2006	Koukouras	Boehm, Midwinter, Hohneker and others	Zometa Sales Rep Focus Groups- Market Research Summary		
PX-5701	3/15/2006	Fazzaro	Jacob and others	Email Subject: Per Capita: 2005 December MAT		
PX-5702	5/24/2006	Kamal	Snowden	Worldwide Plans to be placed in the respective brand section, in the open section of the portal-		
PX-5703	8/15/2006	Cook	Mounier	Re: For Immedicate Review: Standby Statement and Q & A Re: Mayo Consensus Statement		
PX-5704	8/30/2006					Standby/ Q & A Regarding "Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma"
PX-5705	10/4/2006	Mounier	Burrell	Email Subject: Zometa Background		Zometa World Wide Brand Plan-to-One 2007-2011, C4

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5706	10/9/2006	Burrell		Email Subject: Draft Brief ONJ Statement		
PX-5707	10/12/2006	Rao	Burrell	RE: ONJ Business Reply Cards		
PX-5708	10/18/2006	Scott	Burrell	Invitation to Attend Novartis Advisory Board Meeting (November 8-9, New York, NY)- Scott		
PX-5709	10/25/2006	Scott	Burrell	Email Subject: Forgiveness Items		
PX-5710	10/25/2006	Burrell	Blair	Email Subject: FBST Presentations Zometa Tactical Plan Template, Zometa 2006 Overview		Winning for The Patient
PX-5711	10/25/2006	Burrell	Volante	Email Subject: October Zometa ESR		
PX-5712	10/26/2006	Cavuto	Burrell and others	Email Subject: Zometa and General Oncology PRT Agenda- November 1, 2006		
PX-5713	11/9/2006	Kamal	Tarassoff	Subject: Re: Telecon tomorrow		
PX-5714	12/15/2006	Burrell	Timoney, Blair	Email Subject: Safety Flashcard approved by Global Core Team		Putting Osteonecrosis of the Jaw (ONJ) into Perspective



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5715	12/19/2006	Hoppe not	Kamal, Mounier	Email Subject: Zometa in Multiple Myeloma		
PX-5716						Palio Literature
PX-5717						2007 Oncology Business Unit National Meeting - Lead Investigator's Guide
PX-5718	1/11/2007	Lantwicki		Email Subject: Status of jaw osteonecrosis/osteomyelitis reports (as of Dec. 2006)		
PX-5719	1/19/2007	Kamal	Dortok	Email Subject: Novartis Oncology COOP- Action Items Summary: January 2007 COOP		
PX-5720	1/24/2007	Kamal	Potter, DiTrapani, Owen	Email Subject: Final Minutes-PMB Meeting January 16, 2007		
PX-5721	2/8/2007	Burrell	Naughton	Email Subject: Hello Regional Management Team		
PX-5722	2/19/2007	Boehm	Burrell	Urgent: email summary of ZOM turn around plan		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5723	3/2/2007	Naughton	Burrell and others	Email Subject: Zometa Account Requiring resources		
PX-5724	3/8/2007	Tarasoff	Burrell	Email Subject: Draft Version ECC Slides		
PX-5725	3/14/2007	Zometa Brand Team	ONC1, ONC3, ASMs, RDs, OMM	Dental Hotline for Helath Care Professionals		
PX-5726	3/29/2007	Tarasoff	Burrell	Email Subject: Suggested Revisions for ONJ discussion Ideal ONJ Message		
PX-5727	3/30/2007	Burrell	Naughton, Engelhardt	Email Subject: David Epstein's Review		
PX-5728	3/31/2007	Burrell	Naughton, Rao, and others	Email Subject: David Epstein's Business Review		
PX-5729	4/1/2007	Burrell	Brandman	Email Subject: C4 Sub-team meeting re:4th strategic imperative		US ONJ Plan and Tatics
PX-5730	4/6/2007	Rao	Burrell and others	Email Subject: Dental Hotline-First Call received		
PX-5731	4/9/2007	Burrell	Rao, Timoney, Ellis, Blair	Email Subject: Urgent Request-Submit items for S2 Meeting Agenda		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5732	4/12/2007	Burrell	Altmeyer, Volante, McGrath	Re: Aclasta/Zometa Dear HCP letter for your review		
PX-5733	4/12/2007	Burrell	Altmeyer, Volante, McGrath	Email Subject: Aclasta/Zometa Dear HCP letter for your review (unintended damage due to misaligned messages)		
PX-5734	4/13/2007	Burrell	Volante	Email Subject: ECC Meeting Slide Deck Pre-read		US Back-Up Deck
PX-5735	4/14/2007	Mounier	Epstein, Hoppenot, Boehm and others	ZOMETA Pre-read for Monday		
PX-5736	4/16/2007	Koukouras	Burrell, Timoney, Blair, Rao	Email Subject: ONC Behavior Change Qualitative Market Research Final Vendor Report		EIDETICS MD Rationale for Changes in Zometa Use Presented to Novartis April 13, 2007
PX-5737	4/25/2007			Zometa, Reinvigorating Growth and Patient Freedom	Burrell	Zometa, Reinvigorating Growth and Patient Freedom
PX-5738	5/1/2007	Koukouras	Burrell, Timoney, Blair, Rao	Email Subject: intrinsicQ Monthly Databook-March 2007		Bisphosphonate Usage Review March 2007
PX-5739	5/5/2007	Burrell	Blair	Email Subject: Investor Relations Questions		

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5740	5/7/2007	Burrell	Rao	Email Subject: Illumination Brief, Estimate, Task Order, and Timeline- Unbranded ONJ Reprint Center		
PX-5741	5/16/2007	Burrell	Boehm, Volante	Email Subject: Urgent response needed: FDA revised Plan label 21386 Zometa P1- FDA Version		FDA Teleconference 5/15/2007 Zometa Japanese Study 1501 (NDA 21-386, S-002)
PX-5742	5/21/2007	Kamal	Guidi, and others	Email, Scientific Communication Plan, Zometa		
PX-5743	5/21/2007				Kyle, Yee	ASCO 2007 Clinical Update
PX-5744	5/22/2007	Kamal	Boisclair	Email Subject: Re: Info: "American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma'		
PX-5745	6/7/2007	Becker	Burrell and others	Email Subject: C2 Slides: MyDoc and ONJ Flashcard Slides		Evidence on Display: Zometa ONJ Flashcard

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5746	6/9/2007	Kamal	Young	Fw: PUB ALERT: New ASCO 2007 Guidelines in Multiple Myeloma + <<Q & A>>		New ASCO 2007 Clinical Update
PX-5747	6/12/2007				Sabatino	Zoledronic Acid Dental Strategy Update
PX-5748	6/12/2007	Sabatino	Timoney, Burrell	Email Subject: Dental Strategy Update		Zoledronic Acid Dental Strategy Update (June 6, 2007)
PX-5749	6/13/2007	Burrell	Loiset			US Zometa Turn-Around 07 Action Plan
PX-5750	7/24/2007	Burrell	Volante	Email Subject: Zometa Success! "This account had gone from 100% Zometa to 100% Pamidronate based on the Mayo guidelines and ONJ concerns."		
PX-5751	8/22/2007	Burrell	McGinley	Email Subject: Request for Materials "thought we agreed to stress ONJ as a disease rather than a class effect."		
PX-5752	9/13/2007	Scrudato	Burrell	Email Subject: Revised ZRT Deck		Zometa Top Institutions
PX-5753	9/22/2007	Kamal				EGM/SAT meeting actions

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5754	10/8/2007	Burrell	McClung, Volante and others	Email Subject: Zometa Tactical Plan 2008 Ver7.ppt		US Oncology-Zometa 2008 Tactical Plan
PX-5755	10/10/2007	Burrell	Manacek, Naughton	Email Subject:2006 vs 2007 Data: Sloan and Hopkins		
PX-5756	11/2/2007	DiTrapani	Mantovani, Kamal	Email Subject: ON 1st Newsletter: please review by the 8th of November		
PX-5757				Novartis Response to PSC's First Requests for admission in MDL 1760, dated June 23, 2008		Novartis Response to PSC's First Requests for admission in MDL 1760, dated June 23, 2008
PX-5758	1/26/2004	Maladorno	Dunsire and Others	Osteonecrosis Cases as of January 13, 2004		
PX-5759						
PX-5760						Expert Panel Recommendations For the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5761						Zoledronic Acid ONJ Executive Summary
PX-5762					Marx and Stern	Oral Pathology Textbook
PX-5763					Marx	Letter to the Editor: Pamidrona te (Aredia) and Zoledrona te (Zometa) Induced Avascular Necrosis of the Jaws: A Growing Epidemic
PX-5764					Ruggie ro, Carlso n and others	Bisphosph onate- related osteonecr osis of the jaw: backgroun d and guideline s for diagnosis , staging and managemen t
PX-5765					Malado rno, Lombar di, Green, Spaet	Aredia: Clinical Expert Statement : Osteonecr osis of the Maxillofa cial Area July 18, 2003

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5766					Bouquet	Neuropathic Pain in Maxillofacial Osteonecrosis
PX-5767					Shankl and	Medullary and Odontogenic disease in the painful jaw: clinicopathologic review of 500 consecutive lesions
PX-5768	7/21/2003	Tarasoff	Dr. Marx	Follow-up to the Teleconference discussion		
PX-5769						AAOMS Meeting Transcript
PX-5770						
PX-5771						Strategic Advisory Board for Zoledronic Acid Meeting Report 15-17 April 2003
PX-5772						Meeting of the Aclasta International Strategic Advisory Board, 19-20 September 2006



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5773						Executive Summary of the Aclasta/R eclast International Strategic Roundtable held February 22, 2008 in Paris
PX-5774					Gotcher, Jee	
PX-5775					Gotcher, Jee	
PX-5776						Executive Summary from the ONJ Advisory Board, 11-12 February 2006, London
PX-5777					Maladorno, Lombardi, Green, Spaet	Aredia-Clinical Expert Statement : Osteonecrosis of the Maxillofacial Area
PX-5778						Novartis Pharmaceuticals Corporation's Responses to Plaintiffs' Steering Committee's First Request for Admission

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5779						DRAFT-Consensus Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws in Patients-with notes/marginala by Novartis
PX-5780		Marx	Schwartz		Marx	Serum CTX Testing
PX-5781		Marx			Marx	Clinical Concerns of Aledronate Use
PX-5782					Marx	Uncovering the Cause of "Phossy Jaw" Circa 1858 to 1906: Oral and Maxillofacial Surgery Closed Care Files-Case Closed
PX-5783					Marx	Editorial Response-Editorial Opinion Versus Real Data and Knowledge of the Literature

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5784						AAOMS Position Paper on Bisphosph onate- Related Osteonecr osis of the Jaws -2009 Update
PX-5785						Executive Summary From San Antonio Advisory Board Meeting
PX-5786						Executive Summary From San Antonio Advisory Board Meeting
PX-5787						Executive Summary From San Antonio Advisory Board Meeting
PX-5788						Slide Deck
PX-5789						
PX-5790						
PX-5791						
PX-5792						
PX-5793						
PX-5794						
PX-5795						
PX-5796						
PX-5797						

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5798						ONJ Chronolog y
PX-5799						
PX-5800						
PX-5801						
PX-5802						
PX-5803						
PX-5804						
PX-5805						

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-5806						
						Expert Panel* Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004
PX-5807						All versions of the Aredia Label
PX-5808						All versions of the Zometa label
PX-5809						

1 Plaintiff's "Case Specific" Exhibits

Exhibit No.	Title or Description
White	
PX-1000	William White Synopsis Presented in Acheson Deposition.
PX-1001	Affidavit of Custodian of Records, Medical Records of Dr. Guy Acheson of William White Records.
PX-1002	Jackson, Richard F. to Guy Acheson, January 6, 2004, re: Bill White.
PX-1003	Handwritten Notes, RE: Bill White, August 26, 1991.
PX-1004	July 28, 2003, Acheson slides of William White.
PX-1005	May, 2005, Acheson slides of William White.
PX-1006	Black and White Photo of Bill White Mouth Interior.
PX-1007	Black and White Photo of Bill White Mouth Interior.
PX-1008	Bill White X-ray, July 28, 2003
PX-1009	Bill White X-ray
PX-1010	Bill White X-ray indicating Dr. Acheson
PX-1011	Bill White X-ray, July 28, 2003 indicating Dr. Acheson
PX-1012	Bill White X-ray, April 4, 2001 indicating Dr. Acheson
PX-1013	Bill White X-Ray, March 3, 1999 indicating Dr. Acheson
PX-1014	Bill White X-Ray, January 20, 1999 indicating Dr. Acheson
PX-1015	Bill White X-Ray, March 5, 1999 indicating Dr. Acheson
PX-1016	Bill White X-Ray, April 25, 1998 indicating Dr. Acheson
PX-1017	Bill White Diagnostic Film
PX-1018	Bill White Diagnostic Film
PX-1019	January 5, 2004 Appointment Notes
PX-1020	Plaintiff's Fact Sheet - William White
PX-1021	State of William Knox White Supplement to Plaintiff's Fact Sheet by Cheryl White
PX-1022	William K. White, UCD Med Record with contact phone numbers.
PX-1023	Valad, Bart to Martin Calhoun, February 8, 2008, re: documents WILWHI 00020-00158.
PX-1024	Certificate of Death for William Knox White issued October 12, 2006 and Zometa Product Information.
PX-1025	Richman, Carol, MD to William K. White, April 29, 2004, Re: April 21, 2004 letter expressing dissatisfaction with oncology care.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-1026	Letter, White, William and Cheryl to Carol Richman, March 31, 2004, cc: Michael Tanaka, John Macmillan and Jon Overholt, re: dissatisfaction with oncology care
PX-1027	Letter, Tanaka, Michael to Phillip Schneider, April 16, 2003, Re: William White.
PX-1028	Hospital Records; UC Davis; William K. White, June 9, 2004.
PX-1029	Hospital Records; UC Davis; William K. White; Transcription of June 13, 2004.
PX-1030	Hospital Records; UC Davis; William K. White; June 22, 2004.
PX-1031	Hospital Records; UC Davis; William K. White; August 18, 2004.
PX-1032	Hospital Records; UC Davis; William K. White; September 22, 2004 Letter to Jon Overholt from Angela Davies.
PX-1033	Hospital Record; UC Davis; William K. White; October 20, 2004.
PX-1034	Hospital Records; UC Davis; William K. White; November 17, 2004.
PX-1035	Hospital Records; UC Davis; William K. White; November 17, 2004 Transcription of letter to Jon Overholt from Angela Davies.
PX-1036	Hospital Records; UC Davis; William K. White; January 19, 2005.
PX-1037	Hospital Records; UC Davis; William K. White; Transcription of Letter to Jon Overholt from Angela Davis, January 21, 2005.
PX-1038	Hospital Record; UC Davis; Physicians Progress Record; William White; February 2, 2005.
PX-1039	Hospital Records; UC Davis; William K. White; Bone Imaging of Whole Body; February 25, 2005.
PX-1040	Hospital Records; UC Davis; William K. White; March 9, 2005.
PX-1041	Hospital Records; UC Davis; William K. White; March 9, 2005 Transcript of Letter to Jon Overholt from Angela Davies.
PX-1042	Hospital Records; UC Davis; William K. White; June 29, 2005.
PX-1043	Hospital Records; UC Davis; William K. White; July 27, 2005.
PX-1044	Hospital Records; UC Davis; William K. White; October 12, 2005.
PX-1045	Hospital Records; UC Davis; William K. White; October 20, 2005 Transcript of letter to Jon Overholt from Angela Davies.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-1046	Hospital Records; UC Davis; William K. White; November 9, 2005.
PX-1047	Letter Jacob, Rojymon, to Angela Davies, January 5, 2006.
PX-1048	Hospital Records; UC Davis; William K. White; January 12, 2006, Exam by Cheryl Ho, MD.
PX-1049	Hospital Records; UC Davis; William K. White; March 3, 2006; Cheryl Ho Exam.
PX-1050	Hospital Records; UC Davis; William K. White; June 23, 2006 Transcript of letter to Jon Overholt from Angela Davies.
PX-1051	Hospital Records; UC Davis; William K. White; July 19, 2006 Transcript of letter to Jon Overholt from Angela Davies.
PX-1052	Hospital Records; UC Davis; William K. White; July 20, 2006 Transcript of Letter to Jon Overholt from Angela Davis.
PX-1053	Hospital Records; UC Davis; William K. White; August 22, 2006 Transcript of letter to Jon Overholt from Angela Davies.
PX-1054	Email, Linnartz, Ronald to Lynne McGrath, March 30, 2006, re: FDA Audit.
PX-1055	April 6-10, 2005, SWOG Executive Summary.
PX-1056	Hospital Record; UC Davis; William K. White; January 8, 2004.
PX-1057	Hospital Record; UC Davis; William K. White; Inpatient History and Physical; January 6, 2004, John MacMillan.
PX-1058	UC Davis Admission Data Base; William K. White; January 6, 2004.
PX-1059	Hospital Records; UC Davis; William K. White; Handwritten notes; January 6, 2004.
PX-1060	Hospital Records; UC Davis; Additional handwritten notes; January 6, 2004.
PX-1061	Hospital Records; UC Davis; William White; Handwritten Notes; January 7, 2004.
PX-1062	Hospital Records; UC Davis; William White; Handwritten Notes of January 7, 2004.
PX-1063	Hospital Records; UC Davis; William White; Handwritten Notes January 8, 2004.
PX-1064	Hospital Records; UC Davis; William White; Handwritten Notes January 8, 2004.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-1065	Hospital Record; UC Davis; William White; Discharge Summary, January 16, 2004, Eric Boren.
PX-1066	Hospital Record; UC Davis; William White; January 7, 2004.
PX-1067	Fax, Acheson, Guy to Richard Jackson, DDS, October 22, 2003.
PX-1068	X-Ray; Bill White; November 6, 2003.
PX-1069	X-Ray; Bill White; Undated
PX-1070	Surgical Treatment Report; April 27, 2004; William White.
PX-1071	Surgical Treatment; William White; December 4, 2005.
PX-1072	Black and White Photo of William K. White's Mouth Interior.
PX-1073	Fax, Acheson, Guy to Jon Overholt, October 3, 2000; re: Bill White.
PX-1074	Hospital Record; UC Davis; William White; Discharge Diagnosis; January 16, 2004, Eric Boren.
PX-1075	Hospital Record; UC Davis; William White; Transcript of February 25, 2004 letter to Jon Overholt from Michael Tanaka.
PX-1076	Letter, Tanaka, Michael to Jon Overholt, February 25, 2004.
PX-1077	Hospital Record; UC Davis; William White; Carmichael Clinical Note, June 11, 2004.
PX-1078	Hospital Record; UC Davis; William White; Carmichael Clinical Note; January 24, 2005.
PX-1079	Hospital Record; UC Davis; William White; Carmichael Clinical Note, May 25, 2005.
PX-1080	Hospital Record; UC Davis; William White; Carmichael Clinical Note, July 21, 2005.
PX-1081	Hospital Record; UC Davis; William White; Transcript Oncology Clinical Note, January 12, 2006, Cheryl Ho.
PX-1082	Letter, Tanaka, Michael to James Goodnight, October 24, 2001; and other Tanaka Correspondence.
PX-1083	Hospital Record; UC Davis; William K. White; April 1, 2002.
PX-1084	Hospital Record; UC Davis; William White; August 28, 2002.
PX-1085	Hospital Record; UC Davis; William White; Inpatient History and Physical; January 6, 2004.
PX-1086	Radiology Report; UC Davis; January 7, 2004.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-1087	Hospital Record; UC Davis; William White; Discharge Summary, January 16, 2004.
PX-1088	Hospital Record; UC Davis; William White; Transcript of letter from Lana Wania-Galicia to Jon Overholt, January 29, 2004.
PX-1089	Color Photographs of William K. White.
PX-1090	E-mail dated 8/21/06 to Elliot White, Alexis White and Lauren White from William White, one page
PX-1091	Copies of five color photographs
PX-1092	Expert Report, Dec. 15, 2008, Jackson Rebuttal to Royse and Felsenfeld
PX-1093	"Osteonecrosis of the Jaws Associated with Cancer Chemotherapy," Journal of Oral Maxillofacial Surgery, 2003.
PX-1094	X-Ray of William White.
PX-1095	Photocopy picture of William White's mouth.
PX-1096	Photocopy picture of William White's mouth.
PX-1097	Expert Report, Najjar in re White
PX-1098	Rebuttal Report, Najjar in re White
PX-1099	AAOMS Position Paper on BRONJ, 2007
PX-1100	AAOMS Position Paper, Sept. 2006
PX-1101	Article, Ruggiero, et al., "Bisphosphonate-Related Osteonecrosis of the Jaw: Background and Guidelines for Diagnosis, Staging and Managements"
PX-1102	AAOMS Surgical Update, Vol. 20, Iss. 2, "Bisphosphonate-Related Osteonecrosis of the Jaw"
PX-1103	Marx, "Bisphosphonate-induced exposed bone osteonecrosis/ostepetrosis of the jaws: risk factors, recognition, prevention, and treatment."
PX-1104	Table prepared by attorneys
PX-1105	Najjar's Handwritten Notes
PX-1106	Najjar Powerpoint re William White's ONJ.
PX-1107	Letter Dr. Jackson to Dr. Acheson, Jan. 6, 2004
PX-1108	Dr. Acheson Record
PX-1109	Dental Record
PX-1110	Dr. Acheson Records
PX-1111	Panoramic dated July 28, 2003.
PX-1112	White Medical Records
PX-1113	NPC Internal Document, ZAEM-03603364, "Not for use with customers"
PX-1114	Email from Weiss to Tarassoff, Rao, Boyer, Lantwicki re Ettinger Report of AAOMS Sept. 2005 Symposium on BRONJ
PX-1115	NPC Emails

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-1116	NPC Email re Ettinger is a KOL, NPC wants info re MDACC Study
PX-1117	NPC Doc, "Protect, Prepare, Grow Zometa"
PX-1118	NPC Doc, Lung Cancer Ad Board Meeting Notes
PX-1119	Zometa label, 2004
PX-1120	Zometa label, 2005
PX-1121	Zometa label, Mar. 2008
PX-1122	Picture of William White Mouth
PX-1123	Picture of William White Mouth
PX-1124	White, 7/14/2005 Clinic Note
PX-1125	Novartis: Important Drug Precautions for Dental Health Professionals with Patients being Treated for Cancer, May 5, 2005
PX-1126	Letter from Jackson to Acheson, June 22, 2005
PX-1127	White, Synopsis, 1994 to Dec. 19, 2005
PX-1128	Letter from Davies to Jackson, Treatment Options Questions, Aug. 19, 2004
PX-1129	Fax Overholt to Acheson, Oct. 3, 00
PX-1130	Najjar White Powerpoint
PX-1131	Color Photos
PX-1132	Color Photos
PX-1133	Letter Jackson Rebuttal Report
PX-1134	Radiology Report
PX-1135	Radiology Report
PX-1136	Photograph
PX-1137	Zometa Product Description, ZA-0553383 to 0553402
PX-1138	Zometa Product Description, ZA-0704711 to 0704733
PX-1139	Records Produced by Plaintiff
PX-1140	Records Produced by UC Davis Roseville
PX-1141	Records Produced by Guy Acheson, D.D.S.
PX-1142	Records Produced by UC Davis Cancer Center
PX-1143	Records Produced by UC San Francisco
PX-1144	Records Produced by Oregon Health and Science University
PX-1145	Records Produced by Mayo Clinic Scottsdale
PX-1146	Records Produced by Walgreens
PX-1147	Records Produced by Duke University Medical Center
PX-1148	Records Produced by Delta Dental of California
PX-1149	Records Produced by Richard Jackson, D.D.S.
PX-1150	Records Produced by MetLife
PX-1151	Records Produced by Gordon L. Douglass, D.D.S.
PX-1152	Records Produced by Raley's

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-1153	Records Produced by James V. Jouret, D.D.S.
PX-1154	Records Produced by Beverly A. Kodama, D.D.S.
PX-1155	Records Produced by Health Net
PX-1156	Records Produced by Dr. David Sox
PX-1157	Records Produced by Mark H. Zablotsky, D.D.S.
PX-1158	Records Produced by Kennedy Wilson
PX-1159	Records Produced by First Data Corporation
PX-1160	Records Produced by Dr. Thomas O'Dorisio/University of Iowa Hospitals
PX-1161	Records Produced by Assurant Health
PX-1162	Records Produced by Dr. Richard Lockmiller
PX-1163	Records Produced by Doctors Center Medical Group
PX-1164	Records Produced by Unum
PX-1165	Records Produced by Defendant as "ADE" File
PX-1166	Plaintiff's Supplemental Response to Novartis Pharmaceutical's Interrogatory No. 4.
PX-1167	All photographs of William White.
PX-1168	All x-rays/radiographic films of William White.
PX-1169	All medical imaging of William White.
PX-1170	All panorex/dental imaging of William White.

Plaintiff's "Learned Treatise" Exhibits

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Pl Exhibit No..	DATE	AUTHOR(S)	TITLE	CITATION
PX-3001	May-09	Ruggiero, Salvatore L.; Dodson, T.B.; Assael, L.A.; Landesberg, R.; Marx, R.E.; Mehrotra B.	American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws -- 2009 Update	67 Journal of Oral Maxillofacial Surgery 2 (2009)
PX-3002	Jan-09	Reid, Ian	Osteonecrosis of the Jaw -- Who Gets It, and Why?	44 Bone 4 (2009)
PX-3003	2009	Brunello, Antonella; Saia, Georgia; Bedogni, Alberto; Scaglione, Daniela; Basso, Umberto	Worsening of Osteonecrosis of the Jaw During Treatment with Sunitinib in a Patient with Metastatic Renal Cell Carcinoma	44 Bone 173 (2009)
PX-3004	Dec-08	Edwards, Beatrice J.; Gounder, Mrinal; McKoy, June M.; Boyd, Ian; Farrugia, Mathew; Migliorati, Cesar A.; Marx, Robert; Ruggiero, Salvatore; Dimopoulos, Meletios; Raisch, Dennis; Singhal, Seema; Carson, Ken; Obadina, Eniola; Trifilio, Steve	Pharmacovigilance and Reporting Oversight in US FDA Fasttrack Process: Bisphosphonates and Osteonecrosis of the Jw	9 Lancet Oncology 1166 (2008)

PX-3005	Dec-08	Greuter, S.; Schmid, F.; Ruhstaller, T.; Thuerlimann, B.	Bevacizumab-Associated Osteonecrosis of the Jaw	19 Annals of Oncology 2091 (2008)
PX-3006	1-Oct-08	Sarasquete, Maria E.; Garcia-Sanz, R; Marin, L.; Alcoceba, M.; Chillon, M.C.; Balanzategui, A.; Santamaria, C.; Rosinol, L.; de la Rubia, J.; Hernandez, M.T.; Garcia-Navarro, I.; Lahuerta, J.J.; Gonzalez, M.; San Miguel, Jesus F.	Bisphosphonate-Related Osteonecrosis of the Jaw is Associated with Polymorphisms of the Cytochrome P450 CYP2C8 in Multiple Myeloma: A Genome-Wide Single Nucleotide Analysis	112 Blood 2709 (2008)
PX-3007	Oct-08		FDA Career Staff Objected to Agency Preemption Policies	US House of Representatives Committee on Oversight and Government Reform Majority Staff Report, Oct 2008
PX-3008	15-Sep-08	Hatoum, Hind T.; Lin, Swu-Jane; Smith, Mathew R.; Barghout, Victoria; Lipton, Allan	Zoledronic Acid and Skeletal Complications in Patients With Solid Tumors and Bone Metastases -- Analysis of a National Medical Claims Database	113 Cancer 1438 (2008)
PX-3009	Sep-08	Drake, Matthew T.; Clarke, Bart L.; Khosla, Sundeep	Bisphosphonates: Mechanism of Action and Role in Clinical Practice	83 Mayo Clinic Proceedings 1032 (2008)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3010	20-Aug-08	Estilo, Cherry L.; Fornier, Monica; Farooki, Azeez; Carlson, Diane; Bohle, George III; Huryn, Joseph M.	Osteonecrosis of the Jaw Related to Bevacizumab	26 Journal of Clinical Oncology 4037 (2008)
PX-3011	Aug-08	Visekruna, Maja; Wilson, Deborah; McKiernan, Fergus Eoin	Severely Suppressed Bone Turnover and Atypical Skeletal Fragililty	93 Journal of Clinical Endocrinology and Metabolism 2948 (2008)
PX-3012	29-Jul-08	LaVerde, Nicla; Bareggi, Claudia; Garassino, Marina; Borgonova, Karen; Sburlati, Paola; Pedretti, Donata; Bianchi, Celso; Perrone, Silvia; Mihali, Dorian; Cobelli, Stefano; Mantica, Cristina; Rizzo, Aurora; Farina, Gabriella	Osteonecrosis of the Jaw (ONJ) in Cancer Patients Treated With Bisphosphonates: How the Knowledge of a Phenomenon Can Change Its Evolution	___ Support Care Cancer ___ (2008) (e-publication pre-print)
PX-3013	Jun-08	Hess, Lisa M.; Jeter, Joanne M.; Benham-Hutchins, Marge; Alberts, David S.	Factors Associated with Osteonecrosis of the Jaw Among Bisphosphonate Users	121 American Journal of Medicine 475 (2008)

PX-3014	Jun-08	Hoff, Ana O.; Toth, Bela B.; Altundag, K.; Johnson, Marcella M.; Warneke, Carla L.; Hu, Mimi; Nooka, Ajay; Sayegh, Gilbert; Guarneri, Valentina; Desrouleaux, Kimberly; Cui, Jeffrey; Adamus, Andrea; Gagel, Robert F.; Hortobagyi, Gabriel N.	The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates	23 Journal of Bone and Mineral Research 826 (2008)
PX-3015	20-May-08	Dickerson, L.C.; Desai, N.; Walden, E.; Chang, M.; Jiang, Y.; George, T.J.	Osteonecrosis of the Jaw Incidence and Contributing Risk Factors in Cancer Patients Treated with IV Bisphosphonates: A Veterans Administration Healthcare Study (Abstract 20511)	26 Journal of Clinical Oncology (Supp.) Abstract 20511 (2008)
PX-3016	20-May-08	Bamias, A.; Kastritis, E.; Melakopoulos, I.; Gika, D.; Roussou, M.; Migkou, M.; Elevtherakis, Papaiakovou, E.; Dimopoulos, M.A.	Osteonecrosis of the Jaw (ONJ) in Patients with Prostate (PC) or Breast (BC) Cancer Treated with Bisphosphonates: Study of the Effect of the Application of Preventive Measures (Abstract No. 16025)	26 Journal of Clinical Oncology (Supp) Abstract 16025 (2008)
PX-3017	May-08	Sarin, J.; Derossi, S.S.; Akintoye, S.O.	Updates on Bisphosphonates and Potential Pathobiology of Bisphosphonate-Induced Jaw Osteonecrosis	14 Oral Diseases 277 (2008)



1	PX-3018	May-08	Brufsky, A.; Bundred, N.; Coleman, R.; Lambert-Falls, R.; Mena, R.; Hadji, P.; Jin, L.; Schenk, N.; Ericson, S.; Perez, E. A.	Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer Receiving Adjuvant Letrozole	13 Oncologist 503 (2008)
2					
3					
4					
5					
6					
7	PX-3019	May-08	McArthur, H.L.; Estilo, C.; Hury, J.; Williams, T.; Fournier, M.; Traina, T. A.; Howard, J.; Hudis, C.A.; Dickler, M.N.	Osteonecrosis of the Jaw (ONJ) Among Intravenous (IV) Bisphosphonate- and/or Bevacizumab-Treated Patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC) (Abstract 9588).	26 Journal of Clinical Oncology (Supp.) Abst. No. 9588 <a href="http://pediatrica.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abstract_detail_view&amp;confID=55&amp;abstractID=32423">http://pediatrica.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abstract_detail_view&amp;confID=55&amp;abstractID=32423</a> - Accessed 12/8/08
8					
9					
10					
11					
12					
13					
14					
15	PX-3020	May-08	Pampu A.A.; Dolanmaz D, H.H.	Histomorphologic evaluation of the effects of zoledronic acid on mandibular distraction	J Oral Maxillofac Surg 2008 May; 66(5): 905-10
16					
17					
18	PX-3021	Apr-08	Khan, Aliya A.; Sandor;Dore ; Morrison;Al lsahli;Amin ; Peters;Hanley;Chaudry; Dempster;Glorieux;Neville;Talwar; Clokie;Al Mardini;Paul;Khosla;Josse;Sutherland;Lam;Car michael;Blanas;Kendler ;Petak;St.-Marie;Brown ;Evans;Rios ; Compston, J.E.	Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw	35 Journal of Rheumatology 547 (2008) (First Release June 2008)
19					
20					
21					
22					
23					
24					
25					
26					
27					
28					

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3022	Apr-08	Cafro, Anna Maria	Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid	8 Clinical Lymphoma Myeloma 111 (2008)
PX-3023	20-Mar-08	Dodson, Thomas B.; Raje, Noopur S.; Caruso, Paul A.; Rosenberg, Andrew E.	Case 9-2008: A 65-Year-Old Woman With a Nonhealing Ulcer of the Jaw	358 New England Journal of Medicine 1283 (2008)
PX-3024	Mar-08	Pendrys, David G.; Silverman, Stuart L.	Osteonecrosis of the Jaws and Bisphosphonates	6 Current Osteoporosis Reports 31 (2008)
PX-3025	Mar-08	Burkinshaw, Roger; Winter, Matt; Thorpe, Helen; Pedlar, Jon; Coleman, Rob	Osteonecrosis of the Jaw and Dental Related Adverse Events During Adjuvant Therapy for Early Breast Cancer: Initial Dental Safety Findings from the AZURE Study	34 Cancer Treatment Reviews S75 (Supp.) (2008)
PX-3026	21-Feb-08	Ray, Wayne A.	Learning from Aprotinin -- Mandatory Trials of Comparative Efficacy and Safety Needed	358 New England Journal of Medicine 840 (2008)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3027	4-Feb-08	Hoff, Ana O.; Toth, Bela B.; Altundag, K.; Johnson, Marcella M.; Warneke, Carla L.; Hu, Mimi; Nooka, Ajay; Sayegh, Gilbert; Guarneri, Valentina; Desrouleaux, Kimberly; Cui, Jeffrey; Adamus, Andrea; Gagel, Robert F.; Hortobagyi, Gabriel N.	The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates	23 Journal of Bone and Mineral Research 826 (2008) (On Line Publication 2-4-08)
PX-3028	Feb-08	Grant, Bao-Thy; Amenedo, Christopher; Freeman, Katherine; Kraut, Richard A.	Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases	66 Journal of Oral and Maxillofacial Surgery 223 (2008)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3029	Feb-08	Addeo, Raffaele; Nocera, Vincenzo; Faiola, Vincenzo; Vincenzi, Bruno; Ferraro, Gabriella; Montella, Liliana; Guarrasi, Rosario; Rossi, Eugenio; Cennamo, Gregorio; Tonini, Giuseppe; Capasso, Elena; Santini, Daniele; Caraglia, Michele; Del Prete, Salvatore	Management of Pain in Elderly Patients Receiving Infusion of Zoledronic Acid for Bone Metastasis: A Single-Institution Report	16 Support Care Cancer 209 (2008)
PX-3030	Jan-08	Cartsos, Vassiliki M.; Zhu, Shao; Zavras, Athanasios I.	Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A Medical Claims Study of 714,217 People	139 Journal of the American Dental Association 23 (2008)
PX-3031	Jan-08	Grbic, John T.; Landesberg, R.; Lin, S.Q.; Mesenbrink P.; Reid, I.R.; Leung, P.C.; Casas, N.; Recknor, C.P.; Hua, Y.; Delmas, P.D.; Eriksen, Erik F.	Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial	139 Journal of the American Dental Association 32 (2008)

PX-3032	Jan-08	Vieillard, Marie-Helene; Maes, Jean-Michel; Penel, Guillaume; Facon, Thierry; Magro, Leonardo; Bonneterre, Jacques; Cortet, Bernard	Thirteen Cases of Jaw Osteonecrosis in Patients on Bisphosphonate Therapy	75 Joint Bone Spine 34-40 (2008)
PX-3033	Jan-08	Abu-Id, Mario H.; Warnke, Patrick H.; Gottschalk, Joachim; Springer, Ingo; Wiltfang, J.; Acil, Yahya; Russo, Paul A. J.; Kreuzsch, Thomas	"Bis-Phossy Jaws" -- High and Low Risk Factors for Bisphosphonate-Induced Osteonecrosis of the Jaw	36 Journal of Craniomaxillofacial Surgery 95 (2008)
PX-3034	Jan-08	Khamaisi, M.; Elad, S.; Wilkinson, Gregg S.; Kuo, Yong-Fang; Freeman, Jean L.; Goodwin, James S.	Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis	100 Journal of the National Cancer Institute 155 (2008)
PX-3035	Jan-08	Ruggiero Salvatore L.; Woo Sook-Bin	Biophosphonate-Related Osteonecrosis of the Jaws	52 Dental Clinics of North America 111 (2008)
PX-3036	Jan-08	Capsoni, F.	Bisphosphonate-Associated Osteonecrosis of the Jaw in Rheumatology: A Sistematic [sic] Review	60 Reumatismo 6 (2008)
PX-3037	2008	Boonyapakorn, Thacharot; Schirmer, Ingrid; Reichart, Peter A.; Sturm, Isrid; Massenkeil, Gero	Bisphosphonate-Induced Osteonecrosis of the Jaws: Prospective Study of 80 Patients With Multiple Myeloma and Other Malignancies	20 Oral Oncology 1-15 (2008)

PX-3038	2008	Wessel, John H.; Dodson, Thomas B.; Zavras, Athanasios	Zoledronate, Smoking and Obesity are Strong Risk Factors for Osteonecrosis of the Jaw: A Case- Control Study	66 Journal of Oral and Maxillofacial Surgery 625 (2008)
PX-3039	2008	Allen, Matthew R.; Burr, David B.	Mandible Matrix Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate Treatment	66 Journal of Oral and Maxillofacial Surgery 987 (2008)
PX-3040	2008	Ibrahim, Toni; Barbanti, Francesca; Giorgio- Marrano, Gianluca; Mercatali, Laura; Ronconi, Sonia; Vicini, Claudio; Amadori, Dino	Osteonecrosis of the Jaw in Patients With Bone Metastases Treated With Bisphosphonates: A Retrospective Study	13 Oncologist 330 (2008)
PX-3041	2008	Barrett, Stephen	A Critical Look at Cavitation Osteopathosis, NICO, and "Biological Dentistry"	Downloaded 4/7/2008 from <a href="http://www.quackwatch.org/01QuackeryRelatedTopics/cavitation.html">http://www.quackwatch.org/01QuackeryRelatedTopics/cavitation.html</a>
PX-3042	2008	Adamo, Vincenzo; Caristi, Nicola; Sacca, Marcello Maugeri; Ferraro, Giuseppa; Arcana, Concetta; Maisano, Roberto; Santini, Daniele; Tonini, Biuseppe	Current Knowledge and Future Directions on Bisphosphonate- Related Osteonecrosis of the Jaw in Cancer Patients	9 Expert Opinion Pharmacotherapy 1351 (2008)
PX-3043	2008	Bauss, Frieder; Pfister, Thomas; Papapoulos, Socratets	Ibandronate Uptake in the Jaw is Similar to Long Bones and Vertebrae in the Rat	26 Journal of Bone Mineral Metabolism 406-408 (2008)

1	PX-3044	2008	Walter, Christian; Al-Nawas, Bilal; Grotz, Knut 2 A.; Thomas, Christian; 3 Thuroff, Joachim W.; 4 Zinser, Viktoria; 5 Gamm, Heinold; 6 Beck, Joachim; 7 Wagner, Wilfried	Prevalence and Risk Factors of Bisphosphonate- Associated Osteonecrosis of the Jaw in Prostate Cancer Patients With Advanced Disease Treated with Zoledronate	— European Urology — (2008)
8	PX-3045	2008	Dhillon, Sohita; 9 Lyseng- Williamson, 10 Katherine A.	Zoledronic Acid -- A Review of Its Use in the Management of Bone Metastases of Malignancy	68 Drugs 507 (2008)
11	PX-3046	2008	Wimalawansa 12 , Sunil J.	Insight into Bisphosphonate- Associated Osteomyelitis of the Jaw: 13 Pathophysiology, 14 Mechanisms and Clinical Management	7 Expert Opinion Drug Safety 491 (2008)
15	PX-3047	2008	Santini, Daniele; 16 Martini, Federico; 17 Fratto, Maria 18 Elisabetta; 19 Galluzzo, Sara; 20 Vincenzi, Bruno; 21 Agrati, Chiara; 22 Turchi, Federica; 23 Piacentrini , Paola; 24 Rocci, Laura; 25 Manavalan, John S.; 26 Tonini, Giuseppe; 27 Poccia, Fabrizio	In Vivo Effects of Zoledronic Acid on Peripheral T Lymphocytes in Early Breast Cancer Patients	57 Cancer Immunology and Immunotherapy 521 (2008)
28	PX-3048	2008	Pavlakis, N.; Schmidt, R.I.; Stockler, M.	Bisphosphonates for Breast Cancer (Review)	The Cochrane Collaboration (2008)

PX-3049	2008	Bagan, Jose V.; Jimenez, Yolanda; Diaz, Jose M.; Murillo, Judith; Sanchis, Jose M.; Poveda, Rafael; Carbonell, Enrique; Gavalda, Carmen; Scully, Crispian	Osteonecrosis of the Jaws in Intravenous Bisphosphonate Use: Proposal for a Modification of the Clinical Classification	___ Oral Oncology ___ (2008)
PX-3050	2008	Dimopoulos, M.A.; Kastritis, E.; Barmia, C.; Melakopoulos, I.; Gika, D.; Roussou, M.; Migkou, M.; Eleftherakis-Papaiakovou, E.; Christoulas, D.; Terpos, E.; Bamias, A.	Reduction of Osteonecrosis of the Jaw (ONJ) After Implementation of Preventive Measures in Patients with Multiple Myeloma Treated with Zoledronic Acid	___ Annals of Oncology ___ (2008)
PX-3051	2008	Kwek, Ernest Beng Kee; Goh, Seo Kiat; Koh, Joyce Suang Bee; Png, Meng Ai; Howe, Tet Sen	An Emerging Pattern of Subtrochanteric Stress Fractures: A Long-Term Complication of Alendronate Therapy?	39 Injury 224 (2008)
PX-3052	2008	Chang, Jun-Dong; Hur, Mina; Lee, Sang-Soo; Yoo, Je-Hyun; Lee, Kyu Man	Genetic Background of Nontraumatic Osteonecrosis of the Femoral Head in the Korean Population	466 Clinical Orthopedics and Related Research 1041 (2008)
PX-3053	2008	Dai, X.L.; Hong, J.M.; Oh, B.; Cho, Y.S.; Lee, J.Y.; Park, E.K.; Kim, C.Y.; Kim, T.H.; Kim, S.Y.	Association Analysis of Tissue Factor Pathway Inhibitor Polymorphisms and Haplotypes with Osteonecrosis of the Femoral Head in the Korean Population	26 Molecules and Cells -- (2008)



1	PX-3054	2008	Glueck, Charles J.; Freiberg, Richard A.; Wang, Ping	Heritable Thrombophilia- Hypofibrinolysis and Osteonecrosis of the Femoral Head	466 Clinical Orthopedics and Related Research 1034 (2008)
2	PX-3055	2008	Lehrer, Steven; Montazem, Andre; Ramanathan, Lakshmi; Pessin- Minsley, Melissa; Pfail, John; Stock, Richard G.; Kogan, Rita	Normal Serum Bone Markers in Bisphosphonate- Induced Osteonecrosis of the Jaws	106 Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology 389 (2008)
3	PX-3056	2008	McArthur, H.L.; Estilo, C.; Hury, J.; Williams, T.; Fornier, M.; Traina, T. A.; Howard, J.; Hudis, C.A.; Dickler, M.N.	Slides Accompanying Osteonecrosis of the Jaw (ONJ) Among Intravenous (IV) Bisphosphonate- and/or Bevacizumab- Treated Patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC) (Abstract 9588).	schweiz Monatsschr Zahnmed. 2008;118(2):11 3-23. French, German
4	PX-3057	2008	Boonyapakorn, Thacharot; Schirmer, Ingrid; Reichart, Peter A.; Sturm, Isrid; Massenkeil, Gero	Bisphosphonate- Induced Osteonecrosis of the Jaws: Prospective Study of 80 Patients With Multiple Myeloma and Other Malignancies	44 Oral Oncology 857 (2008)
5	PX-3058	2008	Reade, Michael C.; Delaney, Anthony; Bailey, Michael J.; Angus, Derek C.	Bench-to-Bedside Review: Avoiding Pitfalls in Critical Care Meta-Analysis - - Funnel Plots, Risk Estimates, Types of Heterogeneity, Baseline Risk and the Ecologic Fallacy	12 Critical Care 220 (2008)
6	PX-3059	2008	Karsdal MA et al	Osteoclasts secrete non-bone derived signals that induce bone formation	Biochem Biophys Res Commun. 2008
7	PX-3060	2008	De Vernejoul MC	Sclerosing Bone Disorders	Best Prac Res Clin Rheumatol 2008 Marc; 22 (1): 71-83

1	PX-3061	2008	Dhillon S, Lyseng- Williamson KA	Zolendric acid: A review of its use in the management of bone metastases of malignancy	Auckland: Wolters Kluwer Health; 2008
2	PX-3062	2007	Vance, Michael A.	Osteonecrosis of the Jaw and Bisphosphonates: A Comparison with White Phosphorus, Radium, and Osteopetrosis	1 Clinical Toxicology 1- 10 (2007)
3	PX-3063	Dec-07	Jadu, F.; Lee, L.; Pharoah, M.; Reece, D.; Wang, L.	A Retrospective Study Assessing the Incidence, Risk Factors and Comorbidities of Pamidronate-Related Necrosis of the Jaws in Multiple Myeloma Patients	18 Annals of Oncology 2015 (2007)
4	PX-3064	Dec-07	Bertoldo, Francesco; Santini, Daniele; Lo Cascio, Vincenzo	Bisphosphonates and Osteomyelitis of the Jaw: A Pathogenic Puzzle	4 Nature Clinical Practice Oncology 711 (2007)
5	PX-3065	Dec-07	Marx , R.E.; Cillo, J.E., Jr.; Ulloa, J.J.	Oral Bisphosphonate- Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment	65 Journal of Oral and Maxillofacial Surgery 2397 (2007)
6	PX-3066	Dec-07	Diel, Ingo J.; Fogelman, I.; Al- Nawas; B.; Hoffmeister , B.; Migliorati, C.; Gligorov, J.; Vaananen, K.; Pylkkanen, L.; Pecherstorfer, M.; Aapro, M.S.	Pathophysiology, Risk Factors and Management of Bisphosphonate- Associated Osteonecrosis of the Jaw: Is There a Diverse Relationship of Amino- and Non- Aminobisphosphonates ?	64 Critical Reviews in Oncology/Hemat ology 198 (2007)
7	PX-3067	Dec-07	Cheung, R.K.; Leung, K.K.; Lee, K.C.; Chow, T.C.	Sequential non- Traumatic Femoral Shaft Fractures in a Patient on Long-Term Alendronate	13 Hong Kong Medical Journal 485 (2007)
8					

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3068	10-Nov-07	Khosla, Sundeep; Burr, D, Dempster, DW, et al.	Editorial- Bisphosphonat- Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research	22 Journal of Bone and Mineral Research 1479 (2007)
PX-3069	2-Nov-07	Edwards, Beatrice J.; Gounder, Mrinal; McKoy, June M.; Boyd, Ian; Farrugia, Mathew; Migliorati, Cesar A.; Marx, Robert; Ruggiero, Salvatore; Dimopoulos, Meletios; Raisch, Dennis; Singhal, Seema; Carson, Ken; Obadina, Eniola; Trifilio, Steve	Bisphosphonate Use and Osteonecrosis of the Jaw: A Review of the Pharmacovigilance and Reporting of this Serious Adverse Event	Lancet Oncology (Manuscript)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3070	1-Nov-07	Lyles, Kenneth W.; Colon-Emeric, CS; Magaziner, JS; Adachi, JD; Pieper, CF; Mautalen, C; Hyldstrup, L; Recknor, C; Nordsletter, L; Moore, KA; Lavecchia, C; Zhang, J; Mesenbrink, P; Hodgson, PK; Abrams, K; Orloff, JJ; Horowitz, Z; Eriksen, EF; Boonen, S	Zoledronic Acid and Clinical Fractures and Mortality After Hip Fracture	357 New England Journal of Medicine 1799 (2007)
PX-3071	Nov-07	Lam, David K.; Sandor, George K. B.; Holmes, Howard I.; Carmichael, Robert P.; Clokie, Cameron M. L.	Marble Bone Disease: A Review of Osteopetrosis and Its Oral Health Implications for Dentists	73 Journal of the Canadian Dental Association 839 (2007)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3072	Oct-07	Khosla, Sund eep; Burr, D; Cauley, J; De mpster, D; Eb eling, P; Felsenberg, D; Gagel, R; Gil sanz, V; Guise, T; Kok a, S; McCauley, L; McGowan, J; M cKee, M; Mohl a, S; Pendrys, D; Raisz, L; Ruggiero, S; Shafer, D; Shum, L; Silv erman, SL; Va n Poznak, CH; Watts, N; Woo , S- B; Shane, Eli zabeth	Bisphosphonate- Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research	22 Journal of Bone and Mineral Research 1479- 1491 (2007)
PX-3073	Sep-07	Glueck, Charles J.; Freiberg, Richard A.; Wang, Ping	Detecting Thrombophilia, Hypofibrinolysis and Reduced Nitric Oxide Production in Osteonecrosis	18 Seminars in Arthroplasty 184 (2007)
PX-3074	Sep-07	Reid, Ian R.; Bolland, Mark J.; Grey, Andrew B.	Is Bisphosphonate- Associated Osteonecrosis of the Jaw Caused by Soft Tissue Toxicity?	41 Bone 318 (2007)
PX-3075	Sep-07	Chen, Wei- Ming; Liu, Yu-Fen; Tsai, Shih- Feng	Tracing the Genetic Origins of Osteonecrosis of the Femoral Head	18 Seminars in Arthroplasty 175 (2007)

PX-3076	19-Jul-07	Khosla, Sund eep; Burr, D; Cauley, J; Dempster, D; Ebeling, P; Felsenberg, D; Gagel, R; Gilsanz, V; Guise, T; Koksa, S; McCauley, L; McGowan, J; McKee, M; Mohl a, S; Pendrys, D; Raisz, L; Ruggiero, S; Shafer, D; Shum, L; Silverman, S; L; Van Poznak, C; H; Watts, N; Wood, S; B; Shane, Elizabeth	Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research	21 Journal of Bone and Mineral Research -- e-publication prior to print publication
PX-3077	4-Jul-07	Wilkinson, Gregg S.; Kuo, Yong-Fang; Freeman, Jean L.; Goodwin, James S.	Intravenous Bisphosphonate Therapy and Inflammatory Conditions or Surgery of the Jaw: A Population-Based Analysis	99 Journal of the National Cancer Institute 1016 (2007)
PX-3078	4-Jul-07	Woo, Sook-Bin; Solomon, Daniel H.	Bisphosphonate Therapy for Cancer and Prevalence of Inflammatory Jaw Conditions	99 Journal of the National Cancer Institute 986-987 (2007)
PX-3079	Jul-07	Wang, Estee P.; Kaban, Leonard B.; Strewler, Gordon J.; Raje, Noopur; Troulis, Maria J.	Incidence of Osteonecrosis of the Jaw in Patients With Multiple Myeloma and Breast or Prostate Cancer on Intravenous Bisphosphonate Therapy	65 Journal of Oral and Maxillofacial Surgery 1328 (2007)
PX-3080	Jul-07	Corso, A.; Varettoni, M.; Zappasodi, P.; Klersy, C.; Mangiacavalli, S.; Pica, G.; Lazzarino, M.	A Different Schedule of Zoledronic Acid Can Reduce the Risk of Osteonecrosis of the Jaw in Patients With Multiple Myeloma	21 Leukemia 1545 (2007)

PX-3081	10-Jun-07	Kyle, Robert A.; Yee, Gary C.; Sommerfield, Mark R.; Flynn, Patrick J.; Halabi, Susan; Jagannath, Sundar; Orlowski, Robert Z.; Roodman, David G.; Twilte, Patricia; Anderson, Kenneth	American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma	25 Journal of Clinical Oncology 2464 (2007)
PX-3082	Jun-07	Lam, David K.; Sandor, George K. B.; Holmes, Howard I.; Evans, A. Wayne; Clokier, Cameron M. L.	A Review of Bisphosphonate-Associated Osteonecrosis of the Jaws and Its Management	73 Journal of the Canadian Dental Association 417 (2007)
PX-3083	3-May-07	Black, Dennis M; Delmas, PD; Eastell, R; Reid, IR; Boonen, S; Cauley, JA; Cosman, F; Lakatos, P; Leung, PC; Man, Z; Mautalen, C; Mesenbrink, P; Hu, H; Caminis, J; Tong, K; Rosario-Jansen, T; Krasnow, J; Hue, TF; Sellmeyer, D; Eriksen, EF; Cummings, SR	Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis	356 New England Journal of Medicine 1809 (2007)
PX-3084	May-07	Murad, O.M.; Arora, S.; Farag, A.F.; Guber, H.A.	Bisphosphonates and Osteonecrosis of the Jaw: A Retrospective Study	13 Endocrine Practice 232 (2007)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3085	May-07	Murad, Omar M.; Arora, Surender; Farag, Amal F.; Guber, Helena A.	Bisphosphonates and Osteonecrosis of the Jaw: A Retrospective Study	13 Endocrine Practice 232 (2007)
PX-3086	May-07	Weitzman, Richard; Sauter, Nicholas; Erik Fink; Tarassoff, Peter G.; Lacerna, Leo V.; Dias, Rosh; Altmeyer, Anne; Csermak-Renner, Katalin; McGrath, Lynne; Lantwicki, Linda; Hohneker, John A.	Critical Review: Updated Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Cancer Patients -- May 2006	62 Critical Reviews in Oncology/Hematology 148 (2007)
PX-3087	Apr-07	Dannemann, C.; Gratz, K.W.; Riener, M.O.; Zwahlen, R.A.	Jaw Osteonecrosis Related to Bisphosphonate Therapy: A Severe Secondary Disorder	40 Bone 828 (2007)
PX-3088	Apr-07	Tassinari, Davide; Poggi, Barbara; Nicoletti, Stefania; Fantini, Manuela; Tamburini, Emiliano; Possenti, Cinzia; Sartori, Sergio	Zoledronic Acid Treatment at Home: Safety Data from an Observational Prospective Trial	10 Journal of Palliative Medicine 352 (2007)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3089	7-Mar-07	Shinohara, Masahiro; Koga, Takako; Okamoto, Kazuo; Sakaguchi, Shinya; Arai, Kimiko; Yasuda, Hisataka; Takai, Toshiyuki; Kodama, Tatsuhiko; Morio, Tomohiro; Geha, Raif S. ; Kitamura, Daisuke; Kurosaki, Tomohiro; Ellmeier, Wilfried; Takayanagi, Horoshi	Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals	132 Cell 794 (2007)
PX-3090	1-Mar-07	Khamaisi, Mogher; Regev, Eran; Yarom, Noam; Avni, Batia; Leitersdorf, Eran; Raz, Itamar; Elad, Sharon	Possible Association Between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis	92 Journal of Clinical Endocrinology and Metabolism 1172 (2007)
PX-3091	1-Mar-07	Bujanda, D Agular; Sarmiento, U. Bohn; Suarex, M. Cabrera; Morales, J. Agular	Assessment of Renal Toxicity and Osteonecrosis of the Jaws in Patients Receiving Zoledronic Acid for Bone Metastasis	18 Annals of Oncology 556 (2007)
PX-3092	Mar-07	Mavrokokki, Tony; Cheng, Andrew; Stein, Brien; Goss, Alastair	Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia	65 Journal of Oral and Maxillofacial Surgery 415 (2007)

PX-3093	Mar-07	Anonymous	American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws	65 Journal of Oral and Maxillofacial Surgery 369 (2007)
PX-3094	Feb-07	Krueger; C.D.; West, P.M.; Sargent, M.; Lodolce, A.E.; Pickard, A.S.	Bisphosphonate-Induced Osteonecrosis of the Jaw	41 Annals of Pharmacotherapy 276 (2007)
PX-3095	Jan-07	Dunstan, Colin R.; Felsenberg, Dieter; Seibel, Markus J.	Therapy Insight: The Risks and Benefits of Bisphosphonates for the Treatment of Tumor-Induced Bone Disease	4 Nature Clinical Practice Oncology 42 (2007)
PX-3096	2007	Walter, Christian; Groetz, Knut A; Kunkel, Martin; Al-Nawas, Bilal	Prevalence of Bisphosphonate Associated Osteonecrosis of the Jaw Within the Field of Osteonecrosis	15 Support Care Cancer 197 (2007)
PX-3097	2007	Pozzi, S; Marcheselli, R; Sacchi, S; Baldini, L; Angrilli, F; Pennese, E; Quarta, G; Stelitano, C; Caparotti, G; Luminari, S; Musto, P; Natale, D; Broglio, C; Cuoghi, A; Dini, D.; Di Tonno, P; Leonardi, G; Pianeze, G; Pitini, V; Polimeno, G; Ponchi, L; Masini, L; Musso, M; Spriano, M; Pollastrini, G	Bisphosphonate-Associated Osteonecrosis of the Jaw: A Review of 35 Cases and an Evaluation of Its Frequency in Multiple Myeloma Patients	48 Leukemia and Lymphoma 56 (2007)

PX-3098	2007	Marx, Robert E.	Oral & Intravenous Bisphosphonate- Induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment	
PX-3099	2007	Van den Wyngaert, Tim; Huizing, Manon T.; Vermorcken, Jan B.	Osteonecrosis of the Jaw Related to the Use of Bisphosphonates	19 Current Opinion in Oncology 315 (2007)
PX-3100	2007	Ortega, Cinzia; Montemurro, Filippo; Faggiuolo, Roberto; Vormola, Roberto; Nanni, Daniela; Goia, Franco; Gilardino; Marco Ottavio; Aglietta, Massimo	Osteonecrosis of the Jaw in Prostate Cancer Patients With Bone Metastases Treated With Zoledronate: A Retrospective Analysis	46 Acta Oncologica 664 (2007)
PX-3101	2007	Garcia Saenz, Jose Angel; Tarruella, Sara Lopez; Paredes, Beatriz Garcia; Lajusticia, Laura Rodriguez; Villalobos, Laura; Rubio, Eduardo Diaz	Osteonecrosis of the Jaw as an Adverse Bisphosphonate Event: Three Cases of Bone Metastatic Prostate Cancer Patients Treated With Zoledronic Acid	12 Medicina Oral Patalogia Oral Cirugia Bucal E351 (2007)
PX-3102	2007	Woo, Sook- Bin; Kalmar, John R.	Osteonecrosis of the Jaws and Bisphosphonates	100 Alpha Omegan 194-202 (2007)

PX-3103	2007	Santini, Daniele; Vincenzi, Bruno; Galluzzo, Sara; Battistoni, Fabrizio; Rocci, Laura; Venditti, Olga; Schiavon, Gaia; Angeletti, Silvia; Uzzalli, Federica; Caraglia, Michele; Dicuonzo, Giordano; Tonini, Giuseppe	Repeated Intermittent Low- Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long- Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients	13 Clinical Cancer Research 4482 (2007)
PX-3104	2007	Glickman, J. Fraser; Schmid, Andres	Farnesyl Pyrophosphate Synthase: Real-Time Kinetics and Inhibition by Nitrogen-Containing Bisphosphonates in a Scintillation Assay	5 ASSAY and Drug Development Technologies 205 (2007)
PX-3105	2007	Seton, Margaret; Krane, Stephen M.	Uses of Zoledronic Acid in the Treatment of Paget's Disease	3 Therapeutics and Clinical Risk Management 913 (2007)
PX-3106	Dec-06	Felsenberg, D.	Osteonecrosis of the Jaw -- A Potential Adverse Effect of Bisphosphonate Treatment	12 Nature Clinical Practice 662 (2006)
PX-3107	Dec-06	Hadjidakis, Dimitrios J.; Androulakis , Ioannis I.	Bone Remodeling	1092 Annals of the New York Academy of Sciences 385 (2006)
PX-3108	30-Nov- 06	Bilezikian, John P.	Osteonecrosis of the Jaw -- Do Bisphosphonates Pose a Risk?	355 New England Journal of Medicine 2278 (2006)
PX-3109	25-Nov- 06	Waclawski, Eugene R.	Osteonecrosis of the Jaw and Bisphosphonates: Historical Lesson from Occupational Medicine	333 British Medical Journal 1123 (2006)

PX-3110	Oct-06	Ruggiero, Salvatore L.; Fantasia, John; Carlson, Eric	Bisphosphonate-Related Osteonecrosis of the Jaw: Background and Guidelines for Diagnosis, Staging and Management	102 Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Edontology 433 (2006)
PX-3111	Oct-06	Sanna, G.; Preda, L.; Bruschini, R.; Rocca, M. Cossu; Ferretti, S.; Adamoli, L.; Verri, E.; Franceschelli, L.; Goldhirsch, A.; Nolè, F.	Bisphosphonates and Jaw Osteonecrosis in Patients With Advanced Breast Cancer	17 Annals of Oncology 1512 (2006)
PX-3112	Sep-06	Boyde, Alan	Jaw Bone Necrosis and Bisphosphonates: Microanatomical Questions	3 BoneKEy-Osteovision 19 (2006)
PX-3113	Sep-06	Kraj, Maria; Poglod, Ryszard; Maj, Stanislaw; Owczarska, Katarzyna	The Incidence of Jaw Osteonecrosis in Multiple Myeloma Patients Treated With Bisphosphonates.	63 Acta Pol. Pharm. 450 (2006)
PX-3114	10-Aug-06	Whyte, Michael P.	Paget's Disease of Bone	355 New England Journal of Medicine 593 (2006)
PX-3115	Aug-06	Anonymous (ADA Council of Scientific Affairs)	Dental Management of Patients Receiving Oral Bisphosphonate Therapy: Expert Panel Recommendations	137 Journal of the American Dental Association 1144 (2006)

PX-3116	Aug-06	Lacy, Martha Q.; Dispenzieri, A; Gertz, MA; Greipp, PR; Gollbach, KL; Hayman, SR; Kumar, S; Lutz, JA; Rajkumar, SV; Russell, SJ; Witzig, TE; Zeldenrust, SR; Dingli, D; Bergsagel, PL; Fonseca, R; Reeder, CB; Stewart, AK; Roy, V; Dalton, RJ; Carr, AB; Kademani, D; Keller, EE; Viozzi, CF; Kyle, RA	Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma	81 Mayo Clinic Proceedings 1047 (2006)
PX-3117	Aug-06	Kademani, Deepak; Koka, Sreenivas; Lacy, Martha Q.; Rajkumar, S. Vincent	Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy	81 Mayo Clinic Proceedings 1100 (2006)
PX-3118	Aug-06	Van den Wyngaert, T.; Huizing, M.T.; Vermorken, J.B.	Bisphosphonates and Osteonecrosis of the Jaw: Cause and Effect or a Post Hoc Fallacy?	17 Annals of Oncology 1197 (2006)
PX-3119	Jul-06	Dimitrakopoulos, I.; Magopoulos, C.; Karakasis, D.	Bisphosphonate-Induced Avascular Osteonecrosis of the Jaws: A Clinical Report of 11 Cases	35 International Journal of Oral and Maxillofacial Surgery 588 (2006)
PX-3120	Jun-06	Migliorati, C.A.; Siegal, M.A.; Elting, L.S.	Bisphosphonate-Associated Osteonecrosis: A Long-Term Complication of Bisphosphonate Treatment	7 Lancet Oncology 508 (2006)

PX-3121	Jun-06	Zavras, Athanasios I.; Zhu, Shao	Bisphosphonates Are Associated With Increased Risk for Jaw Surgery in Medical Claims Data: Is it Osteonecrosis?	64 Journal of Oral and Maxillofacial Surgery 917 (2006)
PX-3122	16-May- 06	Woo, S.B.; Hellstein, J.W.; Kalmar, J.R.	Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws	144 Annals of Internal Medicine 753 (2006)
PX-3123	3-Feb- 06	Palmqvist, Py; Lundberg, Pernilla; Persson, Emma; Johansson, Anders; Lundgren, Inger; Lie, Anita; Conaway, H. Herschel; Lerner, Ulf H.	Inhibition of Hormone and Cytokine-Stimulated Osteoclastogenesis and Bone Resorption by Interleukin-4 and Interleukin-13 Is Associated with Increased Osteoprotegerin and Decreased RANKL and RANK in a STAT6- dependent Pathway	281 Journal of Biological Chemistry 2414 (2006)
PX-3124	12-Jan- 06	Ray, Wayne A.; Stein, C. Michael	Reform of Drug Regulation -- Beyond an Independent Drug- Safety Board	354 New England Journal of Medicine 194 (2006)
PX-3125	Jan-06	Ruggiero, Salvatore; Gralow, Julie; Marx, Robert E.; Hoff, Ana O.; Schubert, Mark M.; Huryn, Joseph M.; Toth, Bela; Damato, Kathryn; Valero, Vicente	Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer	2 Journal of Oncology Practice 7 (2006)
PX-3126	2006	Naveau, Adrien; Naveau, Bertrand	Osteonecrosis of the Jaw in Patients Taking Bisphosphonates	73 Joint Bone Spine 7-9 (2006)

PX-3127	2006	Dimopoulos, Meletios A.; Kastritis, E.; Anagnostopoulos, A.; Melakopoulos, I.; Gika, D.; Moulopoulos, L.A.; Bamia, C.; Terpos, E.; Tsionos, K.; Bamias, A.	Osteonecrosis of the Jaw in Patients With Multiple Myeloma Treated With Bisphosphonates: Evidence of Increased Risk After Treatment With Zoledronic Acid	91 Haematologica 968 (2006)
PX-3128	2006	Zervas, Kostas; Verrou, Evgenia; Teleloudis, Zisis; Vahtsevanos, Konstantinos; Banti, Anastasia; Mihou, Dinutra; Krikelis, Dimitris; Terpos, Evangelos	Incidence, Risk Factors and Management of Osteonecrosis of the Jaw in Patients With Multiple Myeloma: A Single-Centre Experience in 303 Patients	134 British Journal of Haematology 620 (2006)
PX-3129	2006	Zarychanski, Ryan; Elphee, Erin; Walton, Paul; Johnston, James	Osteonecrosis of the Jaw Associated With Pamidronate Therapy	81 American Journal of Hematology 73 (2006)
PX-3130	2006	Badros, Ashraf; Weikel, D.; Salama, A.; Goloubeva, O.; Schneider, A.; Rapoport, A.; Fenton, R.; Gahres, N.; Sausville, E.; Ord, R.; Meiller, T.	Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors	24 Journal of Clinical Oncology 945 (2006)
PX-3131	2006	Aspenberg, Per	Osteonecrosis of the Jaw: What Do Bisphosphonates Do?	5 Expert Opinion Drug Safety 743 (2006)



PX-3132	2006	Dannemann, C.; Gratz, K.W.; Zwahlen, R.	Clinical Experiences with Bisphosphonate-Induced Osteonecrosis of the Jaws	136 Swiss Medical Weekly 504 (2006)
PX-3133	2006	Hellstein, J.W.; Marek, C.L.	Bisphosphonate Induced Osteonecrosis of the Jaws: An Ounce of Prevention May Be Worth a Pound of Cure	26 Special Care Dentist 8 (2006)
PX-3134	2006	Ortega, C.; Faggiuolo, R.; Vormola, R.; Montemurro, F.; Nanni, D.; Goia, F.; Aglietta, M.	Jaw Complications in Breast and Prostate Cancer Patients Treated With Zoledronic Acid	45 Acta Oncol 216 (2006)
PX-3135	2006	Hoff, A.O.; Toth, B.B.; Altundag, K.; Guarneri, V.; Adamus, A.; Nook, A.K.; Sayegn, G.G.; Johnson, M.M.; Gagel, R.F.; Hortobagyi, G.N.	Osteonecrosis of the Jaw in Patients Receiving Intravenous Bisphosphonate Therapy (Abstract 8528)	24 Journal of Clinical Oncology (Supp.) 8528 (2006) -- 2006 ASCO Annual Meeting Proceedings (post meeting edition)
PX-3136	2006	Van Poznak, Catherine; Ward, Brent B.	Osteonecrosis of the Jaw	17 Current Opinion in Orthopaedics 462 (2006)

PX-3137	2006	Tosi, Patrizia; Zamagni, E.; Cangini, D.; Tacchetti, P.; Di Raimondo, F.; Catalano, L.; D'Arco, A.; Ronconi, S.; Cellini, C.; Offidani, M.; Perrone, G.; Ceccolini, M.; Brioli, A.; Tura, S.; Baccarani, M.; Cavo, Michele	Osteonecrosis of the Jaws in Newly Diagnosed Multiple Myeloma Patients Treated With Zoledronic Acid and Thalidomide- Dexamethasone	108 Blood 3951 (2006)
PX-3138	2006	Schwartz, Harry C.	Osteonecrosis: The Need for an Evidence-Based Approach	64 Journal of Oral and Maxillofacial Surgery 1177 (2006)
PX-3139	2006	Uhl, Kathleen; Cox, Edward; Rogan, Rose; Zeldis, Jerome B.; Hixson, Dena; Furlong, Lesley- Anne; Singer, Sarah; Holliman, Tracy; Beyer, Joanne; Woolever, William	Thalidomide Use in the US -- Experience With Pregnancy Testing in the S.T.E.P.S. Programme	29 Drug Safety 321 (2006)
PX-3140	2006	Huja, Sarandeep S.; Fernandez, Soledad A.; Hill, Kara J.; Li, Yan	Remodeling Dynamics in the Alveolar Process in Skeletally Mature Dogs	288A Anatomical Record Part A 1243 (2006)

PX-3141	2006	National Institute of Arthritis and Musculoskeletal and Skin Diseases	Brochure on Osteonecrosis	
PX-3142	1-Dec-05	Bamias A.; Kastritis E.; Bamia C.; Mouloupoulos, L.A.; Melakopoulos, I.; Bozas G.; Koutsoukou, V.; Gika, D.; Anagnostopoulos, A.; Papadimitriou, C.; Terpos, E.; Dimopoulos, M.A.	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors	23 Journal of Clinical Oncology 8580 (2005)
PX-3143	Dec-05	Melo, Maico D.; Obeid, George	Osteonecrosis of the Jaws in Patients With a History of Receiving Bisphosphonate Therapy: Strategies for Prevention and Early Recognition and Early Recognition	136 Journal of the American Dental Association 1675 (2005)
PX-3144	Dec-05	Migliorati, Cesar A.; Casiglia, Jeffrey; Epstein, Joel; Jacobsen, Peter L.; Siegel, Michael A.; Woo, Sook-Bin	Managing the Care of Patients with Bisphosphonate-Associated Osteonecrosis: An American Academy of Oral Medicine Position Paper	136 Journal of the American Dental Association 1658-1668 (2005)
PX-3145	Nov-05	Marx, Robert E.; Sawatari, Yoh; Fortin, Michel; Broumand, Vishtash	Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment	63 Journal of Oral and Maxillofacial Surgery 1567 (2005)
PX-3146	27-Aug-05	Makani, S.; Mander, C.; Cox, M.; Wragg, K	Studies in Osteonecrosis	199 British Dental Journal 212 (2005)

PX-3147	11-Aug-05	Rosen, Clifford J.	Postmenopausal Osteoporosis	353 New England Journal of Medicine 595 (2005)
PX-3148	1-Aug-05	Donoghue, A. Michael	Bisphosphonates and Osteonecrosis: Analogy to Phossy Jaw	183 Medical Journal of Australia 163 (2005)
PX-3149	7-Jul-05	Durie, B. G. M.; Katz, M.; Crowley, J.	Osteonecrosis of the Jaw and Bisphosphonates	353 New England Journal of Medicine 99 (2005)
PX-3150	7-Jul-05	Maerevoet, M.; Martin, C.; Duck, L.	Osteonecrosis of the Jaw and Bisphosphonates	353 New England Journal of Medicine 100 (2005)
PX-3151	7-Jul-05	Woo, S.G.; Handle, K.; Richardson, P.G.;	Osteonecrosis of the Jaw and Bisphosphonates	353 New England Journal of Medicine 100 (2005)
PX-3152	May-05	Hellstein, John W.; Marek, Cindy L.	Bisphosphonate Osteochemonecrosis (Bis-Phossy Jaw): Is This Phossy Jaw of the 21st Century?	63 Journal of Oral and Maxillofacial Surgery 682 (2005)
PX-3153	May-05	Kohno, Norio; Aogi, Kenjiro; Minami, Hironobu; Nakamura, Seigo; Asaga, Taro; Iino, Yuichi; Watanabe, Toru; Goessl, Carsten; Ohashi, Yasuo; Takashima, Shigemitsu	Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial	23 Journal of Clinical Oncology 3314 (2005)
PX-3154	18-Apr-05	Carter, Glen; Goss, Alastair N.; Doecke, Chris	Bisphosphonates and Avascular Necrosis of the Jaw: A Possible Association	182 Medical Journal of Australia 413 (2005)
PX-3155	Mar-05	Fantasia, John E.; Damm, Douglas D.	Oral Diagnosis: Nonhealing Extraction Site	General Dentistry 161 (March- April 2005)

PX-3156	Mar-05	Agarwala, S.; Jain, D.; Joshi, V.R.; Sule, A.	Efficacy of Alendronate, A Bisphosphonate, in the Treatment of AVN of the Hip. A Prospective Open-Label Study	44 Rheumatology 352 (2005)
PX-3157	Mar-05	Takayanaqi, H.	Mechanistic Insight Into Osteoclast Differentiation in Osteoimmunology	83 Journal of Molecular Medicine 170 (2005)
PX-3158	24-Feb-05	Schneider, Hans G.; Sentry, John	Multiple Myeloma	352 New England Journal of Medicine 840 (2005)
PX-3159	24-Feb-05	Kyle, Robert A.; Rajkumar, S. Vincent	Multiple Myeloma	352 New England Journal of Medicine 841 (2005)
PX-3160	27-Jan-05	Stewart, Andrew F.	Hypercalcemia Associated With Cancer	352 New England Journal of Medicine 373 (2005)
PX-3161	2005	Lenz, J.-H.; Steiner-Krammer, B.; Schmidt, W.; Fietkau, R.; Mueller, P. C.; Gundlach, K. K. H.	Does Avascular Necrosis of the Jaws in Cancer Patients Only Occur Following Treatment With Bisphosphonates?	33 Journal of CranioMaxillofacial Surgery 395 (2005)
PX-3162	2005	Bagan, J.V.; Murillo, J.; Jimenez, Y.; Poveda, R.; Milian, M.A.; Sanchis, J.M.; Silvestre, F.J.; Scully, C.	Avascular Jaw Osteonecrosis in Association With Cancer Chemotherapy: Series of 10 Cases	34 Journal of Oral Pathology and Medicine 120 (2005)
PX-3163	2005	Markiewicz, M. R.; Margarone, J.E. 3rd; Campbell, J.H.; Aguirre, A	Bisphosphonate-Associated Osteonecrosis of the Jaws: A Review of Current Knowledge	136 Journal of the American Dental Association 1669 (2005)

1	PX-3164	2005	Sanna, G.; Zampino, M.G.; Petosi, G.; Nole, F.; Goldhirsch, A.	Jaw Avascular Bone Necrosis Associated With Long-Term Use of Bisphosphonates	16 Annals of Oncology 1207 (2005)
2					
3	PX-3165	2005	Pires, F.R.; Miranda, A.M.M.A.; Cardoso, E.S.; Cardoso, A.S.; Fregnani, E.R.; Pereira, C.M.; Correa, M.E.P.; Almeida, J.P.; de A. Alves, F.; Lopes, M.A.; de Almeida, O.P.	Oral Avascular Bone Necrosis Associated With Chemotherapy and Bisphosphonate Therapy	11 Oral Diseases 365 (2005)
4					
5					
6					
7					
8					
9					
10					
11					
12					
13					
14	PX-3166	2005	Schwartz, Harry C.	Osteonecrosis of the Jaws: A Complex Group of Disorders	63 Journal of Oral and Maxillofacial Surgery 1248 (2005)
15					
16	PX-3167	2005	Migliorati, C. A.; Schubert, M. M.; Peterson, D. E.; Seneda, L. M.	Bisphosphonate- Associated Osteonecrosis of Mandibular and Maxillary Bone: An Emerging Oral Complication of Supportive Cancer Therapy	104 Cancer 83 (2005)
17					
18					
19					
20					
21	PX-3168	2005	Schwartz, Harry C.	Bisphosphonate- Associated Osteonecrosis of the Jaws	63 Journal of Oral and Maxillofacial Surgery 1555 (2005)
22					
23	PX-3169	2005	Guarneri, V.; Donati, S.; Nicolini, M.; Giovannelli , S.; D'Amico, R.; Conte, P.F.	Renal Safety and Efficacy of IV Bisphosphonates in Patients With Skeletal Metastases Treated for up to 10 Years	10 Oncologist 842 (2005)
24					
25					
26					
27					
28	PX-3170	2005	Licata, Angelo A.	Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates	39 Annals of Pharmacotherap y 668 (2005)

1	PX-3171	2005	Odvin, Clarita V.; Zerwekh, Joseph E.; Rao, D. Sudhaker; Maalouf, Naim; Gottschalk, Frank A.; Pak, Charles Y.C.	Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy	90 Journal of Clinical Endocrinology and Metabolism 1294 (2005)
2					
3					
4					
5					
6	PX-3172	2005	Hozo, Stela Pudar; Djulgovic , Benjamin; Hozo, Iztok	Estimating the Mean and Variance From the Median, Range, and the Size of a Sample	5 BMC [BioMed Central] Medical Research Methodology 1 (2005)
7					
8					
9	PX-3173	2005	Ferretti, Gianluigi; Fabi, A.; Carlini, P.; Papaldo, P.; Cordiali Fei, P.; Di Cosimo, S.; Sales, N.; Giannarelli , D.; Alimonti, A.; Di Cocco, B.; D'Agosto, G.; Bordignon, V.; Trento, E.; Cognetti, F.	Zoledronic Acid- Induced Circulating Level Modifications of Angiogenic Factors, Metallo- Proteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients	69 Oncology 35-43 (2005)
10					
11					
12					
13					
14					
15					
16					
17					
18					
19					
20					
21	PX-3174	2005	Doll, R.; Peto, R.; Boreham, J.; Sutherland, I.	Mortality from Cancer in Relation to Smoking: 50 Years Observations on British Doctors	92 British Journal of Cancer 426 (2005)
22					
23					
24	PX-3175	2005	La Grenade, Lois; Lee, Lauren; Weaver, Joyce; Bonnell, Renan; Karwoski, Claudia; Governale, Laura; Brinker, Allen	Comparison of Reporting of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Selective COX-2 Inhibitors	28 Drug Safety 917 (2005)
25					
26					
27					
28					

PX-3176	2005	Junquera, Luis; Rodriguez-Recio, Cristian; Villarreal, Pedro; Garcia-Consuegra, Luis	Autosomal Dominant Osteopetrosis and Maxillomandibular Osteomyelitis	26 American Journal of Otolaryngology -- Head and Neck Medicine and Surgery 275 (2005)
PX-3177	2005	Vaananen, Kalervo	Mechanism of Osteoclast Mediated Bone Resorption -- Rationale for the Design of new Therapeutics	57 Advanced Drug Delivery Reviews 959 (2005)
PX-3178	2005	Jones, J.K.	Determining Causation from Case Reports	Chapter in Pharmacoepidemiology (B.L. Strom, Ed., 4th ed. 2005) at 557
PX-3179	2005	Lasseter, Kenneth C.; Pras A.G.; Denker A.; Santhanagopal A.; Daifotis A.	Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates	25 Clinical Drug Investigation 107 (2005)
PX-3180	2005	Altundag, Kadri; Altundag, Ozden; Gundeslioglu, Ozlem	Multiple Myeloma	352 New England Journal of Medicine 840 (2005)
PX-3181	2005	Young, Dianne	ONJ Reported in Bisphosphonate-Treated Patients -- An Overview	<a href="http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4095s2_index.htm">http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4095s2_index.htm</a>
PX-3182	16-Nov-04	Schuster, M.W.; Dymek, J.M.	Oral Cavity Avascular Bone Necrosis: A Newly Recognized Complication of Intravenous (IV) Bisphosphonate (Abstract 4905) Therapy in Cancer Patients (Abstract 4905).	104 Blood 308b (2004) <a href="http://www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_1071">http://www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_1071</a>
PX-3183	16-Nov-04	Durie, B.G.M.; Katz, M.; McCoy, J.; Crowley, John	Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation With Aredia and Zometa Use (Abstract 756)	104 Blood 216a (2004) <a href="http://www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_4010">http://www.abstracts2view.com/hem_sandiego2004/view.php?nu=HEM4L1_4010</a>



PX-3184	16-Nov-04	Kut, V.; Mehta, J; Tariman, J.	Osteonecrosis of the Jaw in Myeloma Patients Receiving Pamidronate or Zoledronate (Abstract 4933)	104 Blood 315b (2004) ://www.abstrac ts2view.com/he m_sandiego2004 /view.php?nu=H EM4L1_5029
PX-3185	16-Nov-04	Kut, Victoria; , Mehta, J.; Singhal, S.; Bennett, C.	Post-Marketing Assessments of Ser. Adv. Drug Reactions Reported by the Mfr. to the FDA Differ Markedly With Those from an Ind. Pharmacovigilance Prog.: Emp. Findings Based on BP-Assoc. ON Descriptors. by the Res. on AE & Repts. Proj & the Prod. Mfr. (3151)	104 Blood http://www.abs tracts2view.co m/hem_sandiego 2004/view.php? nu=HEM4L1_5234
PX-3186	28-Oct-04	Kyle, Robert A.; Rajkumar, S. Vincent	Multiple Myeloma	351 New England Journal of Medicine 1860 (2004)
PX-3187	15-Sep-04	Lugassy, G.; Shaham, R.; Nemets, A.; Ben- Dor, D.; Nahlieli, O.	Severe Osteomyelitis of the Jaw in Long Term Survivors of Multiple Myeloma: A New Clinical Entity	117 American Journal of Medicine 440 (2004)
PX-3188	15-Jun-04	Rosen, Lee S.; Gordon, David; Tchekmedyia n, N. Simon; Yanagihara, Ronald; Hirsh, Vera; Krzakowski, Maciej; Pawlicki, Marek; de Souza, Paul; Zheng, Ming; Urbanowitz, Gladys; Reitsma, Dirk; Seaman, John	Long-Term Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients With Nonsmall Cell Lung Carcinoma and Other Solid Tumors: A Randomized, Phase II, Double-Blind, Placebo-Controlled Trial	100 Cancer 2613 (2004)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3189	2-Jun-04	Saad, Fred; Gleason, Donald M.; Murray, Robin; Tchekmedyan, Simon; Venner, Peter; Lacombe, Louis; Chin, Joseph L.; Vinholes, Jeferson J.; Goas, J. Allen; Zheng, Ming	Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer	96 Journal of the National Cancer Institute 879 (2004)
PX-3190	Jun-04	Schwartz, Harry C.	Osteonecrosis and Bisphosphonates: Correlation Versus Causation	62 Journal of Oral and Maxillofacial Surgery 763 (2004)
PX-3191	15-May-04	Sweeting, Michael J.; Sutton, Alexander J.; Lambert, Paul C.	What to Add to Nothing? Use and Avoidance of Continuity Corrections in Meta-Analysis of Sparse Data	23 Statistics in Medicine 1351 (2004)
PX-3192	May-04	Ruggiero, Salvatore L.; Mehrotra, Bhoomi; Rosenberg, Tracey J.; Engroff, Stephen L.	Osteonecrosis of the Jaws Associated With the Use of Bisphosphonates: A Review of 63 Cases	62 Journal of Oral and Maxillofacial Surgery 527 (2004)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3193	2-Mar-04	Schett, Georg; Kiechl, Stefan; Redlich, Kurt; Oberhollenzer, Friedrich; Weger, Siegfried; Egger, Georg; Mayr, Agnes; Jocher, Josef; Xu, Qingbo; Pietschmann, Peter; Teitelbaum, Steven; Smolen, Josef; Willeit, Johann	Soluble RANKL and Risk of Nontraumatic Fracture	291 Journal of the American Medical Association 1108 (2004)
PX-3194	Mar-04	Pogrel, M.A.	Bisphosphonates and Bone Necrosis	62 Journal of Oral and Maxillofacial Surgery 391 (2004)
PX-3195	1-Jan-04	Rosen, Lee S.; Gordon, David H.; Dugan, William Jr.; Major, Pierre; Eisenberg, Peter D.; Provencher, Louise; Kaminski, Mary; Simeone, Joe; Seaman, John; Chen, Bee-Lian; Coleman, Robert E.	Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion	100 Cancer 36 (2004)

1	PX-3196	2004	Estilo, C.S.; Van Poznak, C.H.; Williams, T.; Evtimovska, E.; Tkach, L; Halpern, J.L.; Tunick, S.J.; Huryn, J.M.	Osteonecrosis of the Maxilla and Mandible in Patients Treated With Bisphosphonates: A Retrospective Study (Abstract 8088)	22 Journal of Clinical Oncology 8088 (Supp.) S750 (2004) <a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=3684">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abst_detail_view&amp;confID=26&amp;abstractID=3684</a>
2	PX-3197	2004	Berthold, H.K.; Diel, I.J.; Gouni- Berthold, I.	Phossy Jaw Revisited -- Do Bisphosphonates Cause "Bisphossy Jaws"?	27 Drug Safety 920 (2004)
3	PX-3198	2004	Van Poznak, C.H.; Estilo, C.L.; Sauter, N.P.; Hudis, C.A.; Williams, T.; Tunick, S.; Halpern, J.; Huryn, J.M.	Osteonecrosis of the Jaw in Patients With Metastatic Breast Cancer (Abstract No. 3057)	88 Breast Cancer Research and Treatment (Supp. 1) S131 (2004)
4	PX-3199	2004	Carter, G.D.; Goss, A.N.	Bisphosphonates and Avascular Necrosis of the Jaws	27 Australian Prescriber (Supp.) 32 (2004)
5	PX-3200	2004	Lugassy, Gilles; Nemets, Anatoly	Severe Osteomyelitis of the Jaws in Long Term Survivors Multiple Myeloma Patients Treated With Bisphosphonates: A New Clinical Entity (Abstract No. 4900)	104 Blood 307b (2004)
6	PX-3201	2004	Balcewicz- Sablinska, M.K.; Gonzales- Perez, A.; Garcia Rodriguez, L.A.	Risk of Osteonecrosis in Cancer Patients (Abstract P006)	14 Annals of Epidemiology 593 (2004)

1	PX-3202	2004	Estilo, C.S.; Van Poznak, C.H.; Williams, T.; Evtimovska, E.; Tkach, L; Halpern, J.L.; Tunick, S.J.; Huryn, J.M.	Slides Accompanying Osteonecrosis of the Maxilla and Mandible in Patients Treated With Bisphosphonates: A Retrospective Study (Abstract 8088)	22 Journal of Clinical Ecology (Supp.) S750 (2004) <a href="http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abstract_detail_view&amp;confID=26&amp;abstractID=3684">http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&amp;vmview=abstract_detail_view&amp;confID=26&amp;abstractID=3684</a>
2	PX-3203	2004	Cohen, Aaron Michael; Stavri, P. Zoe; Hersh, William R.	A Categorization and Analysis of the Criticisms of Evidence-Based Medicine	73 International Journal of Medical Informatics 35 (2004)
3	PX-3204	2004	Taranta, Anna; Fortunati, Dario; Longo, Maurizio; Rucci, Nadia; Iacomino, Enzo; Aliberti, Ferdinando; Facciuto, Enzo; Migliaccio, Silvia; Bardella, Maria Teresa; Dubini, Antonella; Borghi, Maria Orietta; Sar aifoger, Silvia; Teti, Anna; Bianchi, Maria Luisa	Imbalance of Osteoclastogenesis- Regulating Factors in Patients With Celiac Disease	19 Journal of Bone and Mineral Research 1112 (2004)
4	PX-3205	2004	Green, Jonathan R.	Bisphosphonates: Preclinical Review	9 Oncologist (Supp. 4) 3 (2004)
5	PX-3206	2004	Jewell, Nicholas P.	Statistics for Epidemiology- Attributable Risk	2004 CRC Press

PX-3207	15-Nov-03	Migliorati, Cesar A.	Bisphosphonates and Oral Cavity Avascular Bone Necrosis	21 Journal of Clinical Oncology 4253 (2003)
PX-3208	23-Oct-03	Chang, Jennie T.; Green, Lanh; Beitz, Julie	Renal Failure with the Use of Zoledronic Acid	349 New England Journal of Medicine 1676 (2003)
PX-3209	Oct-03	Tarassoff, Peter; Csermak, Katalin	Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients	61 Journal of Oral and Maxillofacial Surgery 1238 (2003)
PX-3210	Sep-03	Wang, J.; Goodger, N. M.; Pogrel, M. A.	Osteonecrosis of the Jaw Associated With Cancer Chemotherapy	61 Journal of Oral and Maxillofacial Surgery 1104-1107 (2003)
PX-3211	Sep-03	Marx, Robert E.	Pamidronate (Aredia) and Zoledronate (Zometa) Induced Avascular Necrosis of the Jaws: A Growing Epidemic	61 Journal of Oral and Maxillofacial Surgery 1115 (2003)
PX-3212	Sep-03	Kaynak, Deniz; Meffert, R; Bostanci, H; Gunhan, O; Ozkaya, OG	A Histopathological Investigation on the Effect of Systemic Administration of the Bisphosphonate Alendronate on Resorptive Phase Following Mucoperiosteal Flap Surgery in the Rat Mandible	74 Periodontal 2003 No. 9
PX-3213	19-Aug-03	Million Women Study Collaborators	Breast Cancer and Hormone-Replacement Therapy in the Million Women Study	362 Lancet 419 (2003)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3214	15-Aug-03	Rosen, Lee S.; Gordon, David; Tchekmedyian, Simon; Yanagihara, Ronald; Hirsh, Vera; Krzakowski, M.; Pawlicki, M.; de Souza, Paul; Zheng, Ming; Urbanowitz, Gladys; Reitsma, Dirk; Seaman, John J.	Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial -- The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group	21 Journal of Clinical Oncology 3150 (2003)
PX-3215	1-Aug-03	Santini, Daniele; Vincenzi, Bruno; Dicuozzo, Giordano; Avvisati, Giuseppe; Massacesi, Cristian; Battistoni, Fabrizio; Gavasci, Michele; Rocci, Laura; Tirindelli, Maria Cristina; Altomare, Vittorio; Tocchini, Massimo; Bonsignori, Maurizio; Tonini, Giuseppe	Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients	9 Clinical Cancer Research 2893 (2003)
PX-3216	31-Jul-03	Whyte, M. P.; Wenkert, D.; Clements, K.L.; McAlister, W.H.; Mumm, S.	Bisphosphonate Induced Osteopetrosis	349 New England Journal of Medicine 457-463 (2003)

PX-3217	2003	Carter, G.D.; Goss, A.N.	Bisphosphonates and Avascular Necrosis of the Jaws	48 Australian Dental Journal 268 (2003)
PX-3218	2003	Rosen, Lee S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.A.; Coleman, R.E.; Reitsma, DJ.; Chen, B.-L.; Seaman, J.J.	Long-Term Efficacy and Safety of Zoledronic Acid Compared With Pamidronate Disodium in the Treatment of Skeletal Complications in Patients With Advanced Multiple Myeloma or Breast Carcinoma: A Randomized, Double-Blind, Multicenter, Comparative Trial	98 Cancer 1735 (2003)
PX-3219	2003	Pogrel, M.A.; Miller, C.E.	A Case of Maxillary Necrosis	61 Journal of Oral and Maxillofacial Surgery 489-493 (2003)
PX-3220	2003	Marx, Robert E.; Stern D.	Oral and Maxillo-Facial Pathology: A Rationale for Diagnosis and Treatment	
PX-3221	2003	Reuther, T.; Schuster, T.; Mende, U.; Kubler, A.	Osteoradionecrosis of the Jaws As a Side Effect of Radiotherapy of Head and Neck Tumour Patients -- A Report of a Thirty Year Retrospective Review	32 International Journal of Oral and Maxillofacial Surgery 289 (2003)
PX-3222	2003	Hillner, Bruce E.; Ingle, James N.; Chlebowski, Rowan T.; Gralow, Julie; Yee, Gary C.; Janjan, Nora A.; Cauley, Jane A.; Blumenstein, Brent A.; Albain, Kathy S.; Lipton, Allan; Brown, Susan	American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer	21 Journal of Clinical Oncology 4042 (2003)



PX-3223	2003	Alberg, Anthony J.; Samet, Jonathan M.	Epidemiology of Lung Cancer	123 Chest 21S (2003)
PX-3224	2003	Kashiwagi, Maki; Chaoui, Rabih; Stallmach, Thomas; Hurlmann, Sandra; Lauper, Urs; Hebisch, Gundula	Fetal Bilateral Renal Agenesis, Phocomelia, and Single Umbilical Artery Associated with Cocaine Abuse in Early Pregnancy	67 Birth Defects Research (PartA) 951 (2003)
PX-3225	15-Nov- 02	Fournier, Pierrick; Boissier, S.; Filleur, S.; Guglielmi, J.; Cabon, F.; Colombel, M.; Clezardin, P.	Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone- Stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats	62 Cancer Research 6538 (2002)
PX-3226	2-Oct- 02	Saad, Fred; Murray, Donald M.; Murray, Robin; Tchekmedyia n, Simon; Venner, Peter; Lacombe, Louis; Chin, Joseph L.; Vinholes, Jeferson J.; Goas, J. Allen; Chen, Bee	A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone- Refractory Metastatic Prostate Carcinoma	94 Journal of the National Cancer Institute 1458 (2002)
PX-3227	Sep-02	Berenson, James R.; Hillner, Bruce E.; Kyle, Robert A.; Anderson, Ken; Lipton, Allan; Yee, Gary C.; Biermann, J. Sybil	American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma	20 Journal of Clinical Oncology 3719 (2002)

PX-3228	Jul-02	Sung, Eric C.; Chan, Stephen M.; Sakurai, Kari; Chung, Evelyn	Osteonecrosis of the Maxilla as a Complication to Chemotherapy: A Case Report	22 Special Care Dentist 142 (2002)
PX-3229	May-02	Santini, Daniele; Vincenzi, Bruno; Avvisati, Giuseppe; Dicuonzo, Giordano; Battistoni, Fabrizio; Gavasci, Michele; Salerno, Alfredo; Denaro, Vincenzo; Tonini, Giuseppe	Pamidronate Induces Modifications of Circulating Angiogenic Factors in Cancer Patients	8 Clinical Cancer Research 1080 (2002)
PX-3230	Mar-02	Agarwala, A.; Sule, A.; Pai, B.U.; Joshi, V.R.	Alendronate in the Treatment of Avascular Necrosis of the Hip	41 Rheumatology 346 (2002)
PX-3231	Jan-02	van Beek, E.R.; Lowik, C.W.G.M.; Papapoulos, S.E.	Bisphosphonates Suppress Bone Resorption by a Dir. Eff. On Early Osteoclast Precursors w/o Affecting the Osteoclastogenic Capac. Of Osteogenic Cells: The Role of Protein Geranylgeranylation in the Action of Nitrogen-Containing Bisphosphoates on Osteoclast	30 Bone 64 (2002)
PX-3232	2002	Wood, Jeanette; Bonjean, K.; Ruetz, S.; Bellheene, A.; Devy, L.; Foidart, J.M.; Castronovo, V.; Green, Jonathan R.	Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid	302 Journal of Pharmacology and Experimental Therapeutics 1055 (2002)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3233	2003	Marx, Robert E.; Stern, D.	Oral and Maxillofacial Pathology - A Rationale for Diagnosis and Treatment	
PX-3234	15-Aug- 01	Graham, David J.; Drinkard, Carol R.; Shatin, Deborah, Tsong, Yi; Burgess, Margaret J.	Liver Enzyme Monitoring in Patients Treated with Troglitazone	286 Journal of the American Medical Association 831 (2001)
PX-3235	8-May- 01	Motyckova, G.; Weilbaecher , K.N.; Horstmann, M.; Rieman, D.J.; Fisher, D.Z.; Fisher, D.E.	Linking Osteopetrosis and Pycnodysostosis: Regulation of Cathepsin K Expression by the Microphthalmia Transcription Factor Family	98 Proceedings of the National Academy of Sciences 5798 (2001)
PX-3236	1-Apr- 01	Berenson, James R.; Rosen, Lee S.; Howell, Anthony; Porter, Lester; Coleman, Robert E.; Morley, Walter; Drelcer, Robert; Kuross, Steven A.; Lipton, Allan; Seaman, John J.	Zoledronic Acid Reduces Skeletal- Related Events in Patients with Osteolytic Metastases A Double- Blind, Randomized Dose-Response Study	91 Cancer 1191 (2001)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3237	22-Feb-01	Murphy, Trudy V.; Gargiullo, Paul M.; Massoudi, Mehran S.; Nelson, David B.; Jumaan, Aisha O.; Okoro, Catherine A.; Znardi, Lynn R.; Setia, Sabeena; Fair, Elizabeth; LeBaron, Charles W.; Wharton, Melinda; Livingood, John R.	Intussusception Among Infants Given an Oral Rotavirus Vaccine	344 New England Journal of Medicine 564 (2001)
PX-3238	15-Jan-01	Seaman, J;Abdi, E;Andrew Love Cancer Centre;Bell , R;Bendigo Hospital;Bo dy, J;Boston Cancer Group;Quebe Fehling, E;Yunus, F;Journal of Clinical Oncology;Co mprehensive Cancer Institute;I nstitut Jules Bordet;Hon, J;Novartis Pharma;Feis t Weiller Cancer Center;	Zoledronic Acid is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy A Pooled Analysis of Two Randomized Controlled Clinical Trials	19 Journal of Clinical Oncology 558 (2000)
PX-3239	2001	Winqvist, Eric W.; Bauman, Glenn S.; Balogh, Judith	Nontraumatic Osteonecrosis After Chemotherapy for Testicular Cancer: A Systematic Review	24 American Journal of Clinical Oncology 603 (2001)

PX-3240	2001	Shibutani, Toshiaki; Inuduka, Akihiro; Horiki, Itaru; Luan, Qingxing; Iwayama, Yukio	Bisphosphonate Inhibits Alveolar Bone Resorption in Experimentally-Induced Peri-Implantitis in Dogs	12 Clinical Oral Implants Research 109 (2001)
PX-3241	2001	Evans, S. J. W.; Waller, P. C.; Davis, S.	Use of Proportional Reporting Ratios (PRRs) for Signal Generation from Spontaneous Adverse Drug Reaction Reports	10 Pharmacoepidemiology and Drug Safety 483 (2001)
PX-3242	2001	de Vernejoul, M. C.; Benichou, O.	Human Osteopetrosis and Other Sclerosing Disorders: Recent Genetic Developments	69 Calcified Tissue International 1 (2001)
PX-3243	2001	Rosen, L.S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M.; Coleman, R.E.; Reitsma, D.J.; Seaman, J.J.; Chen, B.L.; Ambros, Y.	Zoledronic Acid Versus Pamidronate in the Treatment of Skeletal Metastases in Patients with Breast Cancer or Osteolytic Lesions of Multiple Myeloma: A Phase III, Double-Blind, Comparative Trial	7 Cancer Journal 377 (2001)
PX-3244	2001	Mashiba, T.; Turner, C.H.; Hirano, T.; Forwood, M.R.; Johnston, C.C.; Burr, D.B.	Effects of Suppressed Bone Turnover by Bisphosphonates on Microdamage Accumulation and Biomechanical Properties in Clinically Relevant Skeletal Sites in Beagles	28 Bone 524 (2001)

1	PX-3245	2001	Mashiba, T.; Turner, C.H.; Hirano, T.; Forwood, M.R.; Jacob, D.S.; Johnston, C.C.; Burr, D.B.	Effects of High-Dose Etidronate Treatment on Microdamage Accumulation and Biomechanical Properties in Beagle Bone Before Occurrence of Spontaneous Fractures	29 Bone 271 (2001)
2					
3					
4					
5	PX-3246	2001	Jagdev, S.P.; Purohit, O.P.; Heatley, S.; Herling, C.; Coleman, R.E.	Comparison of the Effects of Intravenous Pamidronate and Oral Clodronate on Symptoms and Bone Resorption in Patients with Metastatic Bone Disease	12 Annals of Oncology 1433 (2001)
6					
7					
8					
9					
10	PX-3247	2001	Carrasquillo, Jorge A; Whatley	Alendronate Does Not Interfere with 99m Tc-Methylene Disphosphonate Bone Scanning	J Nucl Med 2001; 42: 1359-1363
11					
12					
13	PX-3248	2001	H K W Kim	Osteonecrosis and Osteonecrosis of the jaw (ONJ)	J Musculoskelet Neuronal Interact 2007; 7(4):348-349
14					
15	PX-3249	20-Dec- 00	Smalley, Walter; Shatin, Deborah; Wysowski, Diane K.; Gurwitz, Jerry; Andrade, Susan E.; Goodman, Michael; Chan, K. Arnold; Platt, Richard; Schech, Stephanie D.; Ray, Wayne A.	Contraindicated Use of Cisapride: Impact of Food and Drug Administration Regulatory Action	284 Journal of the American Medical Association 3036 (2000)
16					
17					
18					
19					
20					
21					
22					
23					
24					
25	PX-3250	Feb-00	Vaananen, H. Kalervo; Zhao, Haibo; Mulari, Mika; Halleen, Jussi M.	The Cell Biology of Osteoclast Function	113 Journal of Cell Science 377 (2000)
26					
27					
28					

1	PX-3251	2000	Mashiba, Tasuku; Hirano, Toru; Turner, Charles H.;	Suppressed Bone Turnover By Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib	15 Journal of Bone Mineral Research 613 (2000)
2			Forwood, Mark R.;		
3			Johnston, C.Conrad;		
4			Burr, David B.		
5	PX-3252	2000	Hillner, Bruce E.;	American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer	18 Journal of Clinical Oncology 1378 (2000)
6			Ingle, James N.;		
7			Berenson, James R.;		
8			Janjan, Nora A.;		
9			Albain, Kathy S.;		
10			Lipton, Allan; Yee, Gary;		
11			Biermann, J. Sybil;		
12			Chelbowski, Rowan T.;		
13			Pfister, David G.		
14	PX-3253	2000	Ball, Peter	Quinolone-Induced QT Interval Prolongation: A Not- So-Unexpected Class Effect	45 Journal of Antimicrobial Chemotherapy 557 (2000)
15					
16	PX-3254	2000	Sutton, A.J., Abrams, K.R., Jones, D.R., Sheldon, T.A., Song, F.	Methods for meta- analysis in medical research	New York, NY: John Wiley and Sons (2000)
17					
18	PX-3255	1999	Raisz, Lawrence G.	Physiology and Pathophysiology of Bone Remodeling	45 Clinical Chemistry 1353 (1999)
19					
20	PX-3256	Dec-99	Hankey, Benjamin F.; Ries, Lynn A.;	The Surveillance, Epidemiology, and End Results Program: A National Resource	8 Cancer Epidemiology, Biomarkers and Prevention 1117 (1999)
21			Edwards, Brenda K.		
22	PX-3257	Jul-99	Russell, R.G.G.;	Bisphosphonates: From the Laboratory to the Clinic and Back Again	25 Bone 97 (1999)
23			Rogers, M.J.		
24					
25					
26					
27					
28					

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3258	1999	Theriault, Richard L.; Lipton, Allan; Hortobagyi, Gabriel N.; Leff, Richard; Gluck, Stefan; Steward, John F.; Costello, Sean; Kennedy, Ian; Simeone, Joseph; Seman, John J.; Knight, Robert D.; Mellars, Kathleen; Heffernan, Maika; Reitsma, Dirk	Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial	17 Journal of Clinical Oncology 846 (1999)
PX-3259	1999	Beek, Ermond Van, Pieterman, E	Farnesyl Pyrophosphate Synthase is the Molecular Target of Nitrogen-Containing Bisphosphonates	Biochem. And Bioph Re. Comm. 264, 108-111 (1999)
PX-3260	10-Sep-98	Weissman, Neil J.; Tighe, John F.; Gottdiener, John S.; Gwynne, John T.	An Assessment of Heart-Valve Abnormalities in Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or Placebo	339 New England Journal of Medicine 725 (1998)
PX-3261	18-Apr-98	Dally, Ann	Thalidomide: Was the Tragedy Preventable?	351 Lancet 1197 (1998)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3262	15-Apr-98	O'Brien, Katherine L.; Selanikio, J. D.; Hecdivert, C.; Placide, M,-F.; Louis, M.; Barr, D.B.; Barr, J.R.; Hospedales, J.; Lewis, M.J.; Schwartz, B.; Philen, R.M.; St. Victor, S.; Espindola, J.; Needham, L.L.; Denerville, Karl	Epidemic of Pediatric Deaths from Acute Renal Failure Caused by Diethylene Glycol Poisoning	279 Journal of the American Medical Association 1175 (1998)
PX-3263	Mar-98	Barbaglio, Alberto; Cortelazzi, Roberto; Martignoni, Guido; Nocini, Pier Francesco	Osteopetrosis Complicated by Osteomyelitis of the Mandible: A Case Report Including Gross and Microscopic Findings	56 Journal of Oral and Maxillofacial Surgery 393 (1998)
PX-3264	1998	Fleisch, Herbert	Bisphosphonates: Mechanisms of Action	19 Endocrine Reviews 80 (1998)
PX-3265	1998	O'uchi, Naoto; Nishikawa, Haruko; Yoshino, Taiji; Kanoh, Hiroyuki; Motoie, Hiroyuki; Nishimori, Emi; Shimaoka, Toshio; Abe, Tetsushi; Shikama, Hisataka; Fujikura, Takashi; Matsue, Miyoko; Matsue, Ichiro	Inhibitory Effects of YM175, a Bisphosphonate, on the Progression of Experimental Periodontitis in Beagle Dogs	33 Journal of Periodontal Research 196 (1998)

PX-3266	1998	Berenson, James R.; Lichtenstein, Alan; Porter, Lester; Dimopoulos, Meletios A.; Bordoni, Roldolfo; Simeone, Joseph F.; Reitsma, Dirk J.; Heffernan, Maika; Seaman, John; Knight, Robert D.	Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events	16 Journal of Clinical Oncology 593 (1998)
PX-3267	1998	Hortobagyi, G. N.; Theriault, R.L.; Lipton, A.	Long Term Prevention of Skeletal Complication of Metastatic Breast Cancer with Pamidronate	16 Journal of Clinical Oncology 2038 (1998)
PX-3268	1998	Kapitola, J.; Zak, J.	Effect of Pamidronate on Bone Blood Flow in Oophorectomized Rats	47 Physiology Research 237 (1998)
PX-3269	1998	Friedman, L.M.; Furberg, C.D.; DeMets, D.L.	Fundamentals of Clinical Trials (3rd Ed.)	New York, Springer-Verlag
PX-3270	6-Dec-97	Egger, Matthias; Smith, George Davey; Phillips, Andrew N.	Meta-Analysis: Principles and Procedures	315 British Medical Journal 1533 (1997) -- <a href="http://www.bmj.com/cgi/content/full/315/7121/1533">http://www.bmj.com/cgi/content/full/315/7121/1533</a>
PX-3271	28-Aug-97	Connolly, Heidi M.; Crary, Jack L.; McGoon, Michael D.; Hensrud, Donald D.; Edwards, Brooks S.; Edwards, William D.; Schaff, Hartzell V.	Valvular Heart Disease Associated with Fenfluramine-Phentermine	337 New England Journal of Medicine 581 (1997)

1	PX-3272	1997	Ozmen, Y.; Klesper, B.; Lenzen, J.	Osteomyelitis of the Facial Skull in Albers-Schonberg Osteopetrosis	1 Mund Kiefer Gesichtschirur gie 121 (1997)
2	PX-3273	Oct-96	Goldman, S.	The Clinical Impact of Adverse Event Reporting	MEDWATCH, October 1996 at 1-12
3	PX-3274	30-Aug- 96	Gelb, Bruce D.; Shi, Guo-Ping; Chapman, Harold A.; Desnick, Robert J.	Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency	273 Science 1236 (1996)
4					
5					
6	PX-3275	Feb-96	Felix, R.; Hofstetter, W.; Cecchini, M.G.	Recent Developments in the Understanding of the Pathophysiology of Osteopetrosis	134 European Journal of Endocrinology 143 (1996)
7					
8					
9	PX-3276	1996	Hanada, T.; Furuta, S.; Moriyama, I.; Hanamure, Y.; Miyanohara, T.; Ohyama, M.	Maxillary Osteomyelitis Secondary to Osteopetrosis	34 Rhinology 242 (1996)
10					
11					
12					
13					
14	PX-3277	Nov-95	Tyrrell, C.T.; Bruning, P.F.; May- Levin, F.; Rose, C.; Mauriac, L.; Soukop, M.; Ford, J.M.	Pamidronate Infusions as Single- Agent Therapy for Bone Metastases: A Phase II Trial in Patients with Breast Cancer	31A European Journal of Cancer 1976 (1995)
15					
16					
17					
18					
19	PX-3278	1995	Starck, W.J.; Epker, B.N.	Failure of Osseointegrated Dental Implants After Diphosphonate Therapy for Osteoporosis: A Case Report	10 International Journal of Oral and Maxillofacial Implants 74 (1995)
20					
21					
22	PX-3279	Jan-94	Marx, R.E.; Carlson, E.R.; Smith, B.R.; Toraya, N.	Isolation of Actinomyces Species and Eikenella Corrodens From Patients With Chronic Diffuse Sclerosing Osteomyelitis (with discussion)	52 Journal of Oral and Maxillofacial Surgery 26 (1994)
23					
24					
25					
26					
27	PX-3280	30-Dec- 93	Ray, Wayne A.; Griffin, Marie R.; Avorn, Jerry	Evaluating Drugs After Their Approval for Clinical Use	329 New England Journal of Medicine 2029 (1993)
28					

PX-3281	Mar-93	van Holten-Verzantvoort, A.T.M.; Kroon, H.M.; Bijvoet, O.L.M.; Cleton, F.J.; Beex, L.V.A.M.; Blijham, G.; Hermans, J.; Neijt, J.P.; Papapoulos, S.E.; Sleetboom, H.P.; Vermey, P. Zwinderman, A.H.	Palliative Pamidronate Treatment in Patients With Bone Metastases From Breast Cancer	11 Journal of Clinical Oncology 491 (1993)
PX-3282	1992	Brunsvold, Michael A.; Chaves, Eros S.; Kornman, Kenneth S.; Aufdemorte, Thomas B.; Wood, Robert	Effects of a Bisphosphonate on Experimental Periodontitis in Monkeys	63 Journal of Periodontology 825 (1992)
PX-3283	1992	Bouquot, J.E.; Roberts, A.M.; Person, P.; Christian, J.	Neuralgia-Inducing Cavitational Osteonecrosis (NICO) -- Osteomyelitis in 224 Jawbone Samples from Patients With Facial Neuralgia	73 Oral Surgery Oral Medicine Oral Pathology 307 (1992)
PX-3284	1992	Ray, Wayne A.	Psychotropic Drugs and Injuries Among the Elderly: A Review	12 Journal of Clinical Psychopharmacology 386 (1992)
PX-3285	1992	Hommeyer, Steven H.; Varney, Dawn M.; Eary, Janet F.	Skeletal Nonvisualization in a Bone Scan Secondary to Intravenous Etidronate Therapy	33 Journal of Nuclear Medicine 748 (1992)
PX-3286	3-Jul-91	Yusuf, Salim; Wittes, Janet; Probstfield, Jeffrey; Tyroler, Herman A.	Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials	266 Journal of the American Medical Association 93 (1991)

1	PX-3287	1991	Thiebaud, Daniel; Leyvraz, Serge; von Fliedner, Vladimir; Perey, Lucien; Cornu, Pierre; Thiebaud, Sylviane; Burckhardt, Peter	Treatment of Bone Metastases from Breast Cancer and Myeloma With Pamidronate	27 European Journal of Cancer 37 (1991)
2					
3					
4					
5					
6					
7	PX-3288	1991	Sackett, D.L.; Haynes, R.B.; Tugwell, P.	Clinical Epidemiology: A Basic Science for Clinical Medicine (2nd ed.)	
8					
9	PX-3289	1991	Khochtali, H.; Abassi- Bakir, D.	Osteomyelitis of the Jaw and Osteopetrosis	92 Rev Stomatol Chir Maxillofac 273 (1991)
10					
11	PX-3290	1991	Sandler, E. Dayan; Parisi, Marguerite T.; Hattner, Robert S.	Duration of Etidronate Effect Demonstrated by Serial Bone Scintigraphy	32 Journal of Nuclear Medicine 1782 (1991)
12					
13					
14					
15	PX-3291	1990	Nandakumar, H.; Shankaramba , K.B.	Massive Sequestration of the Upper Jaw: A Case Report	28 British Journal of Oral and Maxillofacial Surgery 55 (1990)
16					
17					
18	PX-3292	1990	Eidson, M.; Philen, R.M.; Sewell, C.M.; Vorrhees, R.; Kilbourne, E.M.	L-Tryptophan and Eosinophiliamyalgia Syndrome in New Mexico	335 Lancet 645 (1990)
19					
20					
21					
22	PX-3293	1990	Myers, R.A., R.E. Marx	Use of Hyperbaric Oxygen in Post Radiation Head and Neck Surgery	NCI Monographs, Number 9:151-7
23					
24	PX-3294	Sep-89	Marks, S.C.	Osteoclast Biology: Lessons from Mammalian Mutations	34 American Journal of Medical Genetics 43 (1989)
25					
26					
27	PX-3295	Sep-89	Fouda, N.; Caracatsani s, M.; Hammarstrom , L.	Developmental Disturbances of the Rat Molar Induced by Two Diphosphonates	3 Advances in Dental Research 234 (1989)
28					

PX-3296	1989	Balogh, Judith M.; Sutherland, Susan E.	Osteoradionecrosis of the Mandible: A Review	18 Journal of Otolaryngology 245 (1989)
PX-3297	Sep-88	Griffin, Marie R.; Ray, Wayne A.; Livengood, John R.; Schaffner, William	Risk of Sudden Death Syndrome After Immunization with the Diphtheria- Tetanus-Pertussis Vaccine	319 New England Journal of Medicine 618 (1988)
PX-3298	1988	Lenz, W.	A Short History of Thalidomide Embryopathy	38 Teratology 203 (1988)
PX-3299	1988	Rossi, A.C.; Bosco, L.; Faich, G.A.; Tanner, A.; Temple, R.	The Importance of Adverse Reaction Reporting by Physicians	259 Journal of the American Medical Association 1203 (1988)
PX-3300	1987	Epstein, Joel B.; Wong, Frances L. W.; Stevenson- Moore, P.	Osteoradionecrosis: Clinical Experience and a Proposal for Classification	45 Journal of Oral and Maxillofacial Surgery 104 (1987)
PX-3301	1987	van Merkesteyne , J.P.; Bras, J.; Vermeeren, J.I.; van der Sar, A.; Statius van Eps, L.W.	Osteomyelitis of the Jaws in Pycnocystosis	16 International Journal of Oral and Maxillofacial Surgery 615 (1987)
PX-3302	1987	Hurwitz, E.S.; Barrett, M.J.; Bregman, D.	Public Health Service Study of Reye's Syndrome and Medications	257 Journal of the American Medical Association 1905 (1987)
PX-3303	1987	Marks, S.C.	Osteopetrosis -- Multiple Pathways for the Interception of Osteoclast Function	5 Applied Pathology 172 (1987)
PX-3304	1986	Kelsey, Jennifer L.; Thompson, W.D.; Evans, A.S.	Methods in Observational Epidemiology	
PX-3305	1986	Rothman, Kenneth J.	Modern Epidemiology, 1st Ed.. Chapter 12	

1	PX-3306	1986	Crocket, D.M.; Stanley, R.B.	Osteomyelitis of the Maxilla in a Patient with Osteopetrosis (Albers-Schonberg Disease)	95 Otolaryngology Head & Neck Surgery 117 (1986)
2	PX-3307	1986	Gupta, D.S.; Gupta, M.K.	Osteomyelitis of the Mandible in Marble Bone Disease	15 International Journal of Oral and Maxillofacial Surgery 201 (1986)
3	PX-3308	16-Mar- 85	Gardner, Lytt I.; Welsh- Sloan, Jannell; Cacy, Robert B.	Phocomelia in Infant Whose Mother Took Large Doses of Pyridoxine During Pregnancy	337 Lancet 636 (1985)
4	PX-3309	1985	Osborn, C.V.; Boland, T.	Osteomyelitis of the Mandible in a Patient with Malignant Osteopetrosis	40 Journal of Oral Medicine 76 (1985)
5	PX-3310	Jul-84	Pauwels, E.K.; Feitsma, R.I.	In Vitro Stability of <sup>99</sup> Tcm Bone Scan Preparations from Different Manufacturers Measured by Various Radiopharmaceutical Parameters	5 Nuclear Medicine Communications 467 (1984)
6	PX-3311	1983	Marx, Robert E.	A New Concept in the Treatment of Osteoradionecrosis	41 Journal of Oral and Maxillofacial Surgery 283 (1983)
7	PX-3312	1983	Pocock, S.J.	Clinical Trials: A Practical Approach	New York, John Wiley and Sons
8	PX-3313	1983	Friedman, L.M.; Furberg, C.D.; DeMets, D.L.	Fundamentals of Clinical Trials	Boston: John Wright & Sons
9	PX-3314	1983	Marx, Robert E.	Osteoradionecrosis: A New Concept of Its Pathophysiology	41 Journal of Oral and Maxillofacial Surgery 351 (1983)
10	PX-3315	Feb-82	Shaff, Max I.; Mathis, John M.	Osteomyelitis of the Mandible -- An Initial Feature in Late-Onset Osteopetrosis	108 Archives of Otolaryngology 120 (1982)
11	PX-3316	1982	Schwartz, H.C.	Osteonecrosis of the Jaws: A Complication of Cancer Chemotherapy	4 Head and Neck Surgery 251 (1982)

PX-3317	1981	Gotcher, J.E.; Jee, W.S.S.	The Progress of the Periodontal Syndrome in the Rice Rat -- II. The Effects of a Diphosphonate on the Periodontium	16 Journal of Periodontal Research 441-455 (1981)
PX-3318	1981	Fleisch, H.	Diphosphonates: History and Mechanisms of Action	4 & 5 Metabolic Bone Disease and Related Research 279-288 (1981)
PX-3319	Sep-79	Langmuir, Alexander D.	Guillain-Barre Syndrome: The Swine Influenza Virus Vaccine Incident in the United States of America, 1976-77: Preliminary Communication	72 Journal of the Royal Society of Medicine 660 (1979)
PX-3320	1976	Doll, R.; Peto, R.	Mortality in Relation to Smoking: 20 Years' Observations on Male British Doctors	2 British Medical Journal 1525 (1976)
PX-3321	1974	Bok, P.; van der Waal, I.	Osteomyelitis Secondary to Osteopetrosis: Report of Case	32 Journal of Oral Surgery 769 (1974)
PX-3322	Apr-72	Winer, H.J.; McMahon, R.E.; Olson, R.E.	Palatal Necrosis Secondary to Cytotoxin Therapy: Report of Case	84 Journal of the American Dental Association 862 (1972)
PX-3323	1971	Herbst, A.L.; Ulfelder, H.; Poskanzer, D.C.	Adenocarcinoma of the Vagina: Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Females	284 New England Journal of Medicine 878 (1971)
PX-3324	14-Jan-65	Hill, Austin Bradford	The Environment and Disease: Association or Causation?	58 Proceedings of the Royal Society of Medicine 295 (1965)



1	PX-3325	1964	Bayne- Jones, Stanhope; Burdette, Walter J. ; Cochran, William G. ; Farber, Emmanuel; Fieser, Louis; Furth, Jacob; Hickam, John B. ; LeMaistre, Charles; Schuman, Leonard M. ; Seevers, Maurice H.	Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service	Public Health Service Publication No. 1103 (1964)
2					
3					
4					
5					
6					
7					
8					
9					
10	PX-3326	17-Aug- 01	Dearden, W.F.	The Causation of Phosphorus Necrosis	2 British Medical Journal 408 (1901)
11					
12	PX-3327	29-Jul- 1899	Dearden, W. F.	Fragilitas Ossium Amonst Workers in Lucifer Match Factories	2 British Medical Journal 270- 271 (1899)
13					
14	PX-3328		M. R. Allen	Animal models of osteonecrosis of the jaw	J Musculoskelet Neuronal Interact 2007; 7(4):358-360
15					
16					
17	PX-3329		M. C. de Vernejoul, O. Benichou	Human Osteopetrosis and Other Sclerosing Disorders: Recent Genetic Developments	Calcif Tissue Int (2001) 69:1-6
18					
19	PX-3330		J. Kapitola, J. Zak, Z. Lacinova, V. Justova	Effect of Growth Hormone and Pamidronate on Bone Blood Flow, Bone Mineral and IGF-I Levels in the Rat	Physiol. Res. 49 (Suppl. 1): S101-S106, 2000
20					
21					
22	PX-3334		Allen et al.	Abstract, Allen et al., Exposed bone and oral sequestra following high-dose zoledronate treatment and dental extraction in a beagle dog model	
23					
24					
25					
26	PX-3335	9/25/20 06	AAOMS	AAOMS Position Paper on Bisphosphonate- Related Osteonecrosis of the Jaw Approved Sept. 25, 2006	AAOMS Position Paper on Bisphosphonat e-Related Osteonecrosis of the Jaw Approved Sept. 25, 2006
27					
28					

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

PX-3336	Winter 2007	American Association of Endodontics	Bisphosphonate Associated Osteonecrosis of the Jaw	
PX-3337	July, 2010	Bi, Y., Gao, Y. et al.	Bisphosphonates Cause Osteonecrosis of the Jaw-Like Disease in Mice	Amer. J. of Pathology, Vol. 177, No. 1
PX-3338			Inhibition by Diphosphonates of Bone Resorption in Mice and Comparison with Grey-Lethal Osteopetrosis	
PX-3339		Robert Marx	Clinical Concerns of Alendronate Use	
PX-3340		Khosla	Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors: Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment	
PX-3341		Schwartz	Paget's Disease and Bisphosphonate-Associated Osteonecrosis of the Jaws	
PX-3342		Assael	Temporomandibular Disorders in Surgical Practice: Does Science Support Treatment Decisions?	
PX-3343		Myers, Marx	Consensus Development Conference on Oral Complications of Cancer Therapies: Diagnosis, Prevention and Treatment Use of Hyperbaric Oxygen in Postradiation Head and Neck Surgery	
PX-3344	12/9/2010	MARCHIONE, MARILYNN	Promising bone drug flops in breast cancer study	Associated Press

Exhibit "D": Defendant's Exhibits

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
DX-0001		University of California, San Francisco, Medical Records for William White
DX-0002		Oregon Health and Science University, Medical Records for William White
DX-0003		Records Produced to NPC by Plaintiff for William White
DX-0004		Walgreen Company, Pharmacy Records for William White
DX-0005		Duke University, Medical Records for William White
DX-0006		Delta Dental, Insurance Records for William White
DX-0007		Guy Acheson, D.D.S., American River Dental, Medical Records for William White
DX-0008		University of California, Davis, Medical Records for William White
DX-0009		Drs. Jackson, Heise & Alpha Oral and Maxillofacial Surgery, Medical Records for William White

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		MetLife, Insurance Records for William White
		Gordon L. Douglass, D.D.S., Medical Records for William White
		Raley's, Bel Air Pharmacy, Pharmacy Records for William White
		Beverly A. Kodama, D.D.S., Medical Records for William White
		HealthNet, Insurance Records for William White
		Mark H. Zablotsky, D.D.S., Medical Records for William White
		Steven L. Brown, D.D.S., Medical Records for William White
		The Doctors Center Medical Group, Medical Records for William White
		Photographs of William White Produced by Health Care Providers
		All x- rays/radiologic al films/medical imaging/dental imaging taken of William White
	9/30/2006	Certificate of Death of William White

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
		A randomized, double blind, multi-center, comparative trial of i.v. zoledronate (4 or 8) mg versus i.v. Aredia (90 mg), as an adjunct to standard therapies, in the treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions
Dx-0021	10/16/1998	
		A randomized, double blind, multi-center, comparative trial of i.v. zoledronate (4 or 8) mg versus i.v. Aredia (90 mg), as an adjunct to standard therapies, in the treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions
Dx-0022	7/30/1998	

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12		A randomized, double blind, multi-center, trial to evaluate the safety and efficacy of zoledronate (4 or 8) administered intravenously as an adjuvant to anticancer therapy to patients with any cancer with bone metastases other than breast cancer multiple myeloma or prostate cancer
13	DX-0023 6/26/1998	
14 15 16 17 18		Agarwala S, et al. Alendronate in the Treatment of Avascular Necrosis of the Hip, Rheumatol 2002; 41: 346-347.
19 20 21 22 23		Assouline-Dayane, et al. Pathogenesis and Natural History of Osteonecrosis, Semin Arthritis Rheum 2002; 32(2): 94-124
24 25 26 27 28		Bouquot JE, McMahon RE. Neuropathic Pain in Maxillofacial Osteonecrosis, J Oral Maxillofac Surg 2000; 58: 1003-1020
	DX-0026 00/00/2000	

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 DX-0027	00/00/1969	Fleisch H, Russell RG, et al. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo, Science 1969; 165(899): 1262-64.
9 10 11 12 13 14 15 DX-0028	00/00/1996	Glueck CJ, et al. Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81: 557-566.
16 17 18 19 20 21 22 23 24 DX-0029	00/00/2003	Little DG, Peat RA, McEvoy A, et al. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res (2003) 18:2016-22.
25 26 27 DX-0030	8/7/2003	Machalaba Field Communication to ASM/OSS/RSA/RSD /BRM/RD (Aug. 7, 2003)

28

Ex. No.	Date	Description
1 2 3 4 5 6 7 DX-0031	00/00/1999	Mirzai R, Chang C, Greenspan A, Gershwin ME. The pathogenesis of osteonecrosis and the relationships to corticosteroids, J Asthma 1999; 36(1): 77-95.
8 9 10 11 12 DX-0032	8/25/1999	Open-label, extention trial intravenous infusion of zoledronate vs. Aredia in cancer patients with osteolytic bone metastases
13 14 15 16 17 DX-0033	00/00/2003	Pogrel MA, Miller CE. A Case of Maxillary Necrosis, J Oral Maxillofac Surg 2003; 61: 489-493.
18 19 20 21 22 23 24 DX-0034	08/00/2003	Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates [abstract], J Oral Maxillofac Surg 2003 Aug.; 61(8 Suppl 1):60
25 26 27 28 DX-0035	00/00/1982	Schwartz HC. Osteonecrosis of the Jaws: A Complication of Cancer Chemotherapy, Head Neck Surg 1982; 4: 251-253.



Ex. No.	Date	Description
		Shankland WE. Medullary and Odontogenic Disease in the Painful Jaw: Clinicopathologic Review of 500 Consecutive Lesions, J Craniomandibular Practice 2002; 20(4): 295-303.
DX-0036	00/00/2002	
		Sung EC, et al. Osteonecrosis of the Maxilla as a Complication to Chemotherapy: A Case Report, Spec Care Dentist 2002; 22(4): 142-146.
DX-0037	00/00/2002	
		Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients, J Oral Maxillofac Surg 2003, 61(10): 1238-1239
DX-0038	00/00/2003	
		Winer HJ, et al. Palatal Necrosis Secondary to Cytotoxic Therapy: Report of Case, J Amer Dent Assoc 1972; 84: 862-866.
DX-0039	00/00/1972	

Ex. No.	Date	Description
DX-0040	1991	Napoli et al., Aspergeilosis and necrosis of the maxilla: A case report, J Oral Maxillofacial Surg, 49:532- 534, 1991.
DX-0041	1996	Gruppo et al., The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysi s. J Lab Clin Med 1996;127:481- 489
DX-0042	1997	Glueck et al., Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med 1997;130:540- 543

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10	DX-0043 1998	Glueck et al., A preliminary pilot study of treatment of thrombophilia and hypofibrinolysis and amelioration of the pain of osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:64-73
11 12 13 14 15 16 17 18 19	DX-0044 1998	Glueck et al., Exogenous estrogen therapy may exacerbate thrombophilia, impair bone healing, and contribute to development of chronic facial pain. Cranio, The Journal of Cranio-mandibular Practice 1998;16:143-153
20 21 22 23 24	DX-0045 1998	Glueck, Neuralgia- inducing cavitational osteonecrosis- In Reply, Letter. Oral Surg O 1998;86:5-7

25  
26  
27  
28

Ex. No.	Date	Description
DX-0046	2002	Astrand et al., Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskeletal Disorders, 3:1471-1474, 2002.
DX-0047	2003	Arico et al., Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica, 88:747-753, 2003.
DX-0048	3/1/1992	Bouquot et al., Neuralgia-inducing cavitational osteonecrosis (NICO). Osteomyelitis in 224 jawbone samples from patients with facial neuralgia, Oral Surg. Oral Med. Oral Pathol, 73(3): 307-319 (1992)

Ex. No.	Date	Description
1 2 3 4 5 6 DX-0049	9/1/1992	Bouquot et al., More about neuralgia- inducing cavitation osteonecrosis (NICO), Oral Surg. Oral Med. Oral Pathol, 74(3): 348-350 (1992)
7 8 9 10 11 12 DX-0050	5/28/1987	IND 30145 (May 28, 1987) Notice of Claimed Investigational Exemption for a New Drug [CGP 23339A Disodium APD Pentahydrate]
13 14 15 DX-0051	12/20/1989	Aredia NDA 20036 (Dec 20, 1989) Original New Drug Application
16 17 DX-0052	12/20/1989	Aredia Integrated Summary of Safety
18 19 DX-0053	10/31/1991	Bilstad Ltr. to Hanagan, Aredia Approval Letter
20 21 DX-0054	1/1/1992	1992 Case Files
22 23 DX-0055	1/31/1992	Aredia Periodic Safety Report for the period 01-SEP-1991 to 30-NOV-1991
24 25 26 DX-0056	4/28/1992	Aredia Periodic Safety Report for the period 01-DEC-1991 to 29-FEB-1992
27 28 DX-0057	7/30/1992	Aredia Periodic Safety Report for the period 01-MAR-1992 to 31-MAY-1992

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		Aredia Integrated Summary of Safety
	9/23/1992	
		Aredia Periodic Safety Report for the period 01-JUN-1992 to 31-AUG-1992
	10/28/1992	
		Aredia Periodic Safety Report for the period 01-SEP-1992 to 30-NOV-1992
	1/28/1993	
		Aredia Periodic Safety Report for the period 01-DEC-1992 to 28-FEB-1993
	4/22/1993	
		Aredia Periodic Safety Report for the period 01-MAR-1993 to 31-MAY-1993
	8/3/1993	
		IND 43240 (Aug 12 1993) Investigational New Drug Application [CGP 42446]
	8/12/1993	
		Aredia Integrated Summary of Safety
	10/8/1993	
		Aredia Periodic Safety Report for the period 01-JUN-1993 to 31-AUG-1993
	12/7/1993	
		Aredia Periodic Safety Report for the period 01-SEP-1993 to 30-NOV-1993
	2/14/1994	
		Aredia Periodic Safety Report for the period 01-DEC-1993 to 28-FEB-1994
	4/14/1994	
		Aredia Periodic Safety Report for the period 01-MAR-1994 to 30-APR-1994
	8/10/1994	

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	DX-0069  9/21/1994	Sobel Ltr to Califre
	DX-0070  11/29/1994	Aredia Periodic Safety Report for the period 01-MAY-1994 to 31-JUL-1994
	DX-0071  2/3/1995	Preclinical Report: 3-month intravenous toxicity study in rats
	DX-0072  2/3/1995	CGP 42446: 3-month subcutaneous toxicity study in rats
	DX-0073  2/8/1995	Aredia Periodic Safety Report for the period 01-AUG-1994 to 31-OCT-1994
	DX-0074  2/28/1995	Aredia NDA 20036 (Feb 28, 1995) SNDA: Myeloma
	DX-0075  2/28/1995	Aredia Integrated Summary of Safety
	DX-0076  4/28/1995	Aredia Periodic Safety Report for the period 01-NOV-1994 to 31-JAN-1995
	DX-0077  7/1/1995	ODAC meeting minutes
	DX-0078  8/4/1995	Aredia Periodic Safety Report for the period 01-FEB-1995 to 30-APR-1995
	DX-0079  8/15/1995	Medical Officer Review: Aredia Efficacy Supplement for Myeloma
	DX-0080  9/1/1995	Sobel Ltr. to Birch, Aredia Multiple Myeloma Approval

Ex. No.	Date	Description
1 2 3 4 5	DX-0081 9/19/1995	CGP 42446: 26/52 Week Intravenous Toxicity Study in Mature Dogs (MIN 944045), 26-Week Interim Report
6 7	DX-0082 10/9/1995	Aredia Periodic Safety Report for the period 01-MAY-1995 to 31-JUL-1995
8 9 10 11 12 13 14	DX-0083 10/27/1995	Plasma concentrations of CGP 42 446 during a 3- month subcutaneous toxicity study in rats. Report No.: BPK(CH) 1995/046. Protocol No.: 92-6259
15 16 17	DX-0084 1/12/1996	CGP 42446: 6/12-Month Subcutaneous Toxicity Study in Rats
18 19	DX-0085 1/12/1996	Aredia NDA 20036 (Jan 12, 1996) SNDA: Bone Metastases
20 21	DX-0086 1/12/1996	Aredia Integrated Summary of Safety
22 23 24 25 26	DX-0087 11/13/1996	Preclinical Report CGP 42446: 26/52- week intravenous toxicity study in mature dogs, final report
27 28	DX-0088 11/20/1996	Aredia Periodic Safety Report for the period 01-AUG-1995 to 31-JUL-1996



Ex. No.	Date	Description
DX-0089	4/25/1997	Letter from FDA to Merck Research Laboratories, Attn. Michelle Kloss, Ph.D, NDA 20-560/S-003, S-006
DX-0090	July 1997	Aredia ISS
DX-0091	7/21/1997	Preclinical Report: effects on tibial cancellous bone in a 6/12 month subcutaneous toxicity study in rats. Bone histomorphometry.
DX-0092	8/29/1997	Clinical Trial Report. Protocol 18-Phase I and II. Title: A comparative trial of Aredia versus placebo for the prevention of skeletal-related complications in patients with breast cancer and lytic bone lesions treated with hormonal therapy. Clinical trial phase III

Ex. No.	Date	Description
1		Clinical Trial Report.
2		Protocol 19-
3		Phase I and II.
4		Title:
5		Comparative
6		trial of Aredia
7		versus placebo
8		for the
9		preventionof
10		skeletal-
11		related
12		complications
13		in patients
14		with breast
15		cancer and
16		lytic bone
17		lesions treated
18		with
19		chemotherapy.
20		Clinical trial
21		phase III
22		Aredia
23		Integrated
24		Summary of
25		Safety
26		Aredia Periodic
27		Safety Report
28		for the period
29		01AUG-1996 to
30		31-JUL-1997
31		Summary of
32		Expert Report
33		Author's
34		Meeting
35		Clinical Study
36		protocol 039
37		Aredia Safety
38		Periodic Report
39		Justice Ltr. to
40		Cutler, Aredia
41		osteolytic Bone
42		Metastases
43		Approval Letter
44		Investigators
45		Brochure -
46		Edition 6,
47		replacing
48		Edition 5 -
49		Zoledronate -
50		CGP 42446 (aka
51		ZOL446)

Ex. No.	Date	Description
1 2 3 DX-0101	12/24/1998	Aredia Periodic Safety Report for the period 01-AUG-1997 to 30-OCT-1998
4 5 DX-0102	7/1/1999	Nonclinical Summary of Toxicology Studies,
6 7 8 9 DX-0103	8/9/99	Clinical Trial Serious (Expedited) Adverse Event Experience Report (Patient No. 1303)
10 11 DX-0104	9/18/1999	Clinical trial doc, patient 1303
12 13 DX-0105	10/4/1999	Clinical trial doc, patient
14 15 16 DX-0106	11/11/1999	Summary of nonclinical pharmacology, toxicology and ADME,
17 18 DX-0107	11/11/1999	Comprehensive Study of Toxicology Studies
19 20 DX-0108	12/21/1999	Zometa NDA 21-223
21 22 DX-0109	12/21/1999	Zometa Integrated Summary of Safety
23 24 25 DX-0110	12/23/1999	Investigators Brochure - Amendment 1 to Edition 6 - CGP 42446 (aka ZOL446)
26 27 DX-0111	12/28/1999	Aredia Periodic Safety Report for the period 30-OCT-1998 to 31-OCT-1999
28 DX-0112	5/18/2000	Email communication with FDA re: Data Monitoring Board

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
DX-0113	5/31/2000	Record of Telephone Conversation with FDA re: DSMB
DX-0114	6/9/2000	Correspondence with FDA
DX-0115	9/18/2000	Medical Officer Review of NDA 21-223
DX-0116	9/18/2000	Correspondence with FDA
DX-0117	10/11/2000	Novartis letter enclosing Novartis minutes of September 25, 2000 meeting of the Data Safety Monitoring Board and Renal Advisory Board
DX-0118	10/11/2000	Minutes of the joint meeting of Data Safety Monitoring Board and Renal Advisory Board for Zometa (zoledronic acid) held on 25 September 2000
DX-0119	10/24/2000	Submission to FDA of recommendations of DSMB and RAB
DX-0120	12/28/2000	Aredia Periodic Safety Report for the period 31-OCT-1999 to 30-OCT-2000
DX-0121	4/25/2001	Medical Officer Review of a Complete Response to an Approvable Letter
DX-0122	6/27/2001	Patient: 2382

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		
DX-0123	7/1/2001	Zometa Safety Summary 7/01
DX-0124	7/31/2001	Type 6 NDA Supplement Index
DX-0125	8/1/2001	Zometa Package Insert. T2001-42
DX-0126	8/13/2001	Medical Officer Review of NDA 20-036
DX-0127	8/20/2001	FDA Zometa Drug Approval Package
DX-0128	8/20/2001	FDA Approval Letter from John Jenkins
DX-0129	8/20/2001	Jenkins letter to Ryan
DX-0130	8/21/2001	Zometa NDA 21386 (Aug 21, 2001) Type 6 NDA Supplement (bone metastases)
DX-0131	8/21/2001	Zometa Integrated Summary of Safety
DX-0132	10/4/2001	CGP4244603 Zoledronate; Clinical trial doc, patient 02023
DX-0133	12/6/2001	Correspondence with FDA re: Data Monitoring Board
DX-0134	12/17/2001	Zometa Periodic Safety Report for the period 20-AUG-2001 to 19-NOV-2001
DX-0135	12/21/2001	Aredia Periodic Safety Report for the period 31-OCT-2000 to 30-OCT-2001
DX-0136	1/3/2002	ODAC Briefing Package

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
DX-0137	1/31/2002	ODAC Draft minutes
DX-0138	1/31/2002	ODAC Agenda
DX-0139	1/31/2002	ODAC Tentative Agenda
DX-0140	1/31/2002	ODAC Questions to the Committee
DX-0141	1/31/2002	ODAC Member List
DX-0142	1/31/2002	ODAC Other Voting Participant List: Remote locations, Consultant, Guest Speakers, Patient Rep
DX-0143	1/31/2002	ODAC Briefing Information Document Index
DX-0144	1/31/2002	FDA Clinical Briefing Document for ODAC
DX-0145	1/31/2002	ODAC Meeting Transcript
DX-0146	1/31/2002	ODAC Draft Minutes
DX-0147	2/14/2002	FDA Medical Officer Review of a NDA 21-386
DX-0148	2/22/2002	Pazdur letter to Rinaldi
DX-0149	2/28/2002	Investigators Brochure - Edition 8, replacing Edition 7 - Zoledronate - Zometa (Zoldedronic acid) (aka zoledronate, CGP 42446, ZOL446)

Ex. No.	Date	Description
DX-0150	3/1/2002	Zometa Trial Summary
DX-0151	3/20/2002	Zometa Periodic Safety Report for the period 20-NOV-2001 to 19-FEB-2002
DX-0152	4/4/2002	13-week intravenous infusion (once tri-weekly dosing) toxicity study in dogs. Study No. 0170102. Final. (from PREDI database)
DX-0153	5/17/2002	Clinical Study Protocol ZOL3446E US32
DX-0154	5/17/2002	Clinical Study Protocol ZOL3446E US32 Am. 1
DX-0155	6/17/2002	Zometa Periodic Safety Report for the period 20 Feb 2002 to 19 May 2002
DX-0156	6/19/2002	Zometa Periodic Safety Report for the period 22-Feb-2002 to 21-May-2002
DX-0157	6/19/2002	Zometa Periodic Safety Report for the period 20 Feb 2002 to 19 May 2002

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 DX-0158	6/28/2002	ZOL446: 6-month intravenous infusion (once triweekly dosing) toxicity study in dogs with a 3-week recovery. Covance Study No. 6135-206. Sponsor Reference No. 018037. Final (from PREDI database)
10 11 DX-0159	7/2/2002	Tarassoff e-mail to Green
12 13 DX-0160	7/3/2002	Tarassoff E-Mail to Weiss
14 15 16 DX-0161	7/8/2002	Weiss letter to Ruggiero
17 18 19 20 21 22 23 24 25 26 27 28 DX-0162	7/16/2002	Green E-mail to Ruggiero
DX-0163	8/1/2002	ARGUS Case # PHEH2002US07199
DX-0164	8/27/2002	Clinical Study Protocol ZOL3446E US32 (Abbrev.) Am. 1
DX-0165	9/1/2002	Zometa Periodic Safety Report for the period 22 May 2002 to 21 Aug 2002
DX-0166	9/17/2002	Zometa Periodic Safety Report for the period 20 May 2002 to 19 Aug 2002
DX-0167	10/16/2002	Zometa Integrated Summary of Safety



Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		DSMB Closed Session Minutes DSMB Teleconference 20 November 2002
	11/20/2002	
		Zometa Periodic Safety Report for the period 22 Aug 2002 to 21 Nov 2002
	12/1/2002	
		Weiss E-mail to Abam
	12/6/2002	
		DCT Adverse Event Summary Form (Dec. 6, 2002)
	12/6/2002	
		Abam Ltr. to Migliorati
	12/9/2002	
		MedWatch Report
	12/12/2002	
		Migliorati Letter to Abam
	12/16/2002	
		Zometa Periodic Safety Report for the period 20 Aug 2002 to 19 Nov 2002
	12/17/2002	
		CZOL46/0704
	12/18/2002	
		Aredia Periodic Safety Report for the period 31-OCT-2001 to 30-OCT-2002
	12/20/2002	
		Petrone E-mail to Tarassoff (Jan. 10, 2003)
	1/10/2003	
		Weiss eml to Petrone
	1/13/2003	
		Abam Ltr. to Ruggiero
	1/13/2003	
		Weiss e-mail to Maladorno
	1/13/2003	

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	DX-0182 1/14/2003	Abam E-mail to Renner
	DX-0183 1/15/2003	Abam eml to Brown
	DX-0184 1/16/2003	CS&E DCT Adverse Event Summary
	DX-0185 1/22/2003	MedWatch Report
	DX-0186 1/30/2003	Abam eml to Ross
	DX-0187 2/4/2003	Abam eml to Ruggiero
	DX-0188 2/6/2003	Abam eml to Renner
	DX-0189 2/10/2003	Sablinska eml to Maladorno
	DX-0190 2/12/2003	Abam eml to Ruggiero
	DX-0191 2/12/2003	Abam eml to Ruggiero
	DX-0192 2/20/2003	Annual Report covering period August 20, 2001 through August 19, 2002. NDA No. 21-223 Zometa
	DX-0193 3/1/2003	Zometa Periodic Safety Report for the period 20 Nov 2002 to 19 Feb 2003
	DX-0194 3/6/2003	Abam eml to Ruggiero
	DX-0195 3/14/2003	Ruggiero E-Mail to Abam
	DX-0196 3/17/2003	Maladorno E-mail to Mellor

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		
DX-0197	3/19/2003	Miranda eml to Konecne
DX-0198	3/19/2003	Abam E-mail to Ruggiero
DX-0199	3/21/2003	Zometa Safety Periodic Report
DX-0200	3/25/2003	Fratarcangeli eml to Hei
DX-0201	3/27/2003	Maladorno E-mail to Renner, et al
DX-0202	4/2/2003	Ruggiero E-Mail to Abam
DX-0203	4/3/2003	Abam eml to Ruggiero
DX-0204	4/8/2003	Labeling History NDA 21-386/S-001
DX-0205	4/28/2003	DSMB Closed Session Minutes and Action Items DSMB Meeting 28 April 2003
DX-0206	4/30/2003	Maladorno e-mail to Renner
DX-0207	5/1/2003	Abam E-mail to Maladorno
DX-0208	5/5/2003	E-mail string re: ON Follow-Up
DX-0209	5/8/2003	Maladorno eml to Csernak-Renner
DX-0210	5/14/2003	Abam eml to Ruggiero
DX-0211	5/15/2003	Abam eml to Curtis
DX-0212	5/16/2003	Letter from FDA to Hoffmann-La Roche Inc. Attn. Mark Hope NDA 21-455

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		
DX-0213	5/20/2003	Abam eml to Maladorno
DX-0214	5/20/2003	Abam eml to Ruggiero
DX-0215	5/20/2003	Ruggiero E-Mail to Abam
DX-0216	5/20/2003	Abam E-mail to Ruggiero
DX-0217	6/1/2003	Zometa Periodic Safety Report for the Period 20 Feb 2003 through 19 May 2003
DX-0218	6/1/2003	Zometa Periodic Safety Report for the Period 22 Feb 2003 - 21 May 2003
DX-0219	6/3/2003	Abam E-mail to Maladorno
DX-0220	6/3/2003	Abam E-mail to Marx
DX-0221	6/4/2003	Maladorno E-mail to Fratarcangeli
DX-0222	6/6/2003	Marx, et al. E-Mail to Abam
DX-0223	6/6/2003	Ruiz E-mail to Hei
DX-0224	6/6/2003	Ruiz to Abam
DX-0225	6/6/2003	Hei E-mail to Fratarcangeli, et al
DX-0226	6/9/2003	Ruiz E-mail to Hei
DX-0227	6/9/2003	Spaet E-Mail to Hei
DX-0228	6/9/2003	Tarassoff E-mail to Ruiz

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		
DX-0229	6/10/2003	Tarassoff E-mail to Hei
DX-0230	6/10/2003	Tarassoff E-mail to Ruiz
DX-0231	6/11/2003	Tarassoff E-mail to Ruiz
DX-0232	6/11/2003	6/11/03 Konecne e-mail re Zometa teleconference
DX-0233	6/13/2003	6/13/03 Memo re Action Plan
DX-0234	6/18/2003	Ruggiero eml to Tarrassoff
DX-0235	6/18/2003	Maladorno memo. Re discussion with Bouquot
DX-0236	6/20/2003	Summary points from meeting with Ruggiero
DX-0237	6/20/2003	O'Meyer to Abam, Maladorno, Renner et al
DX-0238	6/20/2003	Goessl to Hei
DX-0239	6/23/2003	IPT Minutes, 6/23/03
DX-0240	6/23/2003	Ruiz e-mail to Tarassoff
DX-0241	6/24/2003	Abam e-mail to Marx
DX-0242	6/26/2003	Hei E-mail to Keller, et al
DX-0243	7/1/2003	Osteonecrosis Action Plan dated 7/1/03
DX-0244	7/3/2003	Machalaba E-mail to Fratarcangeli, et al

Ex. No.	Date	Description
1 2 3 DX-0245	7/8/2003	NPC Kickoff Meeting: Emergency Management Team Minutes
4 5 DX-0246	7/10/2003	Renner E-mail to Dunsire, et al.
6 7 DX-0247	7/11/2003	Novartis Emergency Management Team Minutes
8 9 DX-0248	7/14/2003	Novartis Emergency Management Team Minutes
10 11 DX-0249	7/15/2003	Tarassoff e-mail to Ruiz
12 13 DX-0250	7/16/2003	Novartis Emergency Management Team Minutes
14 15 DX-0251	7/18/2003	Sablinska epidemiological report
16 17 DX-0252	7/18/2003	E-mail string re: Team Meeting Minutes
18 19 20 DX-0253	7/18/2003	Aredia Clinical Expert Statement: Osteonecrosis of the Maxillofacial Area
21 22 DX-0254	7/18/2003	Letter to Pazdur from Koneckne
23 24 DX-0255	7/21/2003	Tarassoff Ltr. to Marx
25 26 DX-0256	7/22/2003	Tarassoff E-mail to Maria Ruiz and Dr. Marx
27 28 DX-0257	7/22/2003	Novartis Emergency Management Team Minutes
DX-0258	7/23/2003	Maladorno E-mail to Close

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		Novartis Emergency Management Team Minutes
	7/24/2003	
		Maladorno E- mail to Abam
	7/25/2003	
		E-mail string re: case report on Aredia in July 31 issue of NEJM
	7/29/2003	
		Novartis Emergency Management Team Minutes
	7/29/2003	
		Novartis Emergency Management Team Minutes
	7/31/2003	
		Ruiz e-mail to Tarassoff
	8/4/2003	
		Williams E-mail to Dr. Marx
	8/4/2003	
		Novartis Emergency Management Team Minutes
	8/7/2003	
		Novartis Emergency Management Team Minutes
	8/14/2003	
		Goldfarb letter to Marx
	8/18/2003	
		Pazdur letter to Sterner
	8/18/2003	
		Novartis Emergency Management Team Minutes
	8/21/2003	
		Zometa Periodic Safety Report for the Period 20 May 2003 - 19 Aug 2003
	9/1/2003	
		Zometa Periodic Safety Report for the Period 22 May 2003 through 21 Aug 2003
	9/1/2003	

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		9/2/03 Dunsire e-mail with Marx Medical Alert
	9/2/2003	
		Maxillary Osteonecrosis: Summary of Related Literature
	9/12/2003	
		NEM Meeting Minutes
	9/15/2003	
		Zometa Periodic Safety Report for the Period 20 May 2003 - 19 Aug 2003
	9/17/2003	
		ARGUS ID: PHEH2006US11546 , Bisphosphonate & Osteonecrosis of the Jaw, Version 4
	9/19/2003	
		NPC ON Site Report
	9/23/2003	
		Special Supplement CBE-0 and Application dated Sept. 23, 2003 re: Zometa with attachments, ZSupp 1 - 49 and
	9/23/2003	
		Havrilla E-mail to Williams, et al
	9/26/2003	
		NDA Labeling Supplement
	9/26/2003	
		Sterner Letter to Orloff
	9/26/2003	
		Williams E-Mail to Abam
	9/30/2003	
		Novartis Emergency Management Team Minutes
	10/1/2003	



Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		E-mail from Steven Williams to Robert Marx re: Osteonecrosis cases
	10/2/03	
	10/2/2003	Williams e-mail to Marx
	10/8/2003	Goessl eml to Maladorno
	10/10/2003	Maladorno E-mail to Goessl, et al
	10/10/2003	Novartis Emergency Management Team Minutes
	10/17/2003	Aredia Clinical Expert Statement: Osteonecrosis of the Maxillofacial Area- September 2003 Overview
	10/27/2003	Hedin Ltr. to Sterner, Aredia
	10/27/2003	Hedin Ltr. to Sterner, Zometa
	11/4/2003	Email from Stefano Fratarcangeli to Margaret Linguri Dean and Peter Tarassoff re: FDA Acknowledgement
	11/6/2003	Novartis Emergency Management Team Minutes
	11/11/2003	E-mail from Deborah Dunsire re: Zometa NEM Update

Ex. No.	Date	Description
1 2 3 4 5 6 DX-0296	11/13/2003	Novartis Emergency Management Team Minutes
7 8 9 10 11 12 DX-0297	11/14/2003	E-mail from Robert Miranda to Geoffrey Cook re Action List from NEM Meeting 11/14/03
13 14 15 16 17 18 19 DX-0298	11/18/2003	Email from Margaret Linguri re: Osteonecrosis letter to Editor JCO with attachments
20 21 22 23 24 25 26 DX-0299	11/21/2003	Chang to Pazdur re: Osteonecrosis
27 28 29 30 31 32 33 DX-0300	11/24/2003	E-mail from Robert Miranda to Carsten Goessl re Zometa New PI available (re: osteonecrosis)
34 35 36 37 38 39 40 DX-0301	12/1/2003	Zometa Periodic Safety Report for the Period (20 Aug 2003 - 19 Nov 2003)
41 42 43 44 45 46 47 DX-0302	12/1/2003	Zometa Periodic Safety Report for the Period (20 Aug 2003 - 19 Nov 2003)
48 49 50 51 52 53 54 DX-0303	12/5/2003	NPC Ad. Bd. Exec. Summary
55 56 57 58 59 60 61 DX-0304	12/5/2003	Osteonecrosis Advisory Board Dec. 5, 2003 Agenda
62 63 64 65 66 67 68 DX-0305	12/5/2003	Novartis Advisory Board Slide Deck
69 70 71 72 73 74 75 DX-0306	12/8/2003	E-mail string re: Update on Zometa Osteonecrosis Advisory Board

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	DX-0307 12/10/2003	Abam E-mail to Tarassoff
	DX-0308 12/10/2003	Tarassoff E-mail to Abam
	DX-0309 12/11/2003	DSMB Closed Session Minutes and Action Items DSMB Meeting 11-12 December 2003
	DX-0310 12/16/2003	E-mail from Katarzyna Sablinska with attachment
	DX-0311 12/18/2003	Zometa Periodic Safety Report for the Period (20 Aug 2003 - 19 Nov 2003)
	DX-0312 12/19/2003	Aredia Clinical Expert Statement, 10/03 Overview,
	DX-0313 12/23/2003	Abam E-mail to Tarassoff
	DX-0314 12/23/2003	Aredia Periodic Safety Report for the period 31-OCT-2002 to 30-OCT-2003
	DX-0315 12/23/2003	Aredia Periodic Safety Report for the period 31-OCT-2002 to 30-OCT-2003
	DX-0316 1/6/2004	Fratarcangeli E-mail to Goessl
	DX-0317 1/16/2004	Cook E-Mail to Goessl, et al.
	DX-0318 1/29/2004	Sablinska E-mail to Maladorno
	DX-0319 2/13/2004	Novartis Advisory Board
	DX-0320 2/20/2004	Miranda E-mail to Narang

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		E-mail correspondence between Miranda and Petraglia re: changes to the Zometa PI received from Dotti Pease of FDA
	2/20/2004	
	2/23/2004	Miranda E-mail to Sterner
	2/24/2004	Miranda e-mail to Pease
	2/24/2004	Miranda e-mail to Pease
	2/25/2004	Pease E-mail to Miranda, et al
	2/25/2004	Miranda to Pease
	2/25/2004	Miranda E-Mail to Pease
	2/25/2004	Miranda E-Mail to Maladorno
	2/25/2004	Maladorno to Miranda
	2/25/2004	Miranda to Dunsire
	2/25/2004	Pease E-mail to Miranda, et al
	2/25/2004	Miranda to Pease
	2/26/2004	Miranda e-mail to Pease
	2/26/2004	Miranda e-mail, forwarding Pease to Petraglia
	2/26/2004	Miranda e-mail to Pease

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		
DX-0336	2/26/2004	Miranda e-mail to Pease
DX-0337	2/26/2004	Miranda e-mail to Pease
DX-0338	2/26/2004	Miranda e-mail to Dunsire et al
DX-0339	2/26/2004	Zometa Zoledronic Acid Injection Concentrate for Intravenous Infusion Rx Only Prescribing Information
DX-0340	2/27/2004	Miranda e-mail to Narang
DX-0341	2/27/2004	Pease e-mail to Miranda
DX-0342	2/27/2004	Pazdur letter to Miranda: Revised labeling approval
DX-0343	3/1/2004	Zometa Package Insert. T2004-27
DX-0344	3/1/2004	Zometa Periodic Safety Report for the Period 20 Nov 2003 through 19 Feb 2004
DX-0345	3/19/2004	Marx fax to Tarassoff
DX-0346	3/19/2004	Abam letter to Marx
DX-0347	3/19/2004	Zometa Periodic Safety Report for the Period 20 Nov 2003 through 19 Feb 2004
DX-0348	3/23/2004	3/23/04 Dunsire e-mail forwarding MDACC info

Ex. No.	Date	Description
DX-0349	3/24/2004	Supplement Approved
DX-0350	3/24/2004	Letter from FDA to Sterner re: Aredia label
DX-0351	3/29/2004	Novartis Advisory Board Meeting - Advisors
DX-0352	3/29/2004	Novartis Advisory Board Meeting Slides
DX-0353	3/29/2004	Investigators Brochure - Edition 9, replacing Edition 8 - Zoledronate - Zometa (Zolnedronic acid) (aka zoledronate, CGP 42446, ZOL446)
DX-0354	3/29/2004	Investigators Brochure - Edition 9, replacing Edition 8 - Zoledronate - Zometa (Zolnedronic acid) (aka zoledronate, CGP 42446, ZOL446)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
		Clinical Study Report. Study NO.
		IT01[ZOL446EIT01]. Title: An open-label clinical study to evaluate the efficacy and tolerability on intravenous Zometa® (zoledronic acid) 4 mg in metastatic breast cancer patients in whom treatment with a bisphosphonate is indicated.
DX-0355	4/15/2004	Development phase: IIIb
DX-0356	4/30/2004	Abam fax to Marx
DX-0357	5/1/2004	Ruggiero E-Mail to Abam
DX-0358	5/5/2004	Novartis Emergency Management Team Minutes
DX-0359	5/6/2004	Chang 'ODS Postmarketing Safety Review' to Pazdur
DX-0360	5/11/2004	Staten to Petraglia NPC re FDA meeting
DX-0361	5/16/2004	Linguri E-mail to Stone, et al
DX-0362	5/17/2004	Goessl E-mail to Zheng
DX-0363	5/21/2004	Urbanowitz E-mail to Goessl
DX-0364	5/24/2004	Cancer Care Patient Advocacy Summit - Attendance List

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28	DX-0365 5/25/2004	Staten fax to Petraglia
	DX-0366 5/26/2004	Novartis Emergency Management Team Minutes
	DX-0367 6/1/2004	Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws
	DX-0368 6/1/2004	Zometa Periodic Safety Report for the Period 20 Feb 2004 through 19 May 2004
	DX-0369 6/21/2004	Briefing Package: Safety Update
	DX-0370 1/21/2005	Dougherty Email to Hei
	DX-0371 1/24/2005	Letter from FDA to Merck & Co., Inc., Attn: Michele Flicker NDA 21-575
	DX-0372 1/26/2005	Petraglia E-Mail to FDA
	DX-0373 1/28/2005	Dougherty Email to Hei
	DX-0374 2/10/2005	Dougherty Email to Zheng
	DX-0375 2/15/2005	Hei Email to Young
	DX-0376 2/22/2005	Hei Email to Dougherty
	DX-0377 2/24/2005	Hei Email to Macerata
	DX-0378 2/24/2005	Hei Email to Dougherty



Ex. No.	Date	Description
DX-0379	3/1/2005	Macerata Email to Lantwicki
DX-0380	3/2/2005	Petraglia E-Mail to Clifford
DX-0381	3/4/2005	www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4095T2.htm, ODAC Transcript Volume 2
DX-0382	3/4/2005	Core Presentation - Zometa ODAC
DX-0383	3/4/2005	ODAC complete package
DX-0384	3/4/2005	ODAC Slide Deck
DX-0385	3/5/2005	Food and Drug Administration. Questions to the Committee, Oncologic Drug Advisory Committee 2005 Mar. 5. available at <a href="http://www.fda.gov/ohrms/dockets/AC/05/questions/2005-4095Q2_02_Zometa-Aredia-Questions.pdf">http://www.fda.gov/ohrms/dockets/AC/05/questions/2005-4095Q2_02_Zometa-Aredia-Questions.pdf</a>

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12		An Open-label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy
	11/22/2006	
13 14 15 16 17		Guideline for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and biological Products
	12/1/998	
18 19		Clinical trial record (Patient Number 006-102)
20 21		Clinical trial record (Patient Number 22640.11160)
22 23		Clinical trial record (Patient Number 2346-20593)
24 25		Clinical trial record (Patient Number 609-2023)
26 27		Clinical trial record (Patient Number 627-2382)
28		Clinical trial record (Patient Number 1694E-1303)

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		Clinical trial record (Patient Number 521-002)
		ARGUS Case # PHEH2002US07199
		CZOL446EUS32 ID 0026-00007
		Ruggiero Medical Advisory
		Protocol 010 Slide Deck,
		Adverse Event Report Form
		Summary of Preclinical Oral Safety Studies, draft
		Integrated Safety Systems Proposal of Services
		CZOL446E U532 App. 6
		Draft Osteonecrosis Study
		Patient information form
		Appendix 7
		Compilation of Aredia Clinical Trials submitted in support of labeling instructions
		Compilation of NPC sponsored medical affairs post-marketing trials in the US

Ex. No.	Date	Description
1 2 3 4 DX-0408		Compilation of Zometa Clinical Trials submitted in support of labeling instructions
5 6 7 8 9 10 DX-0409		American Board of Oral and Maxillofacial Pathology Bylaws, Article XIV - Examinations. <a href="http://www.abomp.org/aboutus.htm#exams2">http://www.abomp.org/aboutus.htm#exams2</a>
11 12 13 14 DX-0410		Roff Memo to Spaet re Osteonecrosis resulting from the use of bisphosphonates in animals
15 16 DX-0411		Regulatory Correspondence
17 18 DX-0412		Regulatory Correspondence
19 20 DX-0413		Regulatory Correspondence
21 22 DX-0414		Regulatory Correspondence
23 24 DX-0415		Regulatory Correspondence
25 26 DX-0416		Regulatory Correspondence
27 28 DX-0417		Regulatory Correspondence
DX-0418		Regulatory Correspondence
DX-0419		Email correspondences to Dr. Marx (various dates)

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		Regulatory Correspondence
		Regulatory Correspondence
	May 1993	Aredia Drug Package Insert
	Jun. 1994	Aredia Drug Package Insert
	Oct. 1994	Aredia Drug Package Insert
	Oct. 1995	Aredia Drug Package Insert
	Oct. 1996	Aredia Drug Package Insert
	Jul. 1998	Aredia Drug Package Insert
	Dec. 1998	Aredia Drug Package Insert
	Jul. 1999	Aredia Drug Package Insert
	Sept. 2001	Aredia Drug Package Insert
	Jul. 2002	Aredia Drug Package Insert
	Jul. 2003	Aredia Drug Package Insert
	Nov. 2003	Aredia Drug Package Insert
	Oct. 2004	Aredia Drug Package Insert
	Apt. 2005	Aredia Drug Package Insert
	Mar. 2006	Aredia Drug Package Insert

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		
DX-0437	Mar. 2002	Zometa Drug Package Insert
DX-0438	Mar. 2003	Zometa Drug Package Insert
DX-0439	Nov. 2003	Zometa Drug Package Insert
DX-0440	Apr. 2004	Zometa Drug Package Insert
DX-0441	Oct. 2004	Zometa Drug Package Insert
DX-0442	Dec. 2004	Zometa Drug Package Insert
DX-0443	May 2005	Zometa Drug Package Insert
DX-0444	Jan. 2006	Zometa Drug Package Insert
DX-0445	2002	Carboplatin Drug Package Inserts
DX-0446	Current	Carboplatin Drug Package Inserts
DX-0447	2002	CPT-11 / Camptosar Drug Package Inserts
DX-0448	Current	CPT-11 / Camptosar Drug Package Inserts
DX-0449	2003	Cisplatin Drug Package Inserts
DX-0450	Current	Cisplatin Drug Package Insert
DX-0451	2003	VP-16 / Etoposide Drug Package Inserts
DX-0452	Current	VP-16 / Etoposide Drug Package Insert
DX-0453	2005	Strontium 89 / Metastron Drug Package Inserts

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		Strontium 89 / Metastron Drug Package Inserts
	Current	
		triamcinolone / Trivaris Drug Package Inserts
	Current	
	2000- present	Physicians' Desk Reference
	12/2/2008	Expert Report of Dr. Janet Arrowsmith
		Current CV of Dr. Janet Arrowsmith
	12/3/2008	Expert Report of Dr. Graham Russell
		Current CV of Dr. Graham Russell
	12/3/2008	Expert Report of Dr. Warren Browner
		Current CV of Dr. Warren Browner
		All rebuttal reports of NPC's Experts
		All updates and supplements to NPC's Experts' Reports
		Adverse Event Reporting System, <a href="http://www.house.gov/stupak/accutane/pl_46.pdf">http://www.hous e.gove/stupak/a ccutane/pl_46.p df</a>
	3/15/2010	PubMed search results of articles re bisphosphonates .
	3/29/2006	Complaint and Jury Demand in White v. NPC
	9/17/2006	Plaintiff's Fact Sheet - William White

Ex. No.	Date	Description
		Estate of William Knox White
		Supplement to Plaintiff's Fact Sheet by Cheryl White
DX-0469	5/16/2007	
		Novartis Pharmaceuticals Corporation's First Set of MDL Requests for the Production of Documents to Cheryl J. White
DX-0470	12/7/2007	
		Novartis Pharmaceuticals Corporation's First Set of MDL Interrogatories to Cheryl J. White
DX-0471	12/7/2007	
		Plaintiff's Response to NPC's First Set of MDL Interrogatories
DX-0472	1/30/2008	
		Plaintiff's Response to NPC's First MDL Requests for Production of Documents
DX-0473	1/30/2008	
		Plaintiff's Supplemental Response to NPC's MDL Interrogatory No. 4
DX-0474	9/12/2008	
		Plaintiff's Second Supplemental Response to NPC's MDL Interrogatory No. 4
DX-0475	12/19/2008	



Ex. No.	Date	Description
1 2 3 4 DX-0476	5/4/2009	Plaintiff's Supplemental Response to NPC's Request for Production of Documents No. 5
5 6 DX-0477	2/9/2009	Plaintiff's Rule 26(a)(2)(a) Statement
7 8 DX-0478		Stedman's Medical Dictionary. 28th Ed. 2005
9 10 11 12 DX-0479		Depositions referenced in NPC's deposition designations and exhibits thereto
13 14 15 16 17 DX-0480	4/2/2009	Deposition of James Vogel in <i>In re Aredia &amp; Zometa</i> Litigation and all accompanying exhibits
18 19 20 21 DX-0481	1/7/2010	Deposition of James Vogel in <i>In re Aredia &amp; Zometa</i> Litigation and all accompanying exhibits
22 23 24 25 26 DX-0482	3/17/2009	Deposition of Talib Najjar in <i>In re Aredia &amp; Zometa Litigation</i> and all accompanying exhibits
27 28 DX-0483	3/18/2009	Deposition of Talib Najjar in <i>In re Aredia &amp; Zometa Litigation</i> and all accompanying exhibits

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
DX-0484	3/19/2009	Deposition of Talib Najjar in <i>In re Aredia &amp; Zometa</i> Litigation and all accompanying exhibits
DX-0485	2/12/2008	Deposition of Michael Tanaka in <i>White v. NPC</i> and all accompanying exhibits
DX-0486	2/13/2008	Deposition of Cheryl White in <i>White v. NPC</i> and all accompanying exhibits
DX-0487	2/13/2008	Deposition of Richard Jackson in <i>White v. NPC</i> and all accompanying exhibits
DX-0488	6/3/2008	Deposition of Guy Acheson in <i>White v. NPC</i> and all accompanying exhibits
DX-0489	6/3/2008	Deposition of Jon Overholt in <i>White v. NPC</i> and all accompanying exhibits
DX-0490	7/18/2008	Deposition of Angela Davies in <i>White v. NPC</i> and all accompanying exhibits
DX-0491	7/30/2008	Deposition of Carol Richman in <i>White v. NPC</i> and all accompanying exhibits

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
DX-0492	7/30/2008	Deposition of Gordon Douglass in <i>White v. NPC</i> and all accompanying exhibits
DX-0493	7/31/2008	Deposition of John MacMillan in <i>White v. NPC</i> and all accompanying exhibits
DX-0494	9/24/2008	Deposition of Cheryl White in <i>White v. NPC</i> and all accompanying exhibits
DX-0495	4/22/2009	Deposition of Richard Jackson in <i>White v. NPC</i> and all accompanying exhibits
DX-0496	4/19/2010	Deposition of Robin Robillard in <i>White v. NPC</i> and all accompanying exhibits
DX-0497	4/20/2010	Deposition of Catherine Alexis Friedman in <i>White v. NPC</i> and all accompanying exhibits
DX-0498	4/20/2010	Deposition of Elliot White in <i>White v. NPC</i> and all accompanying exhibits
DX-0499	6/2/2010	Deposition of Jagdish Lallian in <i>White v. NPC</i> and all accompanying exhibits

Ex. No.	Date	Description
DX-0500	2/16/2009	Deposition of Keith Skubitz in In re Aredia & Zometa Litigation and all accompanying exhibits
DX-0501	4/27/2009	Deposition of Keith Skubitz in In re Aredia & Zometa Litigation and all accompanying exhibits
DX-0502	8/31/2009	Deposition of Keith Skubitz in Stevens v. NPC and all accompanying exhibits
DX-0503	11/23/2009	Deposition of Keith Skubitz in In re Aredia & Zometa Litigation and all accompanying exhibits
DX-0504	5/15/2007	Deposition of Robert Marx in In re Aredia and Zometa Litigation, Vol I & II and all accompanying exhibits
DX-0505	5/18/2007	Deposition of Robert Marx in In re Aredia & Zometa Litigation, Vol III & IV and all accompanying exhibits

Ex. No.	Date	Description
		Deposition of Robert Marx in In re Aredia & Zometa Litigation, Vol V and all accompanying exhibits
DX-0506	3/5/2009	
		Deposition of Robert Marx in In re Aredia & Zometa Litigation, Vol VI and all accompanying exhibits
DX-0507	3/6/2009	
		Deposition of Robert Marx in In re Aredia & Zometa Litigation, Vol VII and all accompanying exhibits
DX-0508	5/26/2009	
		Deposition of Robert Marx in Stevens v. NPC and all accompanying exhibits
DX-0509	7/23/2009	
		Transcript of Trial Testimony of Robert Marx in Stevens v. NPC
DX-0510	10/14/2009	
		Deposition of Robert Marx in In re Aredia & Zometa Litigation and all accompanying exhibits
DX-0511	12/8/2009	
		Transcript of Trial Testimony of Robert Marx in Hogan v. NPC
DX-0512	5/18/2011	

Ex. No.	Date	Description
DX-0513	5/13/2011	Deposition of Robert Marx in In re Aredia & Zometa Litigation and all accompanying exhibits
DX-0514	5/27/2011	Deposition of Robert Marx in Ingram v NPC and all accompanying exhibits
DX-0515	7/25/2011	Deposition of Robert Marx in Rhodes v NPC and all accompanying exhibits
DX-0516	4/16/2009	Deposition of Suzanne Parisian in In re Aredia & Zometa Litigation, Vol I and all accompanying exhibits
DX-0517	4/17/2009	Deposition of Suzanne Parisian in In re Aredia & Zometa Litigation, Vol II and all accompanying exhibits
DX-0518	8/22/2009	Deposition of Suzanne Parisian in Stevens v. NPC and all accompanying exhibits
DX-0519	9/18-9/22/09	Transcript of the Trial Testimony of Suzanne Parisian in Stevens v. NPC nad all accompanying exhibits

Ex. No.	Date	Description
1 2 3 4 5 DX-0520	2/3/2010	Deposition of Suzanne Parisian in In re Aredia & Zometa Litigation and all accompanying exhibits
6 7 8 9 DX-0521	7/26/2010	Deposition of Suzanne Parisian in Bessemer v. NPC and all accompanying exhibits
10 11 12 13 14 DX-0522	2/27/2010	Deposition of Wayne Ray in In re Aredia & Zometa Litigation Vol I and all accompanying exhibits
15 16 17 18 DX-0523	2/20/2009	Deposition of Wayne Ray in In re Aredia & Zometa Litigation Vol I and all accompanying exhibits
19 20 21 22 23 DX-0524	2/21/2009	Deposition of Wayne Ray in In re Aredia & Zometa Litigation Vol II and all accompanying exhibits
24 25 26 DX-0525	9/12/2009	Deposition of Wayne Ray in Stevens v. NPC and all accompanying exhibits
27 DX-0526	4/14/2010	Transcript of Kemp Hearing in Bessemer v. NPC
28 DX-0527	4/23/2010	Transcript of Kemp Hearing in Bessemer v. NPC

Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		Agreement for Expert Witness Services
DX-0528		
DX-0529		Publication listing regarding Prevalence Stratified By Type of Cancer
DX-0530		AAOMS and ASMBR standards
DX-0531		ADA website print-out re ONJ
DX-0532	11/00/1995	Guidance for Industry, Content and format of Investigational New Drug Applications (INDs) for Phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products (Nov. 1995)
DX-0533		Statement of FDA Commissioner Lutter before Congress
DX-0534		Transcript excerpts of Dr. Ruggiero's September 2005 AAOMS Presentation
DX-0535	1/9/2009	U.S. Food and Drug Administration: AERS instructions (revised 1/9/09)
DX-0536		21 CFR 1.21



Ex. No.	Date	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28		21 C.F.R. Part 7
		21 CFR § 56.102(g)
		21 CFR § 56.103(a)
		21 CFR § 56.103(b)
		21 CFR § 56.109(a)
		21 CFR § 56.109(f)
		21 CFR § 56.111(a)(1)
		21 CFR § 56.111(a)(2)
		21 CFR § 56.111(a)(6)
		21 CFR § 56.113
		21 CFR part 201
		21 CFR§ 202.1
		21 CFR § 202.10
		21 CFR § 310.300
		21 CFR § 310.301
		21 CFR § 312
		21 CFR part 314

Ex. No.	Date	Description
1 2 DX-0554		21 CFR 316
3 4 DX-0555		21 CFR part 601
5 6 DX-0556		21 CFR § 812
7 8 DX-0557		21 CFR part 814
9 10 DX-0558		21 U.S.C. § 321
11 12 DX-0559		21 U.S.C. § 352(a)
13 14 DX-0560		21 U.S.C. § 355
15 16 DX-0561		21 U.S.C. § 360
17 18 DX-0562		42 U.S.C. § 282
19 20 DX-0563	2000	American Cancer Society, Cancer Facts & Figures 2000, Atlanta: American Cancer Society (2000)
21 22 DX-0564	2001	American Cancer Society, Cancer Facts & Figures 2001, Atlanta: American Cancer Society (2001)
23 24 DX-0565	2002	American Cancer Society, Cancer Facts & Figures 2002, Atlanta: American Cancer Society (2002)
25 26 DX-0566	2003	American Cancer Society, Cancer Facts & Figures 2003, Atlanta: American Cancer Society (2003)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Ex. No.	Date	Description
DX-0567	2004	American Cancer Society, Cancer Facts & Figures 2004, Atlanta: American Cancer Society (2004)
DX-0568	2005	American Cancer Society, Cancer Facts & Figures 2005, Atlanta: American Cancer Society (2005)
DX-0569		All Exhibits Identified in Plaintiff's Pretrial Statement and the Exhibits Thereto
DX-0570	6/2/2010	Deposition of Sharon Pfeiffer in <i>White v. NPC</i> and all accompanying exhibits
DX-0571	12/3/2008	Expert Report of Dr. David Ettinger
DX-0572		Current CV of Dr. David Ettinger
DX-0573	12/2/2008	Expert Report of Dr. Alan Felsenfeld
DX-0574		Current CV of Dr. Alan Felsenfeld
DX-0575	10/20/2010	Transcript of De Bene Esse Deposition of Talib Najjar in <i>Fussman v. NPC</i>
DX-0576	11/4/2010	Transcript of Trial Testimony of Robert Marx in <i>Fussman v. NPC</i>
DX-0577	9/23/2010	Transcript of Trial Testimony of Robert Marx in <i>Bessemer v. NPC</i>

Ex. No.	Date	Description
DX-0578	9/24/2010	Transcript of Trial Testimony of Robert Marx in Bessemer v. NPC
DX-0579	9/29/2010	Transcript of Trial Testimony of Suzanne Parisian in Bessemer v. NPC
DX-0580	11/3/2010	Transcript of Trial Testimony of Suzanne Parisian in Fussman v. NPC
DX-0581		TASQ Technology, Inc. / First Data Corporation
DX-0582		Photographs of William White Produced by Plaintiff

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28